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Circulating	   angiogenic	   cells	   (CACs)	   are	   early	   predictors	   of	   cardiovascular	   health	   and	   are	  
inversely	  proportional	  to	  related	  outcomes.	  Increased	  number	  and	  function	  of	  CACs	  is	  seen	  in	  
healthy	   individuals	   compared	   with	   individuals	   with	   cardiovascular	   disease	   (CVD).	   Exercise	  
increases	   CAC	   number	   and	   function	   in	   CVD	   populations,	   through	   a	   nitric	   oxide-­‐mediated	  
mechanism.	   Inactivity	   is	  a	  growing	  concern	   in	   industrialized	  nations;	   it	   is	  an	   independent	   risk	  
factor	  for	  CVD	  and	  is	  linked	  to	  increased	  mortality.	  The	  purpose	  of	  this	  study	  was	  to	  understand	  
the	   effect	   of	   reduced	   physical	   activity	   (rPA)	   on	   two	   CAC	   populations	   (CFU-­‐Hill	   and	   CD34+)	   in	  
highly	  active	  individuals.	  We	  examined	  the	  mechanisms	  underlying	  changes	  in	  CAC	  function	  as	  a	  
result	   of	   rPA	   with	   maintained	   energy	   balance.	   The	   two	   sub-­‐populations	   of	   CACs	   responded	  
differently	  to	  rPA.	  CFU-­‐Hill	  CACs,	  decreased	  in	  number	  and	  amount	  of	  intracellular	  nitric	  oxide	  
while	   CD34+	   cells,	   did	   not	   change.	   Gene	   expression	   analyses	   indicated	   that	   oxidative	   stress-­‐	  
related	  genes	  did	  not	  change	  in	  CFU-­‐Hill	  cells	  with	  rPA.	  However,	  correlations	  between	  CFU-­‐Hill	  
cell	  numbers,	  intracellular	  nitric	  oxide,	  and	  genes	  that	  are	  related	  to	  nitric	  oxide	  were	  observed.	  
We	  concluded	  that	  rPA	  caused	  the	  observed	  decrease	  in	  CFU-­‐Hill	  number	  and	  intracellular	  nitric	  
oxide	  through	  a	  decrease	  in	  nitric	  oxide	  cellular	  availability,	  not	  oxidative	  stress.	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Cardiovascular	   disease	   (CVD)	   is	   the	   leading	   cause	   of	   death	   in	   the	   United	   States	   and	  
worldwide.44	  Traditional	  risk	  factors	  for	  CVD	  include	  age,	  sex,	  hyperglycemia,	  high	  cholesterol,	  
inactivity,	  tobacco	  smoke	  and	  diabetes	  mellitus.	  Despite	  the	  identification	  of	  these	  risk	  factors,	  
CVD	   can	   go	   undiagnosed	   in	   individuals	   with	   early	   signs	   of	   the	   disease	   and	   it	   remains	   the	  
dominant	   health	   problem	   worldwide.28	   There	   is	   a	   need	   to	   identify	   novel	   biomarkers	   that	  
indicate	   disease	   progression	   early	   on.	   Detecting	   early	   stages	   of	   CVD	   will	   permit	   early	  
intervention	   and	   reversal	   of	   disease	   by	   lifestyle	   intervention	   may	   be	   easier	   than	   with	   later	  
stages	  of	  disease.	  
Endothelial	   dysfunction	   underlies	   the	   pathophysiology	   of	   a	   number	   of	   cardiovascular	  
diseases	   including	   diabetes	   and	   renal	   failure.11	   The	   endothelial	   cell	   layer	   that	   acts	   as	   the	  
interface	   between	   blood	   and	   underlying	   tissue	   has	   several	   functions	   including	   regulation	   of	  
vascular	  tone	  and	  maintenance	  of	  local	  homeostasis.	  Damage	  to	  the	  endothelium	  decreases	  its	  
ability	   to	  perform	   these	   roles.	   	  However,	   if	   there	   is	   an	  efficient	   repair	  mechanism	   that	  helps	  
maintain	   endothelial	   function	   the	   endothelium	   can	   remain	   in	   a	   state	   of	   homeostasis	   and	  
perform	  its	  roles	  optimally.	  	  
Bone	   marrow	   derived	   vaso-­‐regenerative	   cells	   have	   been	   found	   to	   aid	   in	   the	  
maintenance	  and	  repair	  of	  the	  endothelium.	  These	  cells	  have	  the	  capacity	  to	  differentiate	  into	  




blood	  vessels.	  They	  have	  also	  been	   found	  to	  support	  vascular	   repair	  via	  a	  paracrine	  effect	  by	  
which	  these	  cells	  secrete	   factors	  to	  assist	   repair	  of	  damaged	  endothelium.	  64	  The	  most	  highly	  
studied	  of	  these	  cell	  types	  are	  circulating	  angiogenic	  cells	  (CACs).	  
Interest	  in	  CACs	  has	  been	  directed	  towards	  understanding	  their	  relationship	  to	  CVD	  and	  
mechanisms	   that	   diminish	   their	   regenerative	   potential.	   The	   number	   of	   CACs	   are	   inversely	  
correlated	  to	  the	  Framingham	  Risk	  Score	  for	  CVD	  and	  directly	  related	  to	  endothelial	  function.21	  
Further,	   circulating	   CAC	   numbers	   are	   lower	   in	   patients	  with	   cardiovascular	   events	   and	   these	  
low	  numbers	  	  are	  a	  significant	  predictor	  of	  future	  CVD	  events.55	  Similar	  to	  mature	  endothelial	  
cells,	  CAC	  function	  appears	  to	  be	  related	  to	  intracellular	  nitric	  oxide	  (NO).	  	  Decreased	  CAC	  NO	  
leads	  to	  diminished	  CAC	  differentiation	  and	  incorporation	  into	  vascular	  networks.60	  	  Therefore,	  
interventions	  to	  improve	  circulating	  CAC	  NO,	  and	  CAC	  function	  are	  likely	  important	  to	  decrease	  
CVD.	  	  Exercise	  interventions	  in	  patients	  with	  CVD	  have	  been	  found	  to	  be	  successful	  in	  increasing	  
circulating	  CAC	  number	  and	   function.	  A	   few	  studies	  have	  also	  shown	  that	   these	  cell	  numbers	  
are	   higher	   in	   individuals	   who	   are	   chronically	   active	   compared	   to	   age-­‐matched	   sedentary	  
individuals.5	   	   Importantly,	   exercise	   may	   increase	   CAC	   NO.27,67	   Therefore,	   improvement	   of	  
circulating	  CAC	  and	  maintenance	  of	  CAC	  NO	  may	  be	  key	  mechanisms	   through	  which	  physical	  
activity	  improves	  vascular	  function	  and	  decreases	  rates	  of	  CVD.	  	  
Inactivity	   is	   one	   of	   the	   established	   risk	   factors	   for	   CVD	   and	   it	   is	   also	   associated	  with	  
several	   other	   risk	   factors	   and	  disease	   states	   including	  diabetes	  mellitus,	   high	   cholesterol	   and	  
hyperglycemia.37	   Models	   of	   inactivity	   that	   have	   been	   used	   to	   investigate	   changes	   in	   the	  




provided	   us	   with	   information	   on	   the	   drastic	   cardiorespiratory	   ,	   vessel	   structure	   and	   FMD	  
changes	  that	  can	  occur	  as	  a	  result	  of	  inactivity.58	  However,	  most	  of	  the	  models	  that	  have	  been	  
used	   are	   extreme	   situations,	   very	   often	   confounded	   by	   underlying	   disease	   processes.	   It	  
becomes	   difficult	   to	   make	   any	   direct	   associations	   between	   endothelial	   health	   and	   inactivity	  
when	  using	  such	  models	  of	  inactivity.	  
We	  proposed	  that	  the	  CAC	  NO	  system	  is	   important	  to	  the	  maintenance	  of	  proper	  CAC	  
function	  and	  that	  it	  is	  vulnerable	  to	  reduced	  physical	  activity.	  	  Therefore,	  the	  aim	  of	  this	  study	  
was	   to	   examine	   the	   impact	   of	   reduced	   physical	   activity	   on	   CAC	   NO	   and	   CAC	   number.	   We	  
investigated	   this	   by	   recruiting	   healthy,	   highly	   active,	   endurance	   trained	   runners.	   They	  
completed	   a	   10-­‐day	   period	   of	   reduced	   physical	   activity	   where	   they	   did	   not	   perform	   their	  
regular	  structured	  exercise	  and	  maintained	  energy	  balance.	  	  Blood	  was	  drawn	  before	  and	  after	  
the	   10	   days	   to	   evaluate	   CAC	   number,	   CAC	   NO	   and	   CAC	   gene	   expression	   for	   a	   potential	  
mechanism	  of	  reduced	  CAC	  NO	  production.	  	  
The	  specific	  aims	  and	  hypotheses	  for	  this	  study:	  
Aim	  1:	  To	  study	  the	  effects	  of	  reduced	  physical	  activity	  (rPA)	  on	  circulating	  angiogenic	  cell	  (CAC)	  
number.	  
Hypothesis	  1:	  The	  rPA	  will	  reduce	  CAC	  number.	  	  
	  Aim	  2:	  To	  evaluate	  the	  effects	  of	  rPA	  on	  CAC	  intracellular	  nitric	  oxide	  and	  genes	  that	  are	  




Hypothesis	  2:	  The	  rPA	  will	  cause	  a	  decrease	  in	  CAC	  intracellular	  nitric	  oxide,	  and	  genes	  that	  are	  
regulators	  of	  nitric	  oxide.	  
Aim	  3:	  To	  evaluate	  the	  relationship	  between	  changes	  in	  CAC	  number	  and	  nitric	  oxide-­‐related	  
CAC	  factors.	  
Hypothesis	  3:	  There	  will	  be	  a	  positive	  correlation	  between	  the	  change	  in	  CAC	  number	  and	  the	  




CHAPTER	  2	  	  
LITERATURE	  REVIEW	  
	  
2.1	   	  Introduction	  
This	  literature	  review	  will	  cover	  the	  importance	  of	  studying	  cardiovascular	  disease	  in	  the	  
United	   States	   and	   the	   relevance	   of	   studying	   endothelial	   function	   to	   prevent	   it.	   	   Circulating	  
angiogenic	  cells	  (CACs),	  a	  novel	  biomarker	  for	  CVD	  will	  be	  introduced	  with	  regard	  to	  their	  role	  in	  
endothelial	  maintenance.	  The	  role	  of	  both	  exercise	  and	  the	  impact	  of	  inactivity	  will	  be	  reviewed	  
in	  reference	  to	  the	  number	  and	  function	  of	  CACs.	  Lastly,	  the	  mechanistic	  role	  of	  nitric	  oxide	  and	  
its	  mediators	  in	  maintaining	  a	  healthy	  endothelium	  will	  also	  be	  reviewed.	  	  
2.2	   	  Cardiovascular	  Disease	  and	  Endothelial	  Function	  
I. Cardiovascular	  disease:	  
Cardiovascular	   disease	   (CVD)	   is	   the	   leading	   cause	   of	   death	   worldwide.44	   In	   2007,	   CVD	  
accounted	   for	  1	  of	  every	  3	  deaths	   in	   the	  United	  States	  and	   the	  estimated	  direct	  and	   indirect	  
costs	  associated	  with	  CVD	  were	  $286.6	  billion.52	  Cardiovascular	  disease	  comprises	  of	  a	  group	  of	  
conditions	  which	  include	  high	  blood	  pressure	  (HBP),	  coronary	  heart	  disease	  (CHD),	  heart	  failure	  
(HF),	   stroke,	   angina	   pectoris	   and	   congenital	   cardiovascular	   defects.	   Coronary	   heart	   disease	  
accounts	  for	  about	  half	  the	  CVD-­‐related	  deaths	  while	  the	  others	  account	  for	  anywhere	  between	  
4-­‐16%	   of	   deaths	   from	   CVD.52	   Traditional	   risk	   factors	   for	   CVD	   include	   age,	   gender,	   heredity,	  
smoking,	  high	  blood	  pressure,	  cholesterol,	  physical	  inactivity,	  overweight,	  obesity	  and	  diabetes	  




all	   CV	   events	   occur	   in	   individuals	   without	   traditional	   CVD	   risk	   factors.28	   Therefore	   novel	  
pathways	   of	   risk	   detection	   such	   as	   markers	   for	   inflammation,	   oxidative	   stress,	   endothelial	  
function,	  thrombosis	  and	  coagulation	  need	  to	  be	  further	  studied	  for	  their	  potential	  to	  identify	  
individuals	  at	  risk.	  
II. Endothelial	  function:	  
a. CVD	  and	  endothelium	  
Coronary	   heart	   disease	   which	   accounts	   for	   about	   half	   the	   deaths	   due	   to	   CVD	   in	   the	  
United	  States	  is	  a	  condition	  which	  causes	  changes	  in	  both	  the	  structure	  and	  function	  of	  blood	  
vessels.31	   Blood	   vessels	   are	   lined	   by	   endothelial	   cells	   which	   are	   responsible	   not	   just	   for	  
maintenance	   of	   vascular	   tone	   and	   permeability	   but	   also	   in	   regulating	   leukocyte	   traffic	   and	  
modulating	   vascular	   homeostasis	   and	   thrombosis.48	   As	   with	   any	   physiologically	   responsive	  
tissue,	   the	   endothelium	   is	   susceptible	   to	   injury	   and	  will	   try	   to	   reestablish	   homeostasis	  when	  
injured.	   	   Ross	   characterized	   atherosclerosis	   as	   part	   of	   the	   response	   to	   (endothelial)	   injury.53	  
Early	   in	   the	   disease	   process,	   the	   endothelial	   cells	   become	   dysfunctional.	   The	   endothelial	  
dysfunction	  leads	  to	  migration	  of	  cells	  under	  the	  surface	  of	  the	  endothelium	  where	  monocytes	  
become	   macrophages,	   accumulate	   lipid,	   become	   foam	   cells	   and	   with	   the	   accompanying	  
lymphocytes	  lead	  to	  fatty	  streak	  formation.	  While	  fatty	  streaks	  are	  evident	  in	  children	  and	  are	  
fairly	  reversible,	  repeated	  injury	  leads	  to	  further	  accumulation	  of	  cells	  in	  these	  ‘hot	  spots’	  and	  
ultimately	   leads	  to	   fibrous	  plaque	  formation.53	  The	  progression	  of	   this	  atherosclerotic	  state	   is	  
indicative	  of	  the	  endothelium	  being	  unable	  to	  perform	  one	  of	  its	  primary	  functions-­‐	  protecting	  






b. Nitric	  oxide	  
Endothelial	   dysfunction	   has	   been	   shown	   to	   be	   the	   underlying	   cause	   of	   several	  
cardiovascular	  diseases,	  renal	  failure	  and	  diabetes	  mellitus.11	  Studies	  have	  found	  flow	  mediated	  
dilation	   (FMD)	   to	   be	   as	   effective	   as	   traditional	   risk	   factors	   as	   an	   independent	   predictor	   of	  
endothelial	  dysfunction	  and	  cardiovascular	  events.57	  Changes	  in	  FMD	  are	  primarily	  nitric-­‐oxide	  
mediated.10,57	   Nitric	   oxide	   is	   one	   of	   the	   most	   important	   substances	   released	   by	   the	  
endothelium;	  it	  acts	  as	  a	  vasodilator,	  inhibits	  growth	  and	  inflammation,	  and	  has	  anti-­‐aggregant	  
effects	   on	   platelets.	   It	   helps	  maintain	   a	   healthy,	   non-­‐artherogenic	  milieu	   in	   the	   vasculature.	  
Decreased	   nitric	   oxide	   levels	   on	   the	   other	   hand	   have	   been	   directly	   linked	   to	   endothelial	  
dysfunction	  in	  various	  disease	  states.11	  
c. Lifestyle	  
Shear	   stress	   that	   accompanies	   regular	   exercise	   increases	   the	   synthesis	   and	   release	   of	  
nitric	  oxide	  and	  thus	   improves	  endothelial	   function.43	  Healthy	   lifestyle	   factors	  such	  as	   regular	  
participation	  in	  endurance	  exercise	  have	  been	  shown	  to	  attenuate	  the	  ageing-­‐related	  decline	  in	  
endothelial	   function.51	   Rinder	   et	   al51	   have	   found	   that	   endothelial-­‐dependent	   dilation	   was	  
greater	  in	  older	  athletes	  compared	  with	  age-­‐matched	  healthy	  sedentary	  men.	  While	  sedentary	  
lifestyle	   is	   associated	   with	   endothelial	   dysfunction	   and	   increased	   cardiovascular	   events33	   it	  






d. Maintenance	  of	  endothelial	  function	  
Maintaining	   endothelial	   function	   is	   important	   in	   order	   to	   avoid	   the	   onset	   of	   all	   the	  
cardiovascular	  diseases	  that	  begin	  with	  disruptions	  at	  the	  level	  of	  the	  endothelium.	  Maintaining	  
a	   lifestyle	   that	   promotes	   vascular	   health	   is	   an	   essential	   part	   of	   endothelial	   maintenance.	  
Exercise	   induced	   increases	   in	   shear	   stress	   and	   consequent	   increase	   in	   nitric	   oxide	   consist	   of	  
only	   a	   part	   of	   the	   mechanism	   involved	   in	   maintaining	   a	   healthy	   endothelium.	   Circulating	  
angiogenic	  cells,	  a	  group	  of	  adult	  stem	  cells	  that	  respond	  to	  NO	  release	  (among	  several	  other	  
factors)	   have	   been	   found	   to	   play	   an	   integral	   role	   in	   the	   maintenance	   and	   repair	   of	   the	  
endothelium.64	   They	   do	   so	   by	   forming	   new	   blood	   vessels	   or	   by	   repairing	   pre-­‐existing	  
vasculature.	   They	   mediate	   these	   effects	   by	   either	   directly	   becoming	   incorporated	   into	   the	  
endothelium	  or	  via	  paracrine	  signals.	  The	  numbers	  and	  function	  of	  CACs	  are	  directly	  related	  to	  
endothelial	   function35,21	   and	   they	   are	   considered	   a	   biomarker	   for	   cardiovascular	   disease.56,13	  	  
CACs	  have	  been	  found	  to	  be	  dysfunctional	  in	  individuals	  with	  cardiovascular	  disease21,66	  chronic	  
kidney	  disease17	  and	  diabetes.20	  Studies	  have	  been	  done	  to	  harness	  the	  regenerative	  potential	  
of	   CACs	   to	   repair	   the	   vasculature	   in	   these	  patient	  populations.	  However,	   very	   little	   is	   known	  
about	  the	  mechanisms	  that	  lead	  CACs	  to	  become	  dysfunctional	  in	  healthy	  individuals.	  




2.3	  	   Circulating	  angiogenic	  cells	  (CACs)	  
	  
I. Overview:	  
All	  blood	  cells	  arise	   from	  a	   type	  of	  cell	   called	   the	  hematopoietic	   stem	  cell	   (HSC)	  and	   they	  
have	   the	   potential	   to	   differentiate	   into	   other	   cell	   types.29	   After	   birth,	   the	   bone	   marrow	  
becomes	   the	   major	   factor	   in	   hematopoiesis	   where	   differentiation	   of	   the	   HSCs	   takes	   place.	  
There	  are	  normally	   fewer	  than	  one	  HSC	  per	  5	  x	  104	  cells	   in	   the	  bone	  marrow	  and	  this	  makes	  
them	   difficult	   to	   culture	   in	   vitro.	   However,	   when	   there	   is	   an	   increased	   demand	   for	  
hematopoiesis,	   HSCs	   will	   display	   an	   enormous	   proliferative	   capacity.	   	   Circulating	   angiogenic	  
cells	  (CACs)	  are	  one	  of	  the	  many	  cell	  types	  that	  emerge	  from	  this	  lineage.	  CACs	  were	  discovered	  
in	  1997	  by	  Asahara	  and	  colleagues.3	  They	  are	  a	  population	  of	  hematopoietic	  cells	  that	  can	  be	  
isolated	  from	  circulating	  mononuclear	  cells,	  bone	  marrow	  and	  cord	  blood.	  	  
II. Function	  of	  CACs:	  
Circulating	   angiogenic	   cells	   play	   an	   important	   role	   in	   the	   maintenance	   and	   repair	   of	  
vasculature.	   They	   do	   so	   by	   neo-­‐vascularization-­‐	   formation	   of	   new	   blood	   vessels	   or	   by	   re-­‐
endothelialization-­‐	   repair	   of	   pre-­‐existing	   vasculature.64	   They	  mediate	   these	   effects	   by	   either	  
directly	   becoming	   incorporated	   into	   the	   endothelium	   or	   by	   a	   paracrine	   effect.	   Given	   the	  
appropriate	  stimulus,	  such	  as	  exercise,	  they	  are	  first	  mobilized	  from	  their	  stem-­‐cell	  niche	  in	  the	  
bone	  marrow;	  from	  there,	  they	  migrate	  to	  the	  site	  of	  injury	  in	  the	  vasculature.	  With	  the	  aid	  of	  
several	   other	   signaling	   molecules	   from	   the	   damaged	   vessel	   wall	   they	   either	   become	  
incorporated	   at	   the	   site	   of	   injury	   or	   they	   enhance	   the	   repair	   process	   through	   the	   release	   of	  




outgrowth	  CACs	  such	  as	  CFU-­‐ECs	  that	  work	  via	  this	  paracrine	  mechanism	  by	  providing	  a	  potent	  
mixture	   of	   growth	   factors	   to	   facilitate	   endothelial	   repair.13,22	   The	   paracrine	   effect	   of	  
transplanted	   marrow-­‐derived	   cells	   has	   proved	   to	   be	   a	   critical	   mechanism	   underlying	   the	  
angiogenic	  effect	  of	   cell	   therapy.30	  The	  paracrine	  mechanism	  has	  also	  been	  shown	  to	   restore	  
the	  endothelial	  function	  of	  restored	  carotid	  arteries.18	  	  
While	  acute	  injury	  will	  cause	  an	  increase	  in	  CACs,	  it	  is	  hypothesized	  that	  repeated	  injury	  will	  
eventually	  decrease	  the	  number	  and	  function	  of	  CACs.	  When	  CAC	  number	  is	  reduced	  or	  when	  
the	  function	  of	  CACs	  is	  impaired,	  the	  endothelium	  is	  affected.	  	  The	  endothelium	  is	  the	  first	  site	  
to	   be	   damaged	   before	   an	   atherosclerotic	   plaque	   is	   formed.53	   If	   CAC	   number	   is	   decreased	   or	  
function	  is	  impaired,	  they	  will	  be	  unable	  to	  mitigate	  the	  consequences	  of	  endothelial	  damage.	  
Repeated	   insult	   of	   the	   endothelial	   and	   sub-­‐endothelial	   layers	   can	   lead	   to	   fibrous	   plaque	  
formations.53	  This	  ultimately	  contributes	  to	  cardiovascular	  diseases	  such	  as	  atherosclerosis	  and	  
hypertension.	  	  
III. Types	  of	  CACs:	  
The	   identification	  and	  definition	  of	  CACs	  has	  been	   controversial.	   	   The	  population	  of	  HSCs	  
found	  to	  aid	  in	  the	  maintenance	  and	  repair	  of	  the	  endothelium	  has	  broadly	  been	  termed	  CACs	  
but	  with	  a	   lack	  of	  a	  unified	  definition	  of	  CAC	  to	  date,	  there	   is	  a	  heterogeneous	  nature	  of	  this	  
population.	  	  A	  few	  prominent	  markers	  and	  characteristics	  have	  been	  used	  to	  identify	  these	  cells	  
and	   they	   include:	   CD34,	   CD133,	   CD31,	   VEGFR2,	   CD45	   ,	   acLDL	   uptake,	   UEA-­‐1	   lectin	   binding,	  
eNOS	   and	   vWF	   factor.24	   However	   there	   is	   still	   is	   no	   consensus	   about	   the	   presence	   of	   these	  




been	   used	   to	   broadly	   classify	   them	   into	   either	   early	   or	   late	   outgrowth	   cells	   as	   shown	   in	   the	  
figure	  below.	  
	  
Figure	  1.	  Different	  culturing	  techniques	  that	  lead	  to	  Early	  and	  Late	  Outgrowth	  CACs	  (Hirschi	  et	  
al,	   2008):	   The	   Early	   Outgrowth	   CACs	   aid	   in	   vascular	   recovery	   via	   paracrine	   effect.	   The	   Late	  
Outgrowth	  CACs	  are	  more	  similar	  to	  endothelial	  cells	  and	  aid	  in	  neovascularisation.	  	  
Late	   CACs	   form	   colonies	   after	   about	   2-­‐4	   weeks	   in	   culture,	   they	   have	   been	   shown	   to	  
contribute	  directly	   to	  neovascularization	   (formation	  of	  new	  blood	  vessels)	   and	  have	  a	   robust	  
proliferative	  capacity.70	  They	  have	  a	  cobblestone	  appearance	  and	  are	  more	  similar	   to	  mature	  
endothelial	  cells.	  	  On	  the	  other	  hand,	  early	  CACs	  form	  colonies	  in	  culture	  after	  approximately	  5-­‐
7	   days	   and	   appear	   to	   mediate	   vascular	   repair	   mainly	   via	   a	   paracrine	   effect	   i.e.	   secreting	  




The	   CFU-­‐Hill	   assay	   developed	   by	   Hill	   et	   al21	   has	   been	   commonly	   used	   to	   isolate	   and	  
culture	  these	  early	  outgrowth	  cells	  from	  peripheral	  blood	  mononuclear	  cells.	  By	  the	  5th	  day	  of	  
culture,	   colony-­‐forming	   units	   (CFUs)	   start	   to	   appear	   which	   provides	   us	   with	   a	   quantitative	  
measure	  of	  CAC	  function.	  CAC	  function,	  which	  is	  represented	  by	  the	  capacity	  of	  CACs	  to	  form	  
CFUs	   in	  vitro	  was	  found	  to	  be	  inversely	  related	  to	  cardiovascular	  Framingham	  risk	  score	  and	  a	  
better	   predictor	   of	   vascular	   function	   than	   the	   presence	   or	   absence	   of	   traditional	   CVD	   risk	  
factors21	   (Figure.	   2).	   	   This	   data	   provides	   us	   with	   a	   good	   rationale	   that	   cells	   isolated	   via	   this	  
technique	   may	   be	   clinically	   relevant	   biomarkers	   of	   cardiovascular	   health.	   Studies	   have	  




Figure.	  2	  CAC	  CFUs	  and	  Framingham	  Risk	  Score	  
for	   CVD	   (Hill	   et	   al.,	   2003):	   Higher	   CAC	   colony	  
forming	  units	  (CFUs)	  correlated	  with	  a	  decreased	  
Framingham	   Risk	   Score	   for	   cardiovascular	  
disease	  while	  a	  lower	  CFU	  count	  correlated	  with	  




Much	  of	  the	  work	  with	  CACs	  has	  been	  focused	  on	  individuals	  with	  CVD.	  However,	  there	  
are	  a	   limited	  number	  of	   studies	  examining	   their	   function	   in	  healthy	   individuals.	   	   If	  we	  gain	  a	  




a	   bit	   closer	   to	   understanding	   the	   pathophysiology	   of	   vascular	   disease	   caused	   by	   common	  
lifestyle	  factors.	  	  
2.4	  	   Exercise	  and	  CACs	  
I. Acute	  exercise	  and	  CACs	  
A	   single	  bout	  of	   exercise	   leads	   to	  mobilization	  of	  CACs	   from	   the	  bone	  marrow.	  Acute	  
exercise	   is	   believed	   to	   mobilize	   CACs	   through	   the	   increase	   in	   shear	   stress	   and	   activation	   of	  
endothelial	   nitric	   oxide	   synthase	   (eNOS)	   via	   the	   Phosphoinositide	   3-­‐kinase/	   protein	  
kinase	  (PI3/Akt)	   dependent	  pathway	   (Figure.	   3)35.	   The	   increased	   concentration	  of	   nitric	   oxide	  	  
(NO)	  activates	  Matrix	  Metalloproteinase-­‐9	   (MMP-­‐9),	  essential	   for	   stem	  cell	  mobilization	   from	  
the	   bone	   marrow,	   which	   causes	   mobilization	   of	   the	   resident	   progenitor	   cells	   out	   to	   the	  
peripheral	  
	  
Figure	  3.	  	  Diagram	  depicting	  the	  possible	  
pathways	  by	  which	  exercise	  leads	  to	  repair	  
and	  maintenance	  of	  an	  intact	  endothelial	  
cell	  layer	  through	  CACs	  (Lenk,	  2011):	  
Exercise	  causes	  an	  increase	  in	  vascular	  shear	  
stress	  which	  increases	  NO.	  This	  NO	  in	  turn	  
will	  stimulates	  the	  mobilization	  of	  CACs	  
from	  the	  bone	  marrow.	  Once	  they	  are	  
mobilized	  and	  released,	  they	  will	  go	  to	  the	  
damaged	  endothelium	  where	  they	  will	  
either	  differentiate	  into	  endothelial	  cells	  or	  
secrete	  growth	  factors	  that	  allow	  for	  proliferation	  of	  mature	  endothelial	  cells.
circulation.	   The	   exercise	   induced	   release	   of	   NO	   via	   eNOS	   stimulates	   the	   expression	   of	  




growth	  factor	  (VEGF),	  chemokines	  that	  are	  considered	  to	  play	  an	  important	  role	  in	  trafficking	  of	  
CACs.68,354	  CXC	  chemokine	   cell	   receptor	  4	   (CX-­‐CR4)	  and	  very	   late	  activation	  antigen-­‐	  4	   (VLA4)	  
are	   both	   cell	   surface	   receptors	   that	   are	   essential	   for	   the	   homing	   of	   these	   cells	   to	   the	  
endothelium.7	  Therefore,	  the	  role	  of	  eNOS	  appears	  to	  be	  critical	  in	  the	  liberation	  of	  CACs	  into	  
circulation.35	  
Mobius-­‐Winkler	  et	  al.40	  conducted	  a	  study	  to	  follow	  the	  time-­‐dependent	  release	  of	  CACs	  
during	   and	   after	   a	   4-­‐hour	   bout	   of	   sub-­‐maximal	   (70%	  anaerobic	   threshold)	   cycling	   exercise	   in	  
healthy	  individuals.	  They	  found	  that	  there	  was	  a	  steady	  and	  significant	  increase	  in	  CD34+/KDR+	  
cells	  by	  the	  end	  of	  the	  exercise	  session,	  compared	  to	  baseline.	  They	  found	  a	  similar	  increase	  for	  
CD133+/KDR+	   and	   CD133+	   cells.	   24	   hours	   after	   the	   start	   of	   the	   exercise	   the	   CD34+/KDR+	   cell	  
numbers	  returned	  back	  to	  baseline	  while	  the	  CD133+	  cells	  remained	  elevated	  2	  hours	  after	  the	  
end	  of	  the	  exercise	  and	  were	  slightly	  higher	  than	  baseline	  even	  at	  24	  hours40.	  In	  another	  study	  
that	  looked	  at	  the	  effects	  of	  acute	  exercise	  on	  patients	  with	  CVD	  risk	  factors,	  the	  post-­‐exercise	  
results	  were	  more	  dramatic.50	  After	  5-­‐10	  minutes	  of	  having	  the	  patients	  do	  a	  treadmill/	  bicycle	  
exercise	   to	   exhaustion,	   CD133+/VE	   Cadherin+	   cells	   increased	   by	   400%	   while	   the	   early	  
progenitors,	   cells	   that	   only	   have	   the	   CD133+	   marker,	   increased	   by	   just	   40%.	   The	   cultured	  
angiogenic	   cells	   that	   express	   markers	   for	   monocytes/macrophages,	   increased	   by	   250%.	   Van	  
Craenenbroeck	  et	   al.8	   compared	   the	   results	  of	   graded	  exercise	   testing	  between	  CHF	  patients	  
and	  healthy	  subjects.	  Within	  10	  minutes	  of	  the	  exercise	  they	  found	  that	  the	  CD34+/KDR+	  cells	  
had	  increased	  in	  the	  healthy	  subjects	  and	  remained	  elevated	  after	  2	  hours.	  However,	  with	  the	  




minutes.	   	   	  These	  studies	  highlight	   that	  different	  cell	   types	  seem	  to	   respond	  to	  acute	  exercise	  
differently	  in	  healthy	  individuals	  versus	  individuals	  with	  heart	  disease	  or	  risk	  factors	  for	  CVD.	  
II. Exercise	  training	  and	  CACs:	  
Exercise	  training	  has	  been	  shown	  to	  cause	  an	  increase	  in	  circulating	  CACs	  in	  individuals	  
with	   cardiovascular	   disease.33,66	   Exercise	   training	   can	   also	   positively	   affect	   the	   functional	  
capacity	  of	  CACs.35	  	  In	  contrast	  to	  acute	  bouts	  of	  exercise	  where	  the	  elevation	  in	  CACs	  after	  the	  
exercise	  is	  attenuated	  within	  minutes,	  regular	  physical	  activity	  can	  lead	  to	  an	  elevated	  baseline	  
number	  of	   CACs	   as	  was	  observed	   in	   a	   group	  of	   young	  male	   runners,	   compared	   to	   sedentary	  
controls.5	  	  
Laufs	   et	   al.33	   conducted	   a	   28-­‐day	   exercise	   program	   to	  measure	   the	   resting	   circulating	  
CACs	   in	   patients	   with	   coronary	   artery	   disease	   (CAD).	   They	   found	   the	   resting	   CACs	   in	   these	  
patients	   to	   be	   higher	   at	   the	   end	   of	   the	   program.	   Sarto	   et	   al.54	   investigated	   the	   specific	  
mechanism	   involved	   in	   the	   increased	  CAC	   levels	   in	   CHF	  patients	   after	   exercise	   training.	   They	  
found	  a	  25%	  increase	  in	  resting	  CD34+/KDR+	  CAC	  levels	  in	  CHF	  patients	  in	  response	  to	  8	  weeks	  
of	   supervised	   aerobic	   training.	   They	   also	   saw	   a	   marked	   increase	   in	   two	   CAC	   mobilizing	  
cytokines,	  namely	  VEGF	  and	  SDF-­‐1.	  54	  Their	  results	  were	  accompanied	  by	  an	  increased	  potential	  
of	  generating	  CAC	  colonies.	  Lauf	  et	  al.34	  also	  found	  that	  eNOS−/−mice	  and	  wild-­‐type	  mice	  treated	  
with	  NG-­‐nitro-­‐L-­‐arginine	   methyl	   ester	   (L-­‐NMMA)	   had	   lower	   CAC	   numbers	   at	   baseline	   and	   a	  
significantly	  attenuated	  increase	  of	  CACs	  in	  response	  to	  28	  days	  of	  treadmill	  running.	  The	  wild-­‐




while	  there	  were	  no	  significant	  differences	  seen	  in	  either	  the	  eNOS−/−mice	  or	  the	  wild-­‐type	  mice	  
treated	  with	  L-­‐NMMA	  after	  the	  training.	  	  	  
Jenkins	  et	  al.27	  found	  that	  endurance	  trained	  men	  had	  greater	  resting	  CAC	  intracellular	  
NO	  (NOi)	  compared	  with	  age-­‐matched	  sedentary	  men.	  	  In	  trained	  men	  they	  also	  found	  greater	  
resting	   CAC	   eNOS	   gene	   expression	   and	   lower	   expression	   of	   GP91phox	  which	   is	   a	   subunit	   of	  
NADPH	   oxidase,	   an	   enzyme	   that	   produces	   oxidative	   stress	   in	   the	   vascular	   wall.	   	   Therefore,	  
regular	   physical	   exercise	   appears	   to	   impart	   a	   pro-­‐NO	  and	   anti-­‐oxidative	   stress	   phenotype	  on	  
circulating	  CACs.	  	  	  
Importantly,	  exercise	  training	  may	  alter	  the	  CAC	  response	  to	  acute	  exercise.	  	  Jenkins,	  et	  
al27	   showed	  that	   trained	  men	  had	  a	  significant	   increase	   in	   their	  CFU-­‐EC	  counts	   (a	  measure	  of	  
CAC	  function)	  with	  an	  acute	  bout	  of	  treadmill	  exercise	  whereas	  no	  change	  in	  CFU-­‐EC	  was	  seen	  
in	  the	  untrained	  group	  after	  this	  acute	  exercise.	  	  Further,	  while	  acute	  exercise	  and	  the	  NADPH	  
oxidase	  inhibitor	  apocynin	  both	  increased	  CAC	  NOi	  to	  a	  similar	  extent	   in	  the	  untrained	  group,	  
CAC	  NOi	  was	  still	  lower	  than	  the	  trained	  group,	  and	  the	  trained	  men	  had	  no	  further	  increase	  in	  
CAC	   NOi	   with	   acute	   exercise	   or	   apocynin.	   	   This	   study	   demonstrates	   differences	   in	   the	   CAC	  
response	  to	  acute	  exercise	  based	  on	  training	  status	  and	  that	  while	  decreased	  CAC	  NOi	  may	  be	  
partially	  due	  to	  NADPH	  and	  oxidative	  stress,	  there	  are	  likely	  other	  mechanisms	  that	  alter	  CAC	  
NOi	  with	  exercise.	  	  
Diminishing	   CAC	   levels	   are	   a	   good	   predictor	   of	   disease	   progression	   in	   patients	   with	  
CVD.21	   Exercise	   interventions	   have	   been	   used	   to	   improve	   CAC	   levels	   primarily	   in	   the	   CVD	  




population	  or	  in	  healthy	  people	  is	  still	  unclear.	  The	  improvement	  in	  CAC	  number	  and	  function	  
after	   exercise	   interventions	   in	   individuals	   with	   CVD	   indicates	   the	   potential	   of	   these	   cells	   to	  
respond	   to	   stimuli	   in	   an	   environment	   where	   endothelial	   dysfunction	   may	   have	   already	  
progressed	  to	  a	  significant	  extent.	  However,	  it	  tells	  us	  very	  little	  about	  why	  these	  cells	  started	  
to	  decrease	   in	  number	  and	   function	   in	   the	   first	  place.	  Physical	   inactivity	  has	  been	  associated	  
with	   several	   CVD	   risk	   factors	   that	   include-­‐	   high	   cholesterol,	   high	   blood	   pressure,	   obesity,	  
overweight	  and	  diabetes	  mellitus.37	  While	  we	  are	  starting	  to	  understand	  how	  risk	  factors	  such	  
as	   diabetes	   and	   high	   cholesterol	   affect	   CAC	   function,	   there	   is	   limited	   information	   on	   the	  
deleterious	  effects	  of	  inactivity	  on	  CAC	  number	  and	  function.	  	  




2.5	  	   Inactivity	  and	  CACs	  
I.	  Definitions	  of	  inactivity:	  
Fewer	   than	   5%	   of	   adults	   in	   the	   United	   States	   of	   America	   satisfy	   the	   minimum	   physical	  
activity	  recommendations	  of	  30	  minutes	  per	  day.62	  There	  has	  been	  an	  increase	  in	  the	  amount	  of	  
time	  devoted	  to	  the	  sedentary	  activities	  such	  as	  TV	  viewing	  in	  the	  past	  few	  decades.	  Based	  on	  
data	   from	   the	   Center	   for	   Disease	   Control	   (CDC),	   physical	   inactivity	   and	   poor	   diet	   may	   soon	  
overtake	  tobacco	  as	  a	  leading	  cause	  of	  death.41	  Until	  recently	  the	  health	  risks	  associated	  with	  a	  
sedentary	   lifestyle	   were	   thought	   to	   be	   a	   result	   of	   insufficient	   physical	   activity	   but	   we	   are	  
learning	  that	  this	  is	  different	  from	  inactivity.	  	  
The	  American	  College	  of	  Sports	  Medicine	  (ACSM,	  2006)	  defines	  a	  sedentary	  lifestyle	  as	  “not	  
participating	   in	   a	   regular	   exercise	   program	   or	   not	   meeting	   the	   minimal	   physical	   activity	  
recommendations	  from	  the	  US	  Surgeon	  General”.19	  However,	  sedentary	  behavior	  and	  physical	  
activity	   are	   not	   opposites	   of	   each	  other.	  Owen	  et	   al.46	  was	   among	   the	   first	   to	   challenge	   this	  
when	   he	   reported	   that	   the	   determinants	   of	   sedentary	   behavior	   and	   physical	   activity	   are	  
distinct.	  Marshall	   et	   al.37	   argue	   that	   sedentary	   behavior	   is	   best	   defined	   as	   a	   distinct	   class	   of	  
behaviors	  that	  involve	  sitting	  and	  low	  levels	  of	  energy	  expenditure,	  typically	  less	  than	  1.5	  METs.	  
Finally,	  Tudor-­‐Locke	  et	  al.63	  	  categorize	  sedentary	  individuals	  as	  adults	  with	  <5000	  steps/day,	  a	  
commonly	  used	  cut-­‐off	  point.	  
	  
II. Inactivity	  and	  Metabolic	  Syndrome	  
Recent	  evidence	  claims	  that	  the	  rapid	  increase	  in	  rates	  of	  type	  2	  diabetes	  (T2D)	  is	  primarily	  




T2D	  plays	  a	  role	  in	  the	  degree	  to	  which	  inactivity	  impacts	  the	  individual.	  However,	  Booth	  et	  al.61	  
made	  the	  observation	  that	  10	  days	  of	  bed	  rest	  in	  healthy	  individuals	  reduced	  some	  metabolic	  
markers	  of	  physiologic	  function	  down	  to	  the	  level	  that	  is	  witnessed	  in	  T2D	  offspring	  prior	  to	  bed	  
rest.	  Changes	  at	   the	   level	  of	   gene	  expression	  have	  been	   seen	  with	  9	  days	  of	  bed	   rest	  where	  
several	   insulin	   resistance	   and	   diabetes	   candidate	   genes	   had	   been	   altered	   in	   healthy	  
individuals.2	   Even	   after	   4	   weeks	   of	   exercise	   training	   only	   part	   of	   the	   4500	   genes,	   that	   were	  
initially	   altered,	   were	   partially	   normalized	   to	   the	   pre-­‐bed	   rest	   levels.	   The	   lack	   of	   complete	  
normalization	   underscores	   the	   importance	   of	   maintaining	   the	   minimum	   daily	   exercise	  
recommendations.	  
III. Inactivity	  and	  the	  endothelium:	  	  
	  The	  1953	  study	  conducted	  by	  Morris	  et	  al.	  42	  found	  that	  there	  was	  an	  increased	  incidence	  
of	   coronary	   thrombosis	   for	   the	   drivers	   of	   London’s	   double-­‐decker	   buses	   compared	   to	   the	  
conductors.42	  A	  study	  by	  the	  same	  group	  in	  1958	  found	  that	   ischemic	  myocardial	   fibrosis	  was	  
more	  common	   in	   light	   (sedentary)	  occupations	  and	   it	  appeared	  earlier	   in	   this	  group.42	   It	   also	  
seemed	  to	  be	  more	  severe	  among	  these	  sedentary	  workers,	  especially	  at	  younger	  ages.	  A	  30	  
year	   follow-­‐up	  on	   the	  widely	   cited	  1966	  Dallas	  Bed	  Rest	   study	  presented	  data	  on	   changes	   in	  
VO2max,	   CO	   and	   SV	   that	   emphasized	   the	   detrimental	   role	   of	   inactivity	   on	   cardiovascular	  
health.39	  The	  most	  remarkable	  finding	  was	  that	  3	  weeks	  of	  bed	  rest	   in	  1966	  caused	  a	  greater	  
deterioration	   in	  cardiovascular	  and	  physical	  work	  capacity	   than	  did	  30	  years	  of	  aging	   in	  the	  5	  




Physical	  inactivity	  is	  also	  associated	  with	  changes	  in	  hemodynamic	  stimuli	  which	  exert	  direct	  
effects	   on	   the	   vasculature,	   leading	   to	   remodeling	   and	   a	   proatherogenic	   phenotype.58	   It	   can	  
have	  a	  marked	  effect	  on	  conduit	  arterial	  lumen	  dimension.	  	  There	  are	  dose	  and	  time	  dependent	  
decreases	  in	  arterial	  size	  in	  response	  to	  physical	  inactivity.	  Studies	  that	  looked	  at	  the	  effect	  of	  
inactivity	  of	   the	   lower	   limbs	  and	   femoral	   artery	  diameter	   via	   FMD	   found	   that	   the	  number	  of	  
days	  that	  the	  subjects’	  lower	  limb	  was	  inactive	  was	  directly	  related	  to	  the	  percentage	  decrease	  
in	  femoral	  artery	  diameter.58	  Physical	  inactivity	  leads	  to	  arterial	  stiffness	  in	  subjects	  with	  spinal	  
cord	  injury	  and	  there	  is	  a	  general	  consensus	  in	  the	  literature	  that	  that	  basal	  vascular	  resistance	  
increases	   with	   increased	   physical	   inactivity.	   Increased	   plasma	   levels	   of	   ET1	   (a	   potent	  
vasoconstrictor)	   have	   been	   reported	   after	   4-­‐8	   weeks	   of	   detraining	   in	   healthy	   individuals.36	  
However,	  most	  of	   the	  work	   in	   this	  area	  has	  been	  done	  on	   individuals	  with	  spinal	  cord	   injury,	  
bed-­‐rest	  and	  limb	  immobilization.	  	  
	  
IV. Models	  of	  Inactivity:	  
In	  the	  spinal	  cord	  injury	  and	  limb	  immobilization	  (where	  the	  limb	  is	  in	  a	  cast)	  models,	  there	  
is	   the	  possibility	   that	  the	  disease	  state	  or	  recovery	  processes	  are	  causing	  systemic	  changes	   in	  
the	  endothelium.	  The	   inactivity	  studies	  that	  have	  traditionally	   involved	  complete	  bed-­‐rest	  are	  
also	   extreme	   cases	   because	   these	   models	   lead	   to	   changes	   in	   the	   cardiac,	   respiratory,	   renal	  
systems	   and	   on	   the	   endothelium	   itself.32	   While	   these	   inactivity	   models	   have	   provided	  
invaluable	   information	   about	   the	   detrimental	   effects	   of	   inactivity	   on	   the	   endothelium,	   the	  




were	   placed	   cannot	   be	   disregarded.	   In	   order	   to	   truly	   assess	   the	   effect	   of	   inactivity	   on	   the	  
endothelium	  a	  healthy	  group	  of	  adults	  without	  pre-­‐existing	  diseases	  needs	  to	  be	  studied.	  	  
	  
V. Inactivity	  and	  Nitric	  oxide:	  
a. Importance	  of	  NO	  for	  the	  endothelium	  
Vascular	  endothelial	  cells	  produce	  nitric	  oxide	  (NO)	  by	  the	  enzyme	  NO	  synthase	  (NOS).	  
eNOS,	   the	   predominant	   NOS	   isoform	   in	   the	   vasculature	   is	   responsible	   for	   most	   of	   the	   NO	  
produced	  in	  this	  tissue.14	  	  This	  basal	  NO	  production	  can	  be	  enhanced	  by	  agonists	  such	  as	  Ach,	  
increased	  shearing	  forces	  (e.g.	  exercise	  where	  there	  is	  an	  increase	  in	  blood	  flow)	  and	  under	  the	  
influence	  of	  certain	  cytokines	  during	  inflammation	  and	  infection.31	  NO	  relaxes	  smooth	  muscle,	  
inhibits	  platelet	  function	  and	  inhibits	  inflammatory	  responses.	  It	  represents	  the	  most	  important	  
anti-­‐atherogenic	  defense	  component	  of	  the	  vasculature.14	  
Endothelial	  dysfunction	   is	   frequently	  encountered	  when	  cardiovascular	  risk	   factors	  are	  
present.15	   Cardiovascular	   risk	   factors	   increase	   the	   expression	   and	   activity	   of	  NADPH	  oxidases	  
(NOX)	   in	   the	   vascular	  wall	   which	   enhances	   the	   production	   of	   reactive	   oxygen	   species	   (ROS).	  
Hypertensive	  rats,	  hypercholesterolemia	  and	  models	  of	  diabetes	  mellitus	  have	  been	  associated	  
with	   increased	  activation	  of	  NOX.23,65	  There	   is	  a	  growing	  body	  of	  evidence	   that	  vascular	  NOX	  
plays	   a	   crucial	   role	   in	   the	   phenomenon	   of	   eNOS	   uncoupling	   in	   humans.	  NOS	   uncoupling	   has	  
been	   observed	   in	   patients	  with	   endothelial	   dysfunction	   resulting	   from	  hypercholesterolemia,	  




Endothelial	  nitric	  oxide	  is	  essential	  for	  the	  proper	  functioning	  and	  signaling	  processes	  for	  
CACs,	   which	   play	   an	   important	   role	   in	   protecting	   the	   endothelium.	   Mice	   deficient	   in	   eNOS	  
showed	  reduced	  basal	  CAC	  mobilization	  from	  the	  bone	  marrow1	  as	  well	  as	  CAC	  mobilization	  in	  
response	  to	  exercise	  training.34	  This	  may	  contribute	  to	  the	  reduced	  reparative	  capacity	  of	  these	  
cells	   in	   individuals	  with	  CVD	  who	  have	  a	   reduced	  NO	  bioavailability.	  While	   reduced	  numbers	  
and	   function	   of	   CACs	   have	   been	   linked	   to	   eNOS	   uncoupling	   in	   diabetic	   individuals,	  
differentiation	  and	  adhesion	   into	  pre-­‐existing	   vasculature	   is	   found	   to	  be	   impaired	  with	  eNOS	  
inhibition	  in	  others.60	  	  Therefore,	  decreased	  NO	  bioavailability	  may	  affect	  CACs	  mobilization	  and	  
function.	  
b. Sirt1-­‐	  regulator	  of	  NO:	  
Sirt1,	  also	  known	  as	  Sirtuin1	   is	  an	  NAD+	  dependent	  class	   III	  histone	  deacytelase	  and	  a	  
key	   regulator	   of	   vascular	   endothelial	   homeostasis.49	   Recently,	   it	   was	   shown	   that	   Sirt1	  
expression	   and	   activity	   control	   eNOS	   activity	   via	   deacetylation	   of	   eNOS	   in	   endothelial	   cells.9	  
Blocking	  Sirt1	   function	  via	   transduction	  of	  endothelial	   cells	  with	  a	  deacetylase	  defective	  SIrt1	  
mutant	   decreased	   NO-­‐bioavailability	   and	   decreased	   endothelial-­‐dependent	   vasodilation.38	  	  
Since	   most	   studies	   related	   to	   Sirt1	   have	   been	   related	   to	   caloric	   restriction,	   its	   response	   to	  
exercise	  is	  not	  well	  understood.	  	  	  
Shear	   stress	   on	   endothelial	   cells	   has	   shown	   an	   increase	   in	   Sirt1	   expression	   which	  
correlated	  with	   an	   increase	   in	  NO	  bioavailability.72,38	   Shear	   stress,	   such	   as	   that	  which	   can	  be	  
generated	   by	   blood	   flow	   during	   exercise,	   has	   shown	   to	   accelerate	   the	   proliferation,	  




player	   in	   the	   migration,	   differentiation	   and	   adhesion	   of	   CACs,	   it	   would	   be	   interesting	   to	  
understand	  the	  role	  of	  Sirt1	  in	  its	  regulation	  in	  healthy	  individuals	  independent	  of	  disease.	  
c. Inactivity	  ,	  Sirt1,	  eNOS:	  
Endothelial	   nitric	   oxide	   synthase	   (eNOS)	   function	   and	   consequently	   NO	   production	   is	  
impaired	  with	  physical	  inactivity.33	  	  As	  mentioned	  above,	  while	  decreased	  NADPH	  oxidase	  may	  
in	   part	   be	   responsible	   for	   increased	   CAC	   NOi	   with	   exercise	   training27,	   there	   are	   likely	   other	  
unexplored	  factors	  that	  contribute	  to	  changes	   in	  CAC	  NOi	  related	  to	  exercise	  and	  inactivity.	   If	  
that	   is	   the	   case,	   it	  would	  be	  beneficial	   for	   us	   to	   start	   by	   investigating	   the	  effects	   of	   reduced	  
physical	  activity	  on	  Sirt1,	  which	  ultimately	  controls	  vascular	  homeostasis	  via	  the	  deacetylation	  
of	  eNOS	  in	  CAC.	  This	  will	  not	  only	  inform	  us	  about	  the	  effects	  of	  detraining	  on	  a	  key	  marker	  of	  





Figure	  4.	   	  Genes	   that	  are	  direct	   and	   indirect	   regulators	  of	  nitric	  oxide	   in	   CACs.	  eNOS,	   Sirt1,	  
Cav1,	   SOD1	   can	   lead	   to	   increase	   in	   nitric	   oxide	   production	   whereas	   the	   different	   NADPH	  
(activated	  by	  its	  subunits	  p47phox,	  nox2,	  nox4)	  can	  inhibit	  nitric	  oxide	  production	  while	  causing	  
















2.6 Summary	  of	  literature	  review	  
	  
Traditional	   risk	   factors	   for	   CVD	   do	   not	   inform	   us	   about	   changes	   in	   the	   vasculature	  
although	   damage	   to	   the	   vascular	   endothelium	   is	   one	   of	   the	   first	   signs	   of	   CVD	   progression.	  
Circulating	   angiogenic	   cells	   (CACs)	   are	   responsible	   for	   the	   maintenance	   and	   repair	   of	   the	  
vasculature	   and	   are	   a	   novel	   biomarker	   that	  may	   allow	   for	   the	   early	   detection	   of	   CVD.	   	   CAC	  
function	   is	   strongly	   correlated	  with	   the	  Framingham	  Risk	   Score	   for	  CVD	  and	  CAC	  dysfunction	  
found	  in	  individuals	  with	  CVD.	  	  
Few	  studies	  on	  healthy,	  active	  individuals	  suggest	  that	  exercise	  plays	  an	  important	  role	  
in	  maintaining	  CAC	   function	  when	   compared	   to	   their	   sedentary	   counterparts.	   The	   causes	   for	  
decreases	   in	   CAC	   function	   in	   sedentary,	   healthy	   individuals	   compared	   to	   active,	   healthy	  
individuals	  are	  not	  fully	  known.	  However,	  data	  suggests	  a	  cardio-­‐protective	  effect	  of	  exercise	  on	  
CACs.	   In	  contrast,	   inactivity	   is	   linked	  to	  CVD	  and	  CVD	  risk	  factors	  and	   is	  a	  growing	  problem	  in	  
industrialized	  and	  developing	  nations.	  	  Inactivity	  studies	  involving	  bed-­‐rest,	  limb	  immobilization	  
and	  spinal	  cord	   injury	  have	  shown	  that	   inactivity	  can	  have	  deleterious	  effects	  on	  the	  vascular	  
endothelium.	   However,	   these	   models	   represent	   extreme	   situations	   and	   have	   confounding	  
factors	  (such	  as	  the	  disease	  state)	  inherent	  in	  them.	  In	  order	  to	  study	  the	  effects	  of	  inactivity	  on	  
the	  vascular	  endothelium	  and	  on	  CACs,	  which	  may	  be	  an	  early	  biomarker	  of	  vascular	  damage,	  
we	  propose	  to	  study	  active,	  healthy	  individuals	  and	  reducing	  their	  physical	  structured	  activity.	  
	  In	  this	  study,	  we	  will	  explore	  a	  potential	  mechanism	  for	  changes	   in	  CAC	  function	  with	  
reduced	   physical	   activity.	   	   Cross-­‐sectional	   data	   comparing	   sedentary	   versus	   active,	   healthy	  




related	   to	   nitric	   oxide	   (NO)	   bioavailability	   and	   signaling	   in	   CACs.	   	   Nitric	   oxide	   is	   not	   only	  
important	  for	  the	  functioning	  of	  a	  healthy	  endothelium	  but	  also	  for	  the	  normal	  functioning	  of	  
CACs.	   There	   are	   several	   regulators	   of	   NO	   and	   their	   up-­‐regulation	   or	   down-­‐regulation	   can	  
provide	  us	  with	  information	  regarding	  the	  effect	  of	  the	  inactivity	  perturbation	  on	  NO	  and	  CAC	  
function.	   By	   using	   a	  model	   where	   healthy,	   active	   individuals	   are	   asked	   not	   to	   perform	   their	  
regular	  structured	  exercise	   for	  a	  short	  period	  of	   time,	  we	  hope	  to	  elucidate	   the	  early	  cellular	  

















CHAPTER	  3	  	  
METHODS	  
3.1	  	   Introduction	  
The	   primary	   aim	   of	   this	   study	  was	   to	   examine	   the	   effect	   of	   reduced	   physical	   activity	  
(rPA)	   which	   we	   defined	   as	   10	   days	   of	   reduced	   physical	   activity,	   on	   two	   populations	   of	   CAC	  
(circulating	   angiogenic	   cells).	   This	   chapter	   outlines	   the	   methods	   employed	   to	   answer	   these	  
questions.	  
3.2	  	   Subjects	  	  
The	   participants	   for	   this	   study	  were	   healthy,	   non-­‐smoking	  male	   runners	   between	   the	  
ages	  of	  18-­‐50	  with	  a	  training	  history	  of	  at	  least	  5	  years.	  Participants	  who	  exercised	  above	  3	  days	  
a	  week	  with	  moderate	  to	  intense	  endurance	  exercise	  were	  recruited	  for	  this	  study.	  	  Participants	  
were	   screened	   for	   adequate	   training	   history	   including	   miles	   run	   per	   week	   and	   competition	  
history.	  They	  were	  further	  screened	  for	  history	  of	  cardiovascular,	  lung,	  liver	  disease,	  diabetes	  or	  
cancer,	  and	  they	  could	  not	  be	  on	  any	  medications	  that	  could	  influence	  CAC	  number	  or	  function.	  
Participants	  were	  asked	  to	  stop	  taking	  any	  vitamins	  and	  other	  over	  the	  counter	  medications	  for	  
the	  duration	  of	  this	  study.	  We	  accounted	  for	  these	  factors	  with	  the	  health	  history	  and	  physical	  
activity	  questionnaires.	  (see	  6.2,	  6.3	  in	  Appendix)	  We	  did	  not	  include	  women	  in	  this	  study	  due	  
to	  the	  gender	  differences	  associated	  with	  the	  number	  and	  function	  of	  CACs	  and	  the	  influences	  
of	  the	  uterine	  cycle	  on	  CACs.	  12,25	  	   	  
3.3	   	  Experimental	  Set-­‐up	  
Physical	   activity	   monitors	   (ActiGraph	   GT3X	   and	   Omron	   pedometer)	   were	   used	   to	  




Activity	   logs	   and	   diet	   recalls	   were	   used	   to	   further	   evaluate	   energy	   expenditure	   and	   energy	  
intake	  respectively.	   (see	  6.4-­‐6.8	   in	  Appendix).	  Standard	  blood	  draw	  procedures	  were	  used	  for	  
the	  venipuncture.	  Blood	  for	  CACs	  was	  collected	   into	  6	  EDTA-­‐coated	  10ml	  tubes.	  We	  collected	  
60	  mls	   per	   draw.	   Lipid	   profile	   was	   also	  measured	   at	   baseline	   and	   rPA.	   Baseline	   lipid	   profile	  
results	  were	   also	  used	   as	   an	   additional	   screening	  measure	   to	   verify	   that	   participants	   did	  not	  
have	  any	  CV	  risk	  factors.	  Heart	  rate,	  blood	  pressure	  and	  weight	  were	  recorded	  at	  every	  visit.	  	  
3.4 Protocols	  
	  
Physical	  activity	  measurements	  and	  energy	  expenditure:	  
During	  the	  1st	  visit	  the	  participants	  filled	  out	  and	  handed	  in	  the	  questionnaires	  (physical	  
activity	  and	  health	  history),	  and	  their	  signed	  informed	  consents.	  (see	  6.1-­‐6.3	   in	  Appendix)	  We	  
measured	   their	  weight,	   HR,	   stride	   length	   and	   BP	   during	   this	   time.	  We	   also	   fit	   them	  with	   an	  
Omron	  pedometer	  and	   initialized	  the	  ActiGraph	  GT3X	  activity	  monitor	  for	  them	  to	  wear	  for	  a	  
week,	  with	  specific	   instructions	  of	  when	  to	  wear	  them	  and	  how	  to	  use	  the	  monitor	   logs.	   (see	  
6.4	   in	  Appendix)	  ActiGraph	  and	   the	  pedometer	  were	  worn	  on	   their	   left	   hip,	   secured	  with	   an	  








given	  with	  logs 
Diet	  log	  given 
Visit	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  3 
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  and	  
Diet	  data 
Activity	  monitors	  and	  diet	  
logs	  given	  with	  specific	  
instructions 
Blood	  draw	  2 




ActiGraph	  GT3X	  monitor	  using	  their	  monitor	  logs,	  to	  confirm	  their	  physical	  activity	  levels	  were	  
consistent	  with	  those	  in	  their	  physical	  activity	  questionnaires.	  If	  the	  subjects	  qualified	  in	  terms	  
of	   their	  physical	  activity	  requirement	  and	  their	   lipid	  profile	  results	  were	  all	  within	  the	  normal	  
range,	   then	   they	   were	   asked	   to	   come	   in	   for	   their	   2nd	   visit.	   The	   Actigraph	   data	   from	   their	  
baseline	  week	  was	  further	  analyzed	  using	  the	  NeuralNetwork	  through	  a	  website	  developed	  by	  
Staudenmayer	  et	  al.79	  to	  calculate	  their	  EE	  (energy	  expenditure)	  in	  kcals	  for	  all	  activities	  over	  3	  
METs.	   The	   output	   from	   the	   NeuralNetwork	   utilized	   for	   kcal	   calculations	   was	   the	   METs	  
(kcal/kg/hr).	  This	  was	  used	  to	  approximate	  each	  individual’s	  EE	  based	  on	  their	  body	  weight	  and	  
time	  spent	  in	  activities	  above	  3	  METs	  (approximated	  as	  average	  kcals/day).	  
The	  ActiGraph	  measured	  acceleration	   in	  3	  axes	  and	  over	  a	   specified	   time	  period	   (epoch).	  
The	   acceleration	   signal	   outputs	   helped	   us	   distinguish	   between	   activity	   intensity	   (sedentary,	  
moderate,	   vigorous	   and	   very	   vigorous)	   based	   on	   Freedson	   cut-­‐points80	   using	   the	   ActiLife	  
software.	  Data	  were	   analyzed	   as	   average	  number	  of	  minutes	   spent	   at	   each	   activity	   level	   per	  
day.	   In	   addition	   to	   this,	   participants	  were	   asked	   to	  wear	   the	  Omron	  pedometer	   at	   all	   times,	  
except	   for	  when	   they	  were	   exercising,	   during	   their	   baseline	  week.	   	   They	  were	   also	   asked	   to	  
note	   their	   step	   count	   at	   the	  end	  of	   each	  day	   in	   the	  activity	  monitor	   log.	   From	   their	  baseline	  
week,	  the	  average	  number	  of	  steps/day	  were	  calculated	  and	  participants	  were	  asked	  to	  stay	  at	  
this	  number	  during	  rPA.	  	  
Dietary	  monitoring	  and	  energy	  intake:	  
Participants	  were	  carefully	   counseled	  on	   the	   requirements	   for	   the	   study	   including	  dietary	  




nitrate	  diet	  (see	  6.6	  in	  Appendix)	  3	  days	  prior	  to	  coming	  in	  for	  their	  2nd	  visit	  as	  well	  as	  a	  checklist	  
of	   activities,	   foods	   and	  medications	   to	   avoid	   for	   the	   24	   hours	   prior	   to	   coming	   in.	   (see	   6.5	   in	  
Appendix)	   They	   were	   also	   told	   that	   they	   would	   have	   to	   respond	   to	   3	   dietary	   recalls	   (on	   2	  
weekdays	  and	  1	  weekend	  day)	  over	  the	  course	  of	  the	  baseline	  week,	  which	  was	  administered	  
by	   us	   through	   the	  ASA24	   (Automated	   self	   administered	   24-­‐hour	   dietary	   recall)	   developed	  by	  
the	   National	   Cancer	   Institute	   (url:	  	  
http://appliedresearch.cancer.gov/tools/instruments/asa24/).	   The	   data	   from	   their	   dietary	  
recalls	  were	  used	  to	  calculate	  their	  average	  EI	   (energy	   intake)	   in	  kcals/day.	  Based	  on	  this,	  we	  
calculated	  EI	  –	  EE	  and	  this	  number	  was	  recommended	  to	  them	  as	  their	  goal	  for	  daily	  kcal	  intake	  
for	   their	   10	   days	   in	   rPA.	   We	   created	   an	   account	   for	   each	   subject	   on	   myfitnesspal	   (url:	  
http://www.myfitnesspal.com),	  a	  website	  to	  help	  them	  keep	  track	  of	  their	  daily	  energy	  intake	  
based	  on	  our	  EI	  –	  EE	  kcal	  recommendation.	  Since	  this	  was	  a	  shared	  account,	  we	  could	  also	  log	  
into	  the	  participant’s	  account	  to	  help	  them	  maintain	  their	  goal.	  	  
Cell	  culture	  protocols	  
a. Colony	  forming	  units	  (CFU-­‐Hill)	  assay:	  
CFUs	  were	   cultured	   after	   the	   baseline	   and	   final	   visit.	   	   CFU	   stands	   for	   colony	   forming	  
units.	  The	  CFU-­‐Hill	  assay	  is	  a	  5-­‐day	  culture	  method	  developed	  by	  Hill	  et	  al.	  used	  to	  assess	  CACs	  
based	  on	  CFU	  growth.21	  The	  CFU-­‐Hill	  kit	  was	  purchased	  from	  StemCell	  technologies.	  Peripheral	  
blood	   mononuclear	   cells	   (PBMCs)	   were	   isolated	   from	   the	   blood	   samples	   via	   density	  
centrifugation	  (Ficoll-­‐Paque),	  then	  washed.	  	  	  PBMCs	  were	  placed	  at	  a	  density	  of	  5	  X	  106	  cells	  per	  




(37°,	  5%	  CO2,	  ≥95%	  humidity).	  After	  2	  days,	  non-­‐adherent	  cells	  were	  removed	  and	  counted	  with	  
a	  hemocytometer.	  1	  X	  106	  of	  the	  non	  adherent	  cells	  were	  re-­‐plated	  on	  Day	  2	  into	  wells	  of	  a	  24-­‐
well	   fibronectin-­‐coated	  plate	  with	   fresh	  CFU-­‐Hill	  media.	   	   Cells	  were	   cultured	  under	   the	   same	  
conditions	   (37°,	  5%	  CO2,	  ≥95%	  humidity)	   for	  3	  more	  days.	   	  On	  Day	  5,	   the	  number	  CFUs	  were	  
counted.	   	  CFU	  was	   characterized	  as	  a	   cluster	  of	   cells	   that	   form	  a	   round	  center	  with	  outward	  
radiating	  cells	  and	  quantified	  as	  average	  CFU/well.	  (see	  6.9	  in	  Appendix)	  	  
b. CD34+	  cell	  isolation	  
PBMCs	  were	  isolated	  as	  described	  above	  and	  used	  for	  isolation	  of	  CD34+	  cells.	  These	  
cells	   were	   isolated	   with	   magnetic	   bead	   separation,	   using	   an	   EasySep	   Magnet	   (StemCell	  
Technologies,	  Vancouver,	  BC).	  PBMCs	  were	  suspended	  in	  PBS	  +	  2%	  FBS	  with	  EDTA	  at	  a	  density	  
of	  1.5x105.	   	  The	  CD34+	  selection	  antibody	  cocktail	  was	  added	  at	  100	  uL/ml.	   	  The	  cell/antibody	  
suspension	  was	  incubated	  at	  room	  temperature	  for	  15	  min.	  Magnetic	  nanoparticles	  specifically	  
designed	  to	  select	  CD34+	  cells	  were	  added	  to	  this	  mixture	  (	  100uL/ml)	  and	  incubated	  for	  10	  min.	  
PBS	   +	   2%	   FBS	  with	   EDTA	  was	   added	   to	   a	   volume	   of	   2.5ml	   then	   the	   tube	  was	   placed	   in	   the	  
magnet	  for	  10	  min.	  	  CD34+	  cells	  remain	  magnetically	  attached	  to	  the	  side	  of	  the	  tube	  while	  the	  
supernatant	  was	  poured	  into	  a	  second	  tube	  and	  put	   into	  the	  magnet	  for	  another	  10	  minutes.	  
After	  the	  10	  minutes,	   the	  cells	   that	  were	  poured	  out	  went	  towards	  the	  CD34-­‐	  cells.	  2.5	  ml	  of	  
PBS	  +	  2%	  FBS	  with	  EDTA	  was	  added	  to	  the	  1st	  tube	  which	  was	  put	  into	  the	  magnet	  again	  for	  10	  
minute.	   The	   cells	   that	  were	   poured	  out	  were	   added	   to	   the	  CD34-­‐	   cells.	   The	  CD34+	   cells	   that	  
were	  attached	  to	  the	  walls	  of	  the	  tubes	  were	  collected	   in	  300uL	  of	  1xPBS	  and	  the	  number	  of	  




We	  assessed	  CD34+	  cell	  yield	  with	  this	  protocol	  via	  flow	  cytometry	  analysis.	  CD34+	  cells	  
are	  found	  in	  less	  than	  0.01%	  of	  PBMCs.	  	  We	  found	  that	  our	  protocol	  enriched	  cells	  60%	  (0.6%,	  
see	  6.15	  in	  Appendix).	  	  Cell	  purity	  was	  assessed	  from	  a	  similar	  protocol	  by	  Jenkins,	  et	  al.77	  who	  
reported	  59%	  purity	  in	  the	  positively	  selected	  fraction.	  
c. Intracellular	  Nitric	  Oxide	  (NOi):	  	  
Intracellular	  Nitric	  Oxide	  (NOi)	  was	  measured	  in	  freshly-­‐isolated	  CD34+	  cells	  and	  CFU-­‐Hill	  
cultured	   cells	   using	   4-­‐amino-­‐5-­‐methylamino-­‐2’,7’-­‐difluorofluorescein	   (DAF-­‐FM)	   diacetate	  
fluorescent	   dye	   (Invitrogen,	   Carlsband,	   CA).27	   DAF-­‐FM	   diacetate	   emits	   fluorescence	   when	  
reacting	   with	   an	   intermediate	   of	   NO	   as	   NO	   is	   oxidized	   to	   NO2-­‐.	   	   10uM	  DAF-­‐FM	   in	   PBS	  was	  
added	   to	   the	   cells	   and	   incubated	   for	   30	   minutes	   at	   37°C.	   	   NOi	   was	   measured	   with	   a	  
fluorescence	   plate	   reader	   (PolarStar	   Optima,	   BMG	   Labtech)	   with	   excitation	   and	   emission	  
wavelengths	  of	  488	  and	  535nm,	  respectively.	  	  Wells	  including	  unloaded	  cells,	  no	  cells	  and	  DAF-­‐
FM	  dye,	  and	  PBS	  were	  used	  as	   florescence	  controls.	  We	  added	  an	  additional	  positive	  control	  
SIN-­‐1	  (nitric	  oxide	  donor)	  on	  each	  plate,	  at	  known	  concentrations	  (see	  6.12,	  6.13	  in	  Appendix).	  
Several	   pilot	   tests	   were	   conducted	   to	   test	   for	   the	   appropriate	   gain	   settings,	   DAF-­‐FM	  
concentrations,	   SIN-­‐1	   concentrations	   and	   later,	   to	   account	   for	   intra-­‐assay	   and	   inter-­‐assay	  
variability	  6.5%	  and	  1.1%	  respectively.	  
d. Gene	  expression:	  
RNA	  was	  isolated	  from	  freshly-­‐isolated	  CD34+	  cells	  and	  the	  CFU-­‐Hill	  cells	  at	  the	  5th	  day	  of	  
the	  culture	  assay,	  utilizing	  Trizol	  Reagent.	  The	   isolated	  RNA	  was	  quantified	  using	  a	  Nanodrop	  




master	  mix	  (BioRad).	  	  All	  8	  primers	  used	  for	  the	  gene	  expression	  were	  designed	  and	  purchased	  
from	  Integrated	  DNA	  Technologies	  (Coralville,	  IA).	  Each	  primer	  pair	  was	  optimized	  to	  determine	  
the	  most	  optimal	   temperature	   and	   concentration	   for	   an	  efficiency	  of	   >90%,	  using	   EvaSsofast	  
PCR	  mastermix	   (BioRad,	  Hercules,	  CA).	  All	   gene	  expression	  analyses	  were	   run	   in	   triplicate	  on	  
the	   CFX96	   RT-­‐PCR	   machine	   (Biorad)	   with	   GAPDH	   as	   the	   control	   gene.	   The	   genes	   that	   we	  
analyzed	  were:	  Enos,	  Nox2,	  Nox4,	  Cav1,	  Sirt1,	  P47,	  Sod1	  and	  Inos	  in	  order	  to	  evaluate	  changes	  
in	  nitric	  oxide	  and	  its	  regulators	  after	  rPA.	  The	  results	  were	  analyzed	  and	  presented	  based	  on	  
∆Ct	   values	   and	   fold	   change,	   respectively.	   The	   full	   names,	   functions,	   and	   primer	   pairs	   of	   the	  
analyzed	  genes	  are	  in	  Table	  1.	  	  
Table	  1.	  Names	  and	  regulatory	  roles	  of	  genes	  related	  to	  nitric	  oxide	  




Full	  gene	  name	   Regulatory	  role	  w.r.t.	  nitric	  oxide	   F	  (forward)	  and	  R	  (reverse)	  primer	  sequence	  (5-­‐3'	  direction)	  
Enos	  ,Nos3	   endothelial	   nitric	  oxide	  synthase	   Controls	  availability	  of	  nitric	  oxide
31	  
F:	   GAGGGGAGCTGTTGTAGGG	  	  
R:	   GTGGTAACCAGCACATTTGG	  	  
Cav1	   Caveolin	  1	   eNOS	  related	  membrane	  protein16	  
F:	   AATACTGGTTTTACCGCTTGCT	  
R:	   ATGCCGTCAAAACTGTGTGTC	  
Ssirt1	   Sirtuin	  1	   Regulation	   of	   eNOS	   via	  deacetylation9	  
F:	   CAGTGGCTGGAACAGTGAGA	  
R:	   TCTGGCATGTCCCACTATCA	  
Sod1	   Superoxide	  dismutase	  
Antioxidant	   that	   metabolizes	  
superoxide	   radicals	   and	   prevents	  
oxygen	  toxicity	  45	  
F:	   ATG	  ACT	  TGG	  GCA	  AAG	  GTG	  GAA	  ATG	  
R:	   GTT	  AAG	  GGG	  CCT	  CAG	  ACT	  ACA	  TCC	  
Nox2,	  Cybb	  
NADPH	  oxidase	  2	  
(also	   known	   as	  
gp91phox)	  
Subunit	   of	   NADPH	   oxidase	  
contributing	  to	  ROS	  formation47	  
F:	   AGG	  ATT	  GCC	  TGA	  AGG	  GTT	  CT	  
R:	   AGG	  GCT	  AGC	  TGG	  AGA	  AGA	  CC	  
Nox4	   NADPH	  oxidase	  4	  	   Subunit	   of	   NADPH	   oxidase	  contributing	  to	  ROS	  formation47	  
F:	   CAG	  AAG	  GTT	  CCA	  AGC	  AGG	  AG	  
R:	   GTT	  GAG	  GGC	  ATT	  CAC	  CAG	  AT	  
P47	   phox,	  
Ncf1	  
Phagocytic	  
NADPH	   oxidase	  
subunit	  
Phosphorylation	   of	   p47(phox)	  
subunit	  marks	  NADPH	  activation71	  
F:	   CAC	  GGA	  CAA	  CCA	  GAC	  AAA	  AA	  
R:	   AGA	  ACC	  ACC	  AAC	  CGC	  TCT	  C	  
Inos,	  Nos2	  
Phagocytic	  
NADPH	   oxidase	  
subunit	  
Produces	   NO	   in	   large	   quantities	   in	  
hematopoietic	  cells59	  
F:	   GGC	  CGC	  AGA	  GAA	  CTC	  AGC	  CTC	  A	  





3.5	  	  	   Statistical	  Analyses	  
All	   statistical	   analyses	   were	   performed	   using	   Minitab	   statistical	   software.	   Analyses	  
consisted	  of	  paired	  Student	  T-­‐test	  to	  determine	  differences	  in	  CFU-­‐Hill	  colonies,	  NOi	  and	  gene	  
expression	   from	   before	   to	   after	   10	   days	   of	   rPA.	   	   Correlations	   were	   used	   to	   determine	   the	  
relationship	   between	   the	   change	   in	   CAC	   function	  with	   rPA	   and	   the	   change	   in	   CAC	   NO	   gene	  
regulators.	   	   Reverse	   stepwise	   multiple	   regression	   analysis	   was	   performed	   to	   determine	  
significant	  predictors	  of	  changes	  in	  CFU-­‐Hill,	  and	  NOi.	  Statistical	  significance	  was	  accepted	  at	  an	  
alpha	  level	  of	  less	  than	  0.05.	  	  From	  the	  three	  variables	  analyzed,	  that	  with	  the	  largest	  estimated	  
sample	  size	  (NOi)	  was	  used.27	  To	  obtain	  appropriate	  statistical	  power	  (beta	  =	  0.8;	  alpha	  0.05),	  
10	   participants	   were	   needed.	   Calculations	   were	   based	   on	   an	   effect	   size	   of	   0.6	   Relative	  
fluorescence	  units	  (RFU),	  with	  a	  standard	  deviation	  of	  0.51RFU.	  




CHAPTER	  4	  	  
RESULTS	  
	  
All	   subjects	   recruited	   for	   the	   study	  were	   healthy	   and	   physically	   active.	   Individuals	   on	  
medication	   and	   who	   had	   injuries	   within	   the	   past	   6	  months	   were	   not	   included	   in	   the	   study.	  
Subjects	  were	  primarily	   runners,	  with	  greater	   than	  5	  years	  of	   running	  history.	   	  The	  Actigraph	  
data	  from	  their	  baseline	  week	  was	  used	  to	  verify	  that	  they	  were	  currently	  active.	  	  10	  subjects	  
were	  recruited	  and	  completed	  this	  study.	  However,	  2	  subjects	  were	  excluded	  from	  all	  analyses	  
because	  one	  subject	  did	  not	  adhere	  to	  the	  no-­‐caffeine	  and	  no-­‐alcohol	  requirements	  during	  the	  
24	  hours	  prior	  to	  coming	  in	  for	  the	  final	  visit.	  The	  other	  subject	  was	  excluded	  from	  all	  analyses	  
due	   to	   their	  non-­‐adherence	  of	  decreasing	  physical	   activity	  during	   the	  10	  days	  of	   inactivity	  as	  
shown	  by	  their	  Actigraph	  data	  (physical	  activity	  section	  below).	  	  
4.1	  Subject	  characteristics	  
Subject	  height,	  weight,	   blood	  pressure	  and	  heart	   rate	  was	  measured	  at	   every	   visit.	   In	  
addition	  to	  this,	  a	  lipid	  panel	  was	  evaluated	  by	  the	  lab	  at	  UHS	  during	  their	  screening	  visit	  and	  at	  
their	   final	   visit	   (Table	   1).	   Results	   from	   the	   lipid	   panel	   at	   the	   screening	   visit,	   was	   used	   to	  
determine	  the	  subjects’	  health	  status.	  	  As	  shown	  in	  Table	  1,	  cholesterol,	  triglycerides,	  HDL	  and	  
LDL	   for	  all	   subjects	  were	  within	   the	  normal	   range.	  Weight,	  blood	  pressure,	   resting	  heart	   rate	  
and	  lipid	  profile	  did	  not	  change	  significantly	  with	  rPA,	  compared	  to	  baseline.	  	  
Each	   subject’s	   energy	   expenditure	   was	   calculated	   in	   terms	   of	   kCals	   for	   activities	   >	   3	  




found	  to	  be	  360	  kcals/day.	  Their	  average	  EI	  (energy	  intake)	  based	  on	  data	  through	  their	  dietary	  
recalls	   (2	   week	   days,	   1	   weekend	   day)	   was	   1980	   kcals/day.	   Each	   subject’s	   average	   EE	   was	  
subtracted	  from	  their	  EI	  and	  that	  kcal	  number	  was	  recommended	  to	  them	  in	  order	  to	  maintain	  
their	  weight,	  which	  was	  accomplished	  as	  evidenced	  by	  no	  weight	  change	  from	  before	  to	  after	  
rPA	   (Table	   1,	   p=0.98).	   In	   addition	   to	   this,	   their	   pedometer	   data	   indicated	   that	   their	   average	  
steps/day	  did	  not	  differ	  greatly	  between	  baseline	  and	  rPA	  either	  (Table	  1,	  p=0.67).	  
Table	  2.	  Subject	  Characteristics	  
	  	  	   Baseline	   	   rPA	   	   	  	  
	  	   Mean	   ±	   SE	  	   	   Mean	  	   ±	   SE	  	   	   p-­‐value	  
Age	  (yrs)	  	   25	   ±	   3	   	   	  	   -­‐	   	  	   	   -­‐	  
Height	  (in)	  	   70.4	   ±	   0.8	   	   	  	   -­‐	   	  	   	   -­‐	  
Weight	  (kg)	  	   74.4	   ±	   2.6	   	   74.3	   ±	   2.6	   	   0.98	  
Steps/day	   7431	   ±	   793	   	   6757	   ±	   1339	   	   0.68	  
SBP	  (mmHg)	  	   119	   ±	   5	   	   122	   ±	   5	   	   0.92	  
DBP	  (mmHg)	  	   71	   ±	   4	   	   69	   ±	   2	   	   0.92	  
HR	  (bpm)	   63	   ±	   5	   	   61	   ±	   5	   	   0.76	  
TC	  (mg/dL)	  	   146	   ±	   10	   	   152	   ±	   11	   	   0.69	  
TG	  (mg/dL)	  	   58	   ±	   8	   	   52	   ±	   7	   	   0.57	  
HDL	  (mg/dL)	  	   53	   ±	   13	   	   52	   ±	   16	   	   0.87	  






4.2	  Physical	  activity	  
The	  physical	  activity	  data	  are	   represented	  as	   the	  average	  number	  of	  minutes	  spent	  at	  
each	  activity	   level	  per	  day.	   Figure	  4.	   represents	  all	   activities	  above	  3	  METs,	   termed	  as	  MVPA	  
(moderate-­‐vigorous	   physical	   activity)	   for	   baseline	   and	   rPA.	   The	   average	   amount	   of	   time	   in	  
MVPA	   at	   baseline	   was	   94.5	   minutes/day	   and	   this	   decreased	   by	   29%	   after	   rPA	   to	   67.1	  
minutes/day	  (p=0.11).	  	  The	  subject	  who	  was	  excluded	  from	  this	  study	  due	  to	  non-­‐adherence	  to	  
the	  study	  protocol	  had	   increased	   their	  MVPA	  by	  21%	  after	  rPA,	  relative	  to	  their	  baseline.	  The	  
activity	  monitor	  data	  for	  one	  of	  the	  subjects	  could	  not	  be	  downloaded	  thus	  the	  physical	  activity	  
analyses	  were	  run	  on	  the	  other	  7	  subjects.	  	  
While	   the	   MVPA	   was	   not	   significantly	   different	   between	   baseline	   and	   rPA,	   it	   is	   a	  
combined	  measure	  of	  physical	  activity.	  The	  individual	  components	  within	  MVPA	  provided	  more	  
information	  on	  how	  much	  time	  was	  spent	  by	  each	  subject	  at	  the	  moderate,	  vigorous	  and	  very	  
vigorous	   activity	   levels.	   Subjects	   spent	   an	   average	   of	   64.7	  minutes/day	   at	  moderate	   activity	  
(Figure	  8)	  which	  decreased	  by	  15.8%	  after	  rPA	  to	  54.5	  minutes/day;	  although,	  this	  decrease	  was	  
not	   significant	   (p=0.42).	   The	   average	   time	   spent	   in	   vigorous	   physical	   activity	   (Figure	   9)	   was	  
20.42	   minutes/day	   at	   baseline,	   which	   trended	   towards	   significance	   with	   a	   48.61%	   decrease	  
after	  rPA,	  to	  10.49	  minutes/day	  (p=0.08).	  Very	  vigorous	  activity	  (Figure	  4)	  was	  9.32	  minutes/day	  
at	   baseline,	   this	   also	   trended	   towards	   a	   significant	   decrease	   by	   77.46%	   after	   rPA	   to	   2.10	  
minutes/day	   (p=0.06).	   Combined	   vigorous	   and	   very	   vigorous	   activity	   (Figure	   8)	   was	   29.74	  




minutes/day	   (p=0.01).	   	   Average	   sedentary	   time	   at	   baseline	   increased	   by	   9.18%,	   from	  707.70	  
minutes/day	  to	  772.65	  minutes/day	  after	  rPA	  (p=0.18)	  (Figure	  9).	  
	  
Figure	  4.	  Moderate,	  vigorous	  and	  very	  vigorous	  physical	  activity	  (MVPA)	  in	  minutes	  per	  day	  for	  
baseline	  and	  rPA	  (p=0.42,	  n=7)	  
	  






Figure	  6.	  Vigorous	  physical	  activity	  in	  minutes	  per	  day	  for	  baseline	  and	  rPA	  (p=0.08,	  n=7)	  
	  
	  







Figure	  8.	  Vigorous	  and	  very	  vigorous	  physical	  activity	   in	  minutes	  per	  day	  for	  baseline	  and	  rPA	  








4.3	  Cell	  number	  
The	  average	  number	  of	  CD34+	  enriched	  cells	  per	  subject	  (obtained	  from	  45mls	  of	  blood	  
for	  each	  condition)	  was	  6.59	  x	  106	  cells	  at	  baseline	  (Figure	  7).	  The	  number	  of	  CD34+	  enriched	  
cells	  increased	  by	  9.5%	  after	  rPA	  to	  7.22	  x	  106	  cells	  (p=0.68).	  	  	  
The	   number	   of	   CFU-­‐Hill	   colonies	   significantly	   decreased	   after	   rPA,	   by	   35.69%	   from	  
baseline	   (Figure	   14).	   The	   average	   number	   of	   colonies	   decreased	   from	   16	   colonies/well	   at	  
baseline	  to	  approximately	  10	  colonies/well	  after	  rPA	  (p=0.01).	  	  
	  
	  





Figure	  11.	  CFU-­‐Hill	  colony	  numbers	  at	  baseline	  and	  rPA	  (p=0.01,	  n=8)	  
4.4.	  Intracellular	  Nitric	  Oxide	  
NOi	  (intracellular	  nitric	  oxide)	  was	  measured	  for	  both	  cell	  types	  at	  baseline	  and	  rPA.	  NOi	  
is	  represented	  as	  RFUs	  (relative	  fluorescence	  units)	  by	  using	  PBS	  as	  the	  control	  to	  calculate	  the	  
RFUs	  of	  the	  cells.	  	  CD34+	  NOi	  (Figure	  12	  A,	  B)	  at	  baseline	  was	  16997.64	  RFUs	  which	  decreased	  
by	  9.55%	  to	  15374.78	  RFUs	  after	  rPA	  (p=0.56).	  	  
CFU-­‐Hill	  NOi	  (Figure	  13	  A,	  B)	  decreased	  significantly	  by	  33.84%,	  from	  a	  baseline	  value	  of	  





Figure	   12A.	   CD34+	   cells	   intracellular	   nitric	   oxide	   in	   relative	   fluorescence	   units	   RFUs	   between	  
baseline	  and	  rPA	  (p=	  0.56,	  n=7)	  
	  
Baseline	   	  	  	  	  	  rPA	  
Figure	   12B.	   Individual	   data	   CD34+	   cells	   intracellular	   nitric	   oxide	   in	   relative	   fluorescence	   units	  
RFUs	  between	  baseline	  and	  rPA	  (p=	  0.56	  ,	  n=7)	  
	  
	  
Figure	  13A.	  CFU-­‐Hill	  cells	   intracellular	  nitric	  oxide	   in	  relative	  fluorescence	  units	  RFUs	  between	  





	  	  	  	  	  	  	  	  Baseline	   	  	  	  	  	  	   	  	  	  rPA	  
Figure	   13B.	   Individual	   data	   for	   CFU-­‐Hill	   cells	   intracellular	   nitric	   oxide	   in	   relative	   fluorescence	  
units	  RFUs	  between	  baseline	  and	  rPA	  (p=0.03,	  n=7)	  
	  
4.5	  Gene	  expression	  
Gene	   expression	   is	   expressed	   in	   terms	   of	   fold	   change	   of	   a	   particular	   gene	   after	   rPA,	  
relative	  to	  baseline.	  The	  eight	  genes	  that	  we	  proposed	  to	  investigate	  have	  been	  split	   into	  two	  
broad	   groups	   for	   the	   purpose	   of	   clarity.	   The	   first	   group	   consists	   of	   genes	   that	   directly	   or	  
indirectly	  contribute	  towards	  NO	  (nitric	  oxide)	  production	  in	  both	  cell	  types;	  they	  include	  eNOS,	  
iNOS,	   Sirt1	   and	   Cav1.	   The	   second	   group	   of	   genes	   is	   related	   to	   oxidative	   stress;	   these	   genes	  
include	  Nox2,	  Nox4	  and	  p47phox	  (components	  of	  NADPH	  oxidase)	  and	  SOD1.	  	  	  
Different	  trends	  were	  found	  between	  the	  genes	  that	  contribute	  towards	  the	  production	  
of	  NO	  (eNOS,	  iNOS,	  Sirt1	  and	  Cav1),	  in	  CD34+	  enriched	  cells.	  However,	  none	  of	  the	  differences	  
were	  significant	  between	  baseline	  and	  rPA	  (Figure	  14A).	  Expression	  of	  eNOS	  and	  iNOS	  in	  CD34+	  

















by	  less	  than	  1	  fold	  (p>0.05).	  The	  individual	  data	  (Figure	  14B)	  demonstrates	  the	  variability	  in	  the	  
expression	  of	  these	  genes	  between	  subjects.	  	  
For	   CFU-­‐Hill	   derived	   cells,	   all	   genes	   related	   to	   NO	   tended	   to	   decreased	   after	   rPA,	  
however	   these	   decreases	  were	   not	   significant	   (Figure	   16	   A,	   B).	   The	   expression	   of	   eNOS	   and	  
iNOS	  decreased	  by	   a	   little	   over	   ~1	   fold	   (p=0.07,	   p=0.12	   respectively)	  while	   the	   expression	   of	  
Sirt1	   and	   Cav1	   decreased	   by	   less	   than	   1	   fold	   after	   rPA	   (p>0.05	   for	   both).	   No	   significant	  
differences	  were	  found	  for	  genes	  in	  the	  oxidative	  stress	  group	  Nox2,	  Nox4,	  p47phox	  and	  SOD1	  
(Figure	  15A)	  in	  either	  CD34+	  enriched	  cells	  or	  CFU-­‐Hill	  cells	  (Figure	  17	  A)	  (p>0.05).	  Figure	  15	  B	  
and	  Figure	  17	  B	  illustrate	  the	  individual	  variability	  in	  the	  response	  to	  rPA.	  	  
	  
Figure	   14	   A.	   CD34+	   cells	   eNOS,	   iNOS,	   Sirt1,	   Cav1	   fold	   change	   at	   rPA,	   relative	   to	   baseline	   (p>	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Figure	   14	   B.	   CD34+	   cells	   eNOS,	   iNOS,	   Sirt1,	   Cav1	   fold	   change	   at	   rPA,	   relative	   to	   baseline,	  






















































Figure	  15	  B.	  CD34+	  cells	  Nox2,	  Nox4,	  p47phox	  and	  SOD1	  fold	  change	  at	  rPA,	  relative	  to	  baseline	  
















































Figure	   16	   B.	   CFU-­‐Hill	   cells	   eNOS,	   iNOS,	   Sirt1,	   Cav1	   fold	   change	   at	   rPA,	   relative	   to	   baseline,	  






Figure	   17	   A.	   CFU-­‐Hill	   cells	   Nox2,	   Nox4,	   p47phox	   and	   SOD1	   fold	   change	   at	   rPA,	   relative	   to	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Figure	   17	   B.	   CFU-­‐Hill	   cells	   Nox2,	   Nox4,	   p47phox	   and	   SOD1	   fold	   change	   at	   rPA,	   relative	   to	  
baseline,	  individual	  data	  (p>0.5,	  n=8)	  
4.6	  Correlations	  and	  Regressions	  
Correlations	  were	   calculated	  based	  on	   the	   change	   in	   rPA	   values	   from	  baseline,	   for	   all	  
outcomes.	  In	  the	  CD34+	  enriched	  cells,	  correlations	  that	  initially	  appeared	  to	  be	  significant	  were	  
found	  to	  be	  driven	  entirely	  by	  one	  subject	  when	  graphed.	  	  Therefore,	  only	  the	  outcomes	  from	  
CFU-­‐Hill	  derived	  cells	  have	  been	  presented	  below.	  	  
CFU	  colony	  numbers	  had	  a	  strong	  positive	  correlation	  with	  CFU	  NOi	  (p=0.096,	  R2=0.68),	  




We	  also	  found	  that	  CFU	  NOi	  was	  positively	  correlated	  with	  3	  out	  of	  the	  4	  genes	  that	  contribute	  
towards	  NO	  production-­‐	  CFU	  eNOS	   (p=0.021,	  R2=0.83),	   CFU-­‐Sirt1	   (p=0.043,	  R2=0.77)	   and	  CFU	  
Cav1	  (p=	  0.049,	  R2=0.76),	  as	  seen	  in	  Figure	  19	  A-­‐C.	  	  
We	  found	  positive	  correlations	  between	  CFU	  eNOS	  with	  CFU	  iNOS	  (p=0.015,	  R2=	  0.811),	  
CFU	  Sirt1	   (p=	  0.001,	  R2=	  0.92)	  and	  CFU	  Cav1	   (p=0.006,	  R2=	  0.86),	  which	  were	  also	  genes	   that	  
contribute	  towards	  NO	  production,	  as	  seen	  in	  Figure	  20	  A-­‐C.	  
Multiple	  linear	  regression	  analyses	  were	  run	  on	  each	  response	  outcome	  that	  was	  found	  
to	  have	  strong	  correlations.	  Therefore,	  our	   response	  outcomes	  and	  their	   respective	  predictor	  
variables	  were:	  
Response	  outcome	  1:	  CFU	  colonies,	  predictor	  variables:	  	  CFU	  NOi,	  CFU	  eNOS,	  CFU	  Sirt1	  
Response	  outcome	  2:	  CFU	  NOi,	  predictor	  variables:	  CFU	  eNOS,	  CFU	  Sirt1,	  CFU	  Cav1	  
Response	  outcome	  3:	  CFU	  eNOS,	  predictor	  variables:	  	  CFU	  eNOS,	  CFU	  iNOS,	  CFU	  Sirt1	  
We	   did	   not	   find	   any	   set	   or	   sub-­‐set	   of	   predictor	   variables	   that	   could	   predict	   their	  
respective	  response	  outcomes.	  However,	  we	  did	  confirm	  that	  they	  were	  statistically	  significant	  

























Scatterplot of CFU Noi (cells-pbs) vs CFU colonies
	  



















Scatterplot of CFUeNOS vs CFU colonies
	  













Scatterplot of CFU Sirt1 vs CFU colonies
	  





















Scatterplot of CFUeNOS vs CFU Noi (cells-pbs)
	  














Scatterplot of CFU Sirt1 vs CFU Noi (cells-pbs)
	  

















Scatterplot of CFU Cav1 vs CFU Noi (cells-pbs)
	  















Scatterplot of CFU iNOS vs CFUeNOS
	  

















Scatterplot of CFU Sirt1 vs CFUeNOS
	  













Scatterplot of CFU Cav1 vs CFUeNOS
	  
Figure	  20C:	  Correlation	  of	  CFU	  eNOS	  with	  CFU	  Cav1	  (p=0.006,	  R2=	  0.86)	  
	  




CHAPTER	  5	  	  
DISCUSSION	  
	  
Exercise	  has	  been	  shown	  to	  have	  positive	  effects	  on	  the	  number	  and	  function	  of	  CACs,	  a	  
putative,	   novel	   and	   early	   biomarker	   of	   vascular	   function	   and	   cardiovascular	   health.	   In	   this	  
study,	  we	  were	   interested	   in	   the	  effect	  of	   reduced	  physical	  activity	   in	  healthy,	  active	  men	  on	  
two	   populations	   of	   CACs.	   We	   hypothesized	   that	   the	   reduction	   in	   physical	   activity	   would	  
negatively	   impact	  CAC	  number	  and	   intracellular	  nitric	  oxide-­‐related	   factors.	   	  Some	  of	   the	  key	  
findings	  of	  our	  study	  were:	  1)	   the	   two	  types	  of	  CACs	  we	  evaluated-­‐	  CD34+	  enriched	  cells	  and	  
CFU-­‐Hill	  cells,	  responded	  very	  differently	  to	  rPA,	  with	  decreased	  CFU-­‐Hill	  number	  and	  NOi	  after	  
rPA,	   and	   no	   significant	   changes	   in	   CD34+	   cells	   and	   2)	   changes	   in	   nitric	   oxide-­‐related	   gene	  
expression	  were	  correlated	  to	  changes	  in	  CFU-­‐Hill	  number	  and	  NOi.	  	  	  Importantly,	  we	  were	  able	  
to	   objectively	   measure	   the	   physical	   activity	   of	   our	   subjects	   to	   confirm	   that	   it	   was	   reduced	  
during	   rPA	   and	   use	   energy	   expenditure	   data	   to	   ensure	   that	   participants	   remained	   in	   energy	  
balance	  and	  did	  not	  increase	  weight	  during	  rPA.	  
5.1	  Reduced	  physical	  activity	  model	  
The	   purpose	   of	   this	   study	  was	   to	   understand	   the	   effect	   rPA	   had	   on	   CACs,	   in	   healthy	  
individuals.	  We	  accomplished	  this	  by	  recruiting	  healthy	  men	  who	  were	  primarily	  runners,	  and	  
asking	   them	   to	   reduce	   their	   physical	   activity	   (rPA),	   which	   we	   defined	   as	   discontinuing	   any	  
structured	  physical	  activity	  (i.e.	  regular	  work-­‐outs)	  for	  a	  period	  of	  ten	  days.	  Holloszy	  et	  al.86	  and	  
Witkowski	  et	  al.75	  have	  used	  a	  similar	  model	  where	  male	  athletes	  were	  asked	  to	  stop	  exercising	  




respectively.	   However,	   both	   studies	   noted	   a	   large	   degree	   of	   individual	   variability.	   By	   using	  
physical	  activity	  monitoring	  as	  an	  objective	  measure	   in	  our	  model,	  we	  were	  able	   to	  ascertain	  
whether	   or	   not	   all	   subjects	   adhered	   to	   the	   protocol.	   This	   strategy	   was	   effectively	   used	   to	  
eliminate	   one	   of	   our	   subjects	   from	   all	   analyses	   since	   he	   increased	   his	  MVPA.	  Neither	   of	   the	  
studies	  mentioned	  above	  measured	  physical	  activity,	  objectively.	  
The	   significant	   reduction	   in	   vigorous	   and	   very	   vigorous	   activities	   (>6METs)	   from	  
Actigraph	   data	   (Figure	   8)	   of	   the	   8	   subjects	   that	   were	   compliant,	   helped	   us	   confirm	   their	  
adherence	  to	  the	  protocol.	  Further,	   the	  change	   in	  sedentary	  time	  for	  our	  subjects	  during	  rPA	  
was	  not	  significant	  (Figure	  12).	  	  Existing	  models	  of	  inactivity	  such	  as	  the	  ones	  used	  in	  bed-­‐rest	  
studies32	   and	   spinal	   cord	   injury	   studies39	   do	   not	   take	   into	   consideration	   the	   added	   or	  
independent	  impact	  of	  increasing	  sedentary	  behavior	  on	  the	  cardiovascular	  system.37	  We	  were	  
also	   able	   to	   avoid	   potential	   confounding	   factors	   such	   as	  weight	   gain	   (table	   1)	   and	   increased	  
energy	  intake	  during	  rPA	  by	  taking	  into	  account	  their	  baseline	  energy	  intake	  (via	  dietary	  recalls)	  
and	  energy	  expenditure	  (via	  Actigraph	  monitoring),	  and	  recommending	  individual	  kcal	  amounts	  
to	  each	  subject,	  so	  that	  they	  would	  remain	  in	  energy	  balance	  during	  the	  ten	  days.	  We	  infer	  that	  
energy	  balance	  was	  maintained	  during	  rPA	  given	  that	  their	  weight	  did	  not	  change	  after	  rPA	  and	  
based	  on	  our	  kcal	   recommendations.	  Therefore,	  we	  can	  conclude	  that	  the	  changes	   in	  cellular	  
factors	   that	   we	   observed	   were	   likely	   due	   to	   the	   reductions	   in	   structured	   physical	   activity	  
(vigorous	  and	  very	  vigorous	  activity)	  over	  the	  10	  days.	  
5.2	  rPA	  response	  of	  CFU-­‐Hill	  CAC	  
	  We	   found	   that	   in	   response	   to	   rPA,	   CFU-­‐Hill	   number	   and	  NOi	   significantly	   decreased,	  




affected	   by	   rPA.	   	   CFU-­‐Hill	   derived	   cells	   are	   predictive	   of	  major	   cardiovascular	   events.	   66	   The	  
Framingham	  risk	  score	  for	  CVD	  is	  inversely	  related	  with	  the	  number	  of	  CFUs.	  21	  At	  the	  level	  of	  
the	  vascular	  endothelium,	  there	  is	  a	  strong	  correlation	  between	  the	  CFU-­‐Hill	  colony	  count	  and	  
flow-­‐mediated	  brachial	  reactivity.	  21	  With	  10	  days	  of	  rPA,	  we	  were	  able	  to	  observe	  a	  significant	  
decrease	  in	  the	  number	  of	  CFU-­‐Hill	  colonies	  (Figure	  14).	  These	  findings	  are	  similar	  with	  results	  
from	  a	  recent	  study	  by	  Witkowski	  et	  al.75	  however,	  the	  reduction	   in	  CFU-­‐Hill	  colonies	  with	  10	  
days	  of	  detraining	  was	  not	  statistically	  significant	  in	  their	  population	  of	  older	  endurance	  trained	  
men.	  	  Two	  main	  differences	  between	  the	  studies	  were	  the	  objective	  activity	  monitoring	  and	  the	  
age	  and	  training	  history	  of	  the	  men.	  	  Objective	  monitoring	  of	  rPA	  allowed	  us	  to	  assess	  changes	  
in	  compliant	  individuals,	  whereas	  compliance	  was	  not	  verified	  with	  monitoring	  in	  the	  Witkowski	  
et	  al	  75	  study.	  	  Second,	  Witkowski	  et	  al	  75	  recruited	  older	  men	  with	  a	  long-­‐term	  training	  history	  
(over	   20	   years),	   therefore	   the	   age	   of	   the	   men	  may	   have	   added	   variability	   due	   to	   unknown	  
factors	  related	  to	  age	  and	  CFU-­‐Hill	  colonies.	  
CFU-­‐Hill	   colonies	   are	   a	   mixed	   population	   of	   cells	   that	   consist	   of	   monocytes	   and	  
lymphocytes	   and	   few	   endothelial	   progenitors.83,84,85	   Their	   primary	   function	   appears	   to	   be	  
support	   of	   angiogenesis	   and	   endothelial	   repair	   via	   a	   paracrine	  mechanism,	   or	   the	   release	   of	  
vaso-­‐supportive	  factors.	   13,56	  The	  generation	  of	  a	  colony	  in	  this	  assay	  requires	  appropriate	  cell	  
communication	  and	  motility.	   	  With	  fewer	  colonies,	  rPA	  appeared	  to	  disrupt	  that	  signaling	  and	  
communication.	  
Nitric	   Oxide	   has	   been	   shown	   to	   be	   essential	   for	   proper	   function	   in	   angiogenic	   cell	  




paracrine	  signaling	  to	  promote	  vascular	  repair	  and	  growth.1	  We	  observed	  significant	  decreases	  
in	   CFU-­‐Hill	   NOi	   with	   rPA	   and	   a	   strong	   correlation	   between	   the	   change	   in	   CFU-­‐Hill	   colony	  
number	   and	   CFU-­‐Hill	   NOi	   (p=0.046,	   R2=0.82).	  We	   also	   saw	   correlations	   between	   changes	   in	  
CFU-­‐NOi	   with	   changes	   in	   CFU	   gene	   expression	   for	   eNOS,	   Sirt1	   and	   Cav1.	   While	   all	   3	   genes	  
tended	  to	  decrease,	  eNOS	  tended	  to	  decrease	  the	  most	  after	  rPA.	  	  eNOS	  is	  one	  of	  the	  primary	  
contributors	  of	  NO,	  shown	  to	  greatly	  affect	  CAC	  mobility	  and	  health.	  eNOS	  expression	  is	  altered	  
in	  health	  and	  disease,	  with	  and	  without	  exercise	  training	  .67	  	  
Oxidative	  stress,	  primarily	  contributed	  by	  NADPH	  oxidase	  in	  endothelial	  cells	  and	  CACs,	  
has	  been	  known	  to	  decrease	  NO	  production	  and	  thought	  to	  do	  so	  via	  eNOS	  uncoupling.27	  	  In	  a	  
study	  by	  Jenkins	  et	  al27	  they	  compared	  NOi	  in	  CFU-­‐Hill	  cells	  between	  active	  and	  sedentary	  men.	  
They	   also	   observed	   a	   significant	   difference	   in	   the	  NOi	   of	   the	   CFU-­‐Hill	   cells	   between	   the	   two	  
groups.	  Their	  group	  of	  sedentary	  control	  subjects	  were	  matched	  for	  age,	  weight	  and	  BMI	  to	  the	  
active	  group,	  and	  the	  differences	  in	  the	  NOi	  between	  groups	  was	  partially	  explained	  by	  NADPH	  
oxidase-­‐related	  oxidative	  stress	   in	  the	  sedentary	  group	  whereas	  NADPH	  oxidase	  inhibition	  did	  
not	  increase	  NOi	  any	  further	  in	  the	  active	  group.	  	  Interestingly,	  our	  gene	  expression	  results	  also	  
do	  not	   indicate	  any	   increased	  oxidative	  stress	  for	  our	  active	  participants	  since	  we	  did	  not	  see	  
any	  changes	  in	  Nox2,	  Nox4	  and	  p47phox	  or	  SOD1.	  	  Interestingly,	  our	  gene	  expression	  results	  do	  
not	  indicate	  any	  increased	  oxidative	  stress	  since	  we	  did	  not	  see	  any	  changes	  in	  Nox2,	  Nox4	  and	  
p47phox	  or	  SOD1.	  Further,	  iNOS	  is	  only	  activated	  when	  inflammation	  is	  present	  (such	  as	  IL-­‐6	  or	  
TNF-­‐a)	  and	  in	  response	  to	  oxidative	  stress.31	  While	  not	  significant,	  the	  CFU	  iNOS	  from	  our	  study	  




does	  not	  appear	  to	  be	  due	  to	  increased	  oxidative	  stress	  with	  rPA.	  Another	  mechanism	  is	  likely	  
involved	  in	  the	  decreased	  CFU-­‐Hill	  NOi	  observed	  after	  rPA.	  	  
Our	  gene	  expression	  data	  show	  some	  evidence	  that	  eNOS	  downregulation,	  potentially	  
through	  SIRT1,	  may	  be	  the	  mechanism	  involved	  in	  reduced	  CFU-­‐Hill	  NOi.	  	  Cav1	  (a	  component	  of	  
eNOS)	   and	   Sirt1	   (an	   indirect	   regulator	   of	   eNOS)	   were	   similarly	   decreased	   and	   were	   both	  
independently	  correlated	  with	   the	  changes	   in	  CFU-­‐NOi.	  Sirt1,	  an	  NADP+	  dependent	  molecule,	  
works	  indirectly	  via	  deacetylation	  of	  eNOS.	  49	  It	  has	  most	  commonly	  been	  studied	  in	  reference	  
to	   insulin	   resistance	   and	   its	   upregulation	   has	   shown	   to	   positively	   improve	   outcomes	   via	  
activation	  (deacetylation)	  of	  eNOS.76	  Blocking	  of	  Sirt1	  has	  shown	  to	  decrease	  NO-­‐bioavailability	  
and	   endothelial-­‐dependent	   vasorelaxation.49	   Interestingly,	   caloric	   restriction	   has	   also	   been	  
shown	   to	   cause	   the	   deacetylation	   of	   eNOS	   via	   a	   Sirt1	   pathway,38	   which	   is	   one	   of	   the	  many	  
reasons	  why	  we	  attempted	  to	  ensure	  that	  our	  subjects	  remained	  in	  energy	  balance	  during	  the	  
10	  days	  of	  rPA	  and	  followed	  a	  very	  specific	  low-­‐nitrate	  diet	  3	  days	  prior	  to	  coming	  in	  for	  both	  
testing	  visits.	  Therefore	  the	  correlations	  seen	  between	  Sirt	  1,	  eNOS	  and	  CFU-­‐NOi	  were	  not	  likely	  
due	  to	  changes	  in	  caloric	  intake.	  
It	   is	   unclear	   what	   stimulus	   evoked	   by	   rPA	   caused	   changes	   in	   CFU-­‐Hill	   NOi.	   	   NO	  
availability	  is	  essential	  for	  the	  migration	  and	  homing	  of	  CACs	  from	  the	  bone	  marrow	  34	  but	  it	  is	  
not	  known	  what	   stimulus	   related	   to	  exercise	  alters	   cellular	   factors	  within	  CACs.	   	   Shear	   stress	  
due	  to	  increased	  blood	  flow	  (e.g.	  during	  running)	  is	  one	  of	  two	  basic	  pathways	  for	  increased	  NO	  
production	   in	  mature	  endothelial	  cells.	   31	  The	  second	  pathway	  for	  NO	  production	   is	   receptor-­‐




amounts	  of	  shear-­‐stress	  on	  the	  cardiovascular	  system	  was	  greatly	  reduced	  since	  their	  vigorous	  
and	  very	  vigorous	  activity	  was	  significantly	  decreased	  (Figure	  8).	  Additionally,	  our	  subjects	  were	  
asked	  to	  follow	  a	  low-­‐nitrate	  diet	  for	  3	  days	  prior	  to	  each	  testing	  visit	  and	  they	  were	  asked	  to	  
avoid	  alcohol,	  caffeine	  and	  any	  medication	   for	  24	  hours	  prior	   to	   their	  visit,	   factors	   that	  could	  
influence	  NO.	  	  Further,	  we	  believe	  that	  there	  was	  no	  external	  influence	  of	  the	  second	  (receptor-­‐
stimulated)	  pathway	  by	  which	  NO	  formation	  could	  be	  influenced	  since	  we	  were	  able	  to	  control	  
for	  possible	  stimulants	  from	  food	  and	  medication.	  Therefore	  the	  significantly	  decreased	  NOi	  in	  
the	  CFU-­‐Hill-­‐derived	  cells	  (Figure	  16)	  would	  indicate	  that	  this	  effect	  was	  most	  likely	  mediated	  by	  
the	   decreased	   shear	   stress	   during	   rPA.	   With	   a	   protocol	   similar	   to	   our	   current	   protocol,	  
Witkowski.	   et	   al75	   showed	   that	   changes	   in	   CAC	  were	   strongly	   correlated	  with	   flow	  mediated	  
dilation.	  Since	  we	  know	  that	  changes	  in	  FMD	  are	  primarily	  nitric-­‐oxide	  mediated,10,57	  	  it	  supports	  
the	  possibility	  that	  the	  significantly	  decreased	  CFU-­‐Hill	  numbers	  and	  NOi	  we	  observed	  were	  due	  
to	  a	  reduction	  in	  shear	  stress	  during	  rPA.	  	  
5.3	  CD34+	  cell	  response	  
CD34+	   cells	   are	   hematopoietic	   and	   endothelial	   progenitors.	   	   When	   CACs	   were	   first	  
discovered	  by	  Asahara	  et	  al.	  in	  1997,	  they	  were	  identified	  as	  CD34+	  cells.3	  The	  number	  of	  CD34+	  
cells	  are	  negatively	  correlated	  with	  CVD	  risk	  and	  they	  are	  an	   independent	  predictor	  of	   future	  
cardiac	  events.13	  The	  CD34+	  surface	  marker	   is	   still	  one	  of	   the	  most	  widely	  used	  and	  accepted	  
markers	   to	   define	   CACs	   and	   they	   have	   shown	   great	   therapeutic	   potential	   through	   their	  
application	  in	  a	  number	  of	  clinical	  trials.13,56	  	  Clinical	  trials	  for	  individuals	  with	  acute	  myocardial	  




cells	   for	   their	   intervention.56	   Trials	   have	   reported	   generally	   positive	   outcomes	   such	   as	  
improvements	  in	  symptoms	  and	  LVEF	  (left	  ventricular	  ejection	  fraction).	  
Selective	   activation	   of	   beneficial	   genes	   (e.g.	   eNOS)	   and	   selective	   blockade	   of	   non-­‐
beneficial	  genes	   (e.g.	  NADPH	  oxidase)	   in	  CD34+	  cells	  has	  shown	  to	  correct	   the	  vasoreparative	  
dysfunction	   in	   diabetic	   individuals.73,74	   	   Jenkins	   et	   al.	   observed	   that	  NO	   and	  NADPH	   in	   CD34+	  
cells	   were	   significantly	   different	   in	   sedentary	   versus	   active	   individuals	   77	   Using	   a	   detraining	  
model	   that	  was	   similar	   to	   our	   study,	  Witkowski	   et	   al.	   found	   that	   the	   number	   of	   CD34+	   cells	  
significantly	  decreased	  after	  10	  days	  of	  detraining	  in	  highly	  active	  individuals.75	  Based	  on	  these	  
data,	  we	  hypothesized	   that	   rPA	  would	   lead	   to	  a	  decrease	   in	  CD34+	  cell	  number,	  mediated	  by	  
decreases	   in	   NO	   and	   increased	   NADPH.	   However,	   we	   observed	   that	   our	   CD34+	   cells	   were	  
resistant	  to	  the	  effects	  of	  rPA.	  	  
Studies	   investigating	   the	   acute	   effect	   of	   exercise	   on	   men	   (mean	   age	   ~33yrs),	   have	  
shown	  CD34+	  cells	  increase	  after	  acute	  exercise.81	  Further,	  while	  the	  study	  by	  Witkowski	  et	  al.	  
found	  a	  decrease	  in	  CD34+	  cells	  after	  detraining,	  they	  are	  the	  only	  study	  to	  date	  that	  has	  used	  a	  
detraining	   model	   to	   show	   the	   effect	   of	   exercise	   cessation	   on	   CD34+	   cells.75	   Differences	   in	  
changes	  in	  CD34+	  cell	  number	  with	  rPA	  between	  the	  two	  studies	  might	  also	  be	  attributable	  to	  
the	  difference	   in	  methods	  used	   to	   isolate	   and	  quantify	   the	  CD34+	   cells.	  We	  used	   a	  magnetic	  
separation	   technique	   to	   isolate	  our	  CD34+	   cells,	   and	  Witkowski	  et	   al.	   used	   flow	  cytometry	   to	  
quantify	  the	  number	  of	  CD34+	  cells.75	  Flow	  cytometry	  was	  used	  by	  them	  to	  count	  the	  number	  of	  
CD34+	   cells	  within	   the	   population	   of	  mononuclear	   cells	   that	   they	   collected,	   by	   using	   specific	  




CD34+	   cells	   using	   a	   CD34+	   specific	   antibody.	   However,	   the	   cells	   attained	   through	   magnetic	  
separation	   are	   an	   enriched	   population	   of	   CD34+	   cells	   that	   have	   been	   positively	   selected.	  
Therefore,	   when	   we	   make	   inferences	   regarding	   any	   of	   our	   outcomes,	   they	   must	   be	   made	  
keeping	  in	  mind	  that	  ours	  is	  an	  enriched,	  not	  pure	  population	  of	  cells.	  Using	  the	  flow	  cytometry	  
analyses	  for	  our	  study	  would	  have	  been	  useful.	  However,	  it	  would	  have	  been	  at	  the	  cost	  of	  not	  
being	  able	  to	  measure	  gene	  expression	  or	  NOi.	  	  
One	  of	  the	  major	  differences	  between	  the	  current	  study	  and	  that	  by	  Witkowski,	  et	  al,	  as	  
mentioned	  above,	  is	  the	  mean	  age	  of	  the	  participants;	  the	  mean	  age	  of	  their	  participants	  was	  
~63yrs	  compared	  to	  24yrs	  in	  our	  population.	  75	  It	  has	  been	  found	  that	  older	  subjects	  have	  lower	  
CD34+	  cells	  compared	  to	  young	  individuals.13	  	  Therefore,	  it	  is	  possible	  that	  since	  our	  population	  
was	  young	  and	  active,	   their	  CD34+	  cells	  were	   less	  susceptible	   to	   the	  effect	  of	   rPA	  than	  older,	  
active	  men.	  	  
Stem	   and	   progenitor	   cells	   are	   known	   to	   have	   a	   robust	   antioxidant	   capacity	   and	   are	  
therefore	  believed	  to	  be	  more	  resilient	  in	  an	  oxidative-­‐stress	  environment.78	  Upon	  exposure	  to	  
increased	   ROS	   concentrations,	   CAC	   expression	   of	   antioxidant	   enzymes	   such	   as	   catalase,	  
glutathione	   peroxidase	   and	   manganese	   superoxide	   dismutase	   (MnSOD),	   was	   found	   to	   be	  
significantly	   higher.	   This	   makes	   them	   equipped	   to	   be	   protected	   against	   an	   oxidative	   stress	  
environment	   and	   is	   characteristic	   of	   their	   progenitor	   cell	   character.78	   As	   CD34+	   cells	   are	  
hematopoietic	  and	  endothelial	  progenitors,	  it	  is	  possible	  that	  the	  CD34+	  cells	  from	  our	  subject	  
population	  were	  unaffected	  by	  rPA	  because	  they	  were	  more	  fortified	  compared	  with	  CFU-­‐Hill	  




systemic	  shear	  stress	  with	  rPA	  is	  responsible	  for	  the	  changes	  in	  CFU-­‐Hill	  CACs	  as	  noted	  above,	  
CD34+	  CACs	  may	  not	  be	  as	  responsive	  to	  changes	  in	  shear	  as	  CFU-­‐Hill	  CACs.	  	  However,	  the	  exact	  
mechanism	   by	   which	   CD34+	   cells	   are	   resistant	   to	   rPA	   compared	   to	   the	   CFU-­‐Hill	   cells	   is	   not	  
known	  and	  warrants	  further	  investigation.	  
5.4	  Limitations	  
One	  limitation	  of	  our	  work	  is	  the	  challenge	  of	  isolating	  a	  pure	  population	  of	  CD34+	  cells.	  
In	  order	  to	  have	  100%	  of	  our	  isolated	  cells	  be	  CD34+	  we	  would	  have	  to	  draw	  approximately	  2L	  
of	  blood.	  While	  we	  certainly	  had	  an	  enriched	  population	  of	  CD34+	  cells,	  the	  other	  mononuclear	  
cells	  present	  in	  the	  samples	  might	  explain	  some	  of	  the	  variability	  of	  the	  results	  observed	  in	  our	  
outcomes.	  Further,	   in	  order	  to	  obtain	  as	  many	  cells	  as	  possible	  for	  analysis,	  we	   identified	  our	  
CD34+	   CAC	   population	   on	   only	   1	   cell	   surface	   marker.	   CD34+	   cell	   marker	   is	   ubiquitous	   to	  
hematopoietic	   and	   endothelial	   progenitor	   cells	   and	   was	   the	   original	   marker	   that	   identified	  
endothelial	   progenitor	   cells.3	   While	   it	   is	   still	   currently	   used	   as	   the	   identifying	   marker	   for	  
isolation	  and	  use	  of	   cells	   in	   cardiovascular	   regenerative	   therapies,	   56	   identification	  of	   specific	  
CAC	  populations	  would	  require	  multiple	  markers	  and	  improve	  understanding	  of	  the	  diverse	  CAC	  
family.	  
Several	   studies	   have	   found	   a	   large	   degree	   of	   individual	   variability	   in	   CAC	   response	   to	  
changes	  in	  physical	  activity,	  especially	  in	  healthy	  individuals.	  Although	  we	  attempted	  to	  obtain	  
a	   profile	   of	   individuals	   who	   were	   primarily	   runners	   with	   similar	   characteristics,	   no	   CVD	   risk	  




individual	   variability,	   indicating	   that	   there	   are	   still	   unknown	   factors	   that	   contribute	   to	   the	  
number	  and	  function	  of	  CACs.	  	  
A	  second	  limitation	  of	  our	  study	  was	  the	  measurement	  of	  sedentary	  behavior	  using	  the	  
activity	   monitor	   Actigraph	   GT3X.	   While	   the	   Actigraph	   is	   well	   suited	   to	   measure	   moderate,	  
vigorous	   and	   very	   vigorous	   activities,	   it	   is	   not	   the	   most	   accurate	   at	   measuring	   sedentary	  
behavior.82	  The	  primary	  objective	  of	  this	  study	  was	  to	  ensure	  that	  our	  subjects	  decreased	  their	  
structured	  physical	  activity	  (vigorous	  and	  very	  vigorous	  activity)	  during	  rPA,	  which	  is	  a	  goal	  we	  
were	   able	   to	   achieve	   using	   the	   Actigraph	   monitor.	   However,	   we	   must	   be	   cautious	   when	  
drawing	  conclusions	  about	  sedentary	  behavior	  using	  the	  Actigraph	  outputs	  since	  this	  particular	  
monitor	  is	  not	  sensitive	  enough	  to	  measure	  it	  accurately.	  	  
5.5	  Conclusion	  
Our	  hypotheses	   for	   this	   study	  were	   that	   rPA	  would	   cause	  a	  decrease	   in	  CAC	  number,	  
intracellular	  NO	  and	  genes	  related	  to	  NO.	  We	  further	  hypothesized	  that	  the	  number	  of	  CAC	  and	  
nitric	  oxide	   related	   factors	  would	  be	   related	   to	  one	  another.	  Based	  on	  our	   results,	  we	   found	  
that	   the	   CFU-­‐Hill	   cells	   did	   follow	   the	   direction	   of	   our	   hypothesis	   while	   the	   CD34+	   remained	  
unaffected.	  	  
We	   observed	   decreases	   in	   CFU-­‐Hill	   colony	   numbers,	  NOi	   and	   eNOS	   and	   found	   strong	  
correlations	  between	  all	   these	  outcomes.	   Further	  NOi	  was	   strongly	   correlated	  with	   Sirt1	   and	  
Cav1	  (NO	  regulators).	  Since	  we	  did	  not	  see	  any	   increases	   in	  oxidative	  stress	  markers	  that	  can	  
cause	   to	   decrease	   NO,	   further	   research	   is	   needed	   in	   order	   to	   understand	   the	   cellular	  
mechanisms	  behind	  the	  decreases	  observed.	  Just	  as	  shear	  stress	   is	  hypothesized	  as	  the	  cause	  




during	   the	  10	  days	  of	   rPA	  was	  one	  of	   the	  mechanisms	   through	  which	   the	  CFU-­‐Hill	   cells	  were	  
decreased	  in	  number	  and	  function.	  	  
Our	  data	  is	  novel	  in	  that	  we	  were	  able	  to	  show	  how	  the	  cells	  derived	  from	  this	  assay	  are	  
sensitive	  to	  reductions	  in	  physical	  activity,	  in	  healthy	  individuals.	  Given	  the	  inverse	  relationship	  
between	   CFU-­‐Hill	   colony	   numbers	   and	   the	   Framingham	   risk	   score	   for	   CVD,	   there	   is	   a	   larger	  
implication	  with	  these	  findings.	  Fewer	  than	  5%	  of	  Americans	  adhere	  to	  the	  minimum	  physical	  
activity	  guidelines	  and	  could	  be	  at	  risk	  for	  CVD	  early	  on.	  It	  is	  important	  for	  us	  to	  take	  advantage	  
of	   this	   novel	   biomarker	   and	   further	   investigate	   ways	   it	   can	   be	   used	   for	   early	   detection	   and	  
prevention	  of	  CVD.	  	  





QUESTIONNAIRES,	  INFORMED	  CONSENT	  AND	  PROTOCOLS	  
6.1:	  Informed	  consent	  
	  
Consent	  Form	  for	  Participation	  in	  a	  Research	  Study	  
University	  of	  Massachusetts	  Amherst	  
	  
Principal	  Investigator:	  	   	   Sarah	  Witkowski,	  Ph.D.	   	   	  
Study	  Title:	   	   	   	   Inactivity	  and	  Cardiovascular	  Disease	  	  
Sponsor:	   	   	   	   UMASS	  Amherst	  Faculty	  Research	  Grant	  	  
1.	  WHAT	  IS	  THIS	  FORM?	  
This	  form	  is	  called	  a	  Consent	  Form.	  It	  will	  give	  you	  information	  about	  the	  study	  so	  you	  can	  make	  
an	  informed	  decision	  about	  participation	  in	  this	  research	  study.	  
	  
This	  consent	  form	  will	  give	  you	  the	  information	  you	  will	  need	  to	  understand	  why	  this	  study	  is	  
being	  done	  and	  why	  you	  are	  being	  invited	  to	  participate.	  	  It	  will	  also	  describe	  what	  you	  will	  
need	  to	  do	  to	  participate	  and	  any	  known	  risks,	  inconveniences	  or	  discomforts	  that	  you	  may	  
have	  while	  participating.	  	  We	  encourage	  you	  to	  take	  some	  time	  to	  think	  this	  over	  and	  ask	  
questions.	  	  If	  you	  decide	  to	  participate,	  you	  will	  be	  asked	  to	  sign	  this	  form	  and	  you	  will	  be	  given	  
a	  copy	  for	  your	  records.	  
	  
2.	  WHO	  IS	  ELIGIBLE	  TO	  PARTICIPATE?	  
Healthy	  men	  and	  women	  age	  18-­‐50	  years	  old	  who	  have	  been	  participating	  in	  regular	  endurance	  
running	  exercise	  for	  over	  10	  years	  are	  eligible	  to	  participate	  in	  this	  study.	  	  Participants	  must	  
weigh	  over	  110lbs.	  	  Regular	  running	  exercise	  history	  should	  include	  at	  least	  3	  days/week	  of	  
moderate	  to	  intense	  activity.	  	  All	  participants	  must	  be	  healthy,	  non-­‐smoking	  and	  free	  of	  
cardiovascular	  disease,	  diabetes,	  lung	  disease,	  and	  cancer.	  Participants	  cannot	  be	  taking	  
medications	  for	  high	  cholesterol,	  high	  blood	  pressure,	  erectile	  dysfunction,	  or	  diabetes	  and	  





3.	  WHAT	  IS	  THE	  PURPOSE	  OF	  THIS	  STUDY?	  
The	  purpose	  of	  this	  research	  study	  is	  to	  evaluate	  the	  effect	  of	  short-­‐term	  inactivity	  (detraining)	  on	  
age-­‐related	  factors	  of	  cells	  found	  in	  your	  blood	  that	  may	  be	  related	  to	  the	  development	  of	  
cardiovascular	  diseases.	  	  Our	  objective	  is	  to	  determine	  whether	  stopping	  regular	  exercise	  will	  
result	  in	  changes	  in	  factors	  that	  protect	  your	  blood	  cells	  from	  aging	  and	  disease.	  
	  
4.	  WHERE	  WILL	  THE	  STUDY	  TAKE	  PLACE	  AND	  HOW	  LONG	  WILL	  IT	  LAST?	  
The	  research	  for	  this	  study	  will	  be	  performed	  in	  the	  Kinesiology	  Department	  at	  the	  University	  of	  
Massachusetts	  in	  Amherst,	  MA.	  	  Each	  participant	  will	  be	  asked	  to	  come	  to	  our	  laboratory	  3	  
times,	  a	  screening	  visit,	  and	  2	  testing	  visits.	  	  There	  will	  be	  1	  week	  between	  the	  first	  and	  second	  
testing	  visits	  and	  10	  days	  between	  the	  second	  and	  third	  testing	  visit.	  	  The	  1st	  visit	  will	  last	  about	  
1	  hr,	  the	  2nd	  and	  3rd	  visit	  last	  for	  2	  hrs	  each,	  for	  a	  total	  of	  about	  4	  hours.	  	  Your	  total	  participation	  
will	  last	  a	  span	  of	  3	  weeks.	  
	  
5.	  WHAT	  WILL	  I	  BE	  ASKED	  TO	  DO?	  
If	  you	  agree	  to	  take	  part	  in	  this	  study	  you	  will	  be	  given	  a	  health	  history	  and	  physical	  activity	  
questionnaires	  to	  fill	  out.	  Following	  this	  you	  will	  be	  asked	  to	  come	  to	  the	  lab	  for	  a	  screening	  visit.	  	  	  
	  
Visit	  #1:	  Screening/Familiarization:	  During	  this	  visit	  you	  will:	  1)	  Review	  the	  informed	  consent,	  
2)	  clarify	  any	  questions	  we	  might	  have	  about	  your	  health	  history,	  training/competition	  history,	  
3)	  provide	  us	  with	  documentation	  from	  your	  doctor	  with	  results	  from	  your	  most	  recent	  physical	  
(within	  the	  past	  9	  months),	  4)	  have	  your	  blood	  pressure	  taken,	  5)	  have	  a	  blood	  sample	  taken	  for	  
a	  general	  blood	  chemistry	  screen,	  6)	  get	  fitted	  with	  two	  activity	  monitors	  and	  6)	  be	  familiarized	  
you	  with	  the	  protocols	  we	  will	  be	  performing	  for	  visits	  2	  and	  3.	  
	  
Blood	  pressure:	  During	  this	  visit,	  to	  evaluate	  your	  blood	  pressure,	  we	  will	  ask	  you	  to	  sit	  quietly	  
for	  several	  minutes.	  	  A	  cuff	  will	  be	  placed	  around	  your	  upper	  arm.	  	  We	  will	  inflate	  this	  cuff	  then	  
slowly	  release	  the	  pressure	  while	  we	  listen	  for	  the	  blood	  pressure	  in	  the	  vessel	  with	  a	  





Blood	  chemistry	  screen:	  To	  evaluate	  your	  blood	  chemistry	  profile,	  we	  will	  use	  a	  needle	  to	  
withdraw	  about1	  tablespoon	  of	  blood	  from	  the	  vein	  in	  your	  arm	  (about	  15ml)	  
	  
Activity	  monitors:	  We	  will	  also	  fit	  you	  with	  an	  activity	  monitor	  (ActiGraph)	  as	  well	  as	  a	  
pedometer	  (Omron)	  that	  you	  will	  wear	  at	  your	  hip	  to	  evaluate	  the	  amount	  of	  physical	  activity	  
and	  step	  count	  over	  the	  course	  of	  1	  week.	  	  During	  this	  week,	  we	  will	  ask	  that	  you	  wear	  these	  
monitors	  and	  perform	  the	  tasks	  (exercise	  and	  otherwise)	  that	  you	  perform	  in	  a	  typical	  week.	  
You	  will	  be	  asked	  to	  take	  the	  pedometer	  off	  during	  your	  exercise.	  After	  1	  week,	  you	  will	  return	  
to	  the	  lab	  to	  have	  the	  monitors	  removed	  and	  your	  second	  testing	  visit.	  
	  
The	  ActiGraph	  is	  a	  wearable	  activity	  monitor	  worn	  at	  the	  hip.	  	  It	  weighs	  19	  gms	  and	  its	  size	  is	  
46mm	  x	  33mm	  x	  15mm	  and	  can	  monitor	  an	  individual's	  activity	  for	  up	  to	  7	  days.	  	  The	  ActiGraph	  
is	  secured	  to	  the	  hip	  using	  an	  elastic	  belt.	  It	  can	  be	  worn	  over	  your	  clothes	  or	  under	  it.	  You	  will	  
be	  instructed	  to	  remove	  the	  ActiGraph	  during	  bathing,	  swimming	  and	  sleeping.	  These	  are	  the	  
only	  times	  the	  ActiGraph	  should	  be	  removed.	  	  
	  
The	  Omron	  is	  a	  pedometer	  that	  weighs	  28	  gms,	  its	  size	  is	  47	  mm	  ×	  66	  mm	  ×	  16	  mm	  and	  you	  will	  
wear	  this	  on	  the	  elastic	  belt	  with	  the	  ActiGraph.	  The	  Omoron	  will	  monitor	  your	  step	  count	  for	  7	  
days.	  In	  addition	  to	  keeping	  the	  Omron	  off	  when	  the	  ActiGraph	  is	  off,	  you	  will	  also	  be	  asked	  to	  
remove	  it	  when	  you	  are	  exercising.	  	  
	  
Monitor	  and	  Diet	  logs:	  You	  will	  be	  given	  an	  activity	  log	  where	  you	  will	  be	  asked	  to	  record	  times	  
that	  the	  monitors	  are	  removed	  and	  worn	  again.	  Reasons	  for	  monitor	  removal	  will	  also	  be	  
recorded.	  At	  the	  end	  of	  the	  7-­‐day	  period,	  you	  will	  return	  the	  logs	  along	  with	  the	  ActiGraph	  and	  
the	  Omron.	  
You	  will	  also	  be	  given	  a	  diet	  log	  in	  order	  to	  keep	  a	  detailed	  account	  of	  your	  food	  intake	  
throughout	  the	  day	  during	  the	  7	  days	  that	  you	  will	  also	  be	  wearing	  the	  activity	  monitor.	  We	  will	  
explain	  to	  you	  how	  you	  need	  to	  log	  these	  details	  and	  you	  will	  also	  be	  counseled	  on	  stopping	  any	  





If	  you	  remain	  qualified	  for	  the	  study,	  or	  you	  meet	  the	  inclusion	  criteria	  and	  do	  not	  meet	  the	  
exclusion	  criteria	  mentioned	  above,	  we	  will	  schedule	  you	  for	  2	  testing	  visits.	  We	  will	  also	  
familiarize	  you	  with	  the	  measurements	  we	  will	  perform	  during	  visits	  2	  and	  3.	  	  
	  
Testing	  Visit	  #2:	  Testing	  Prior	  to	  your	  second	  testing	  visit,	  we	  will	  ask	  that	  you	  perform	  an	  
exercise	  session	  between	  36-­‐	  24	  hours	  prior	  to	  your	  visit	  and	  that	  you	  do	  not	  perform	  any	  other	  
exercise	  in	  the	  24	  hours	  directly	  before	  your	  visit.	  You	  will	  also	  be	  asked	  to	  refrain	  from	  caffeine	  
or	  alcohol	  during	  those	  24	  hours.	  In	  addition,	  we	  ask	  that	  you	  refrain	  from	  taking	  any	  
medications	  (including	  vitamins)	  48	  hours	  prior	  to	  coming	  in.	  	  Because	  eating	  affects	  substances	  
in	  the	  blood,	  we	  will	  also	  ask	  that	  you	  refrain	  from	  eating	  or	  drinking	  anything	  other	  than	  water	  
for	  12	  hours	  prior	  to	  your	  visit.	  	  When	  you	  arrive	  in	  the	  lab,	  we	  will	  ask	  you	  to	  give	  us	  your	  
ActiGraph,	  Omron,	  diet	  and	  monitor	  logs.	  	  
Following	  this	  we	  will	  have	  you	  lay	  quietly	  for	  a	  few	  minutes	  and	  then	  draw	  blood	  from	  the	  vein	  
in	  your	  arm.	  We	  will	  draw	  about	  4-­‐5	  tablespoons	  of	  blood	  (about	  50ml).	  	  	  
	  
Next,	  we	  will	  have	  you	  lay	  quietly	  in	  a	  room	  for	  30	  minutes	  then	  perform	  a	  flow-­‐mediated	  
dilation	  (FMD).	  This	  will	  involve	  the	  use	  of	  an	  ultrasound	  machine	  to	  visualize	  an	  artery	  in	  your	  
non-­‐dominant	  arm.	  We	  will	  then	  inflate	  a	  blood	  pressure	  cuff	  right	  above	  your	  elbow	  and	  keep	  
it	  inflated	  for	  5	  minutes.	  After	  5	  minutes	  the	  cuff	  will	  be	  rapidly	  deflated	  so	  that	  we	  can	  get	  
another	  image	  of	  your	  artery.	  	  
	  
We	  will	  provide	  you	  with	  a	  snack	  and	  beverage	  at	  the	  end	  of	  the	  testing	  visit.	  
	  
During	  the	  next	  10	  days,	  you	  will	  be	  asked	  to	  be	  inactive.	  	  This	  means	  that	  you	  cannot	  perform	  
your	  regular	  physical	  activity	  workouts.	  	  We	  will	  also	  give	  you	  the	  pedometer	  and	  activity	  
monitor	  again	  that	  measures	  your	  activity.	  	  The	  pedometer,	  activity	  monitor,	  diet	  and	  activity	  
logs	  will	  be	  given	  back	  to	  you	  for	  these	  10	  days	  so	  you	  can	  keep	  a	  record	  like	  you	  did	  for	  the	  
previous	  week.	  You	  will	  use	  the	  pedometer	  to	  help	  ensure	  that	  you	  are	  staying	  as	  inactive	  as	  
possible,	  at	  less	  than	  5000	  steps/day.	  	  During	  these	  10	  days	  you	  will	  also	  be	  counseled	  on	  how	  





Testing	  Visit	  #	  3:	  Testing:	  After	  10	  days,	  you	  will	  be	  asked	  to	  return	  to	  the	  lab	  with	  the	  monitors	  
and	  the	  logs.	  	  You	  will	  again	  be	  asked	  to	  refrain	  from	  eating	  or	  drinking	  anything	  besides	  water	  
for	  12	  hours	  prior	  to	  this	  visit	  and	  no	  caffeine	  or	  alcohol	  for	  24	  hours	  prior	  to	  the	  visit.	  In	  
addition,	  we	  will	  ask	  you	  to	  refrain	  from	  taking	  any	  medications	  (i.e.	  aspirin,	  ibuprofen,	  
decongestants)	  for	  the	  48	  hours	  prior	  to	  this	  visit.	  
	  
After	  having	  you	  rest	  quietly	  for	  a	  few	  minutes	  we	  will	  draw	  about	  4-­‐5	  tablespoons	  of	  blood	  
(about	  50ml).	  	  Next,	  we	  will	  have	  you	  lie	  quietly	  for	  30	  minutes	  and	  perform	  a	  FMD	  again	  like	  
we	  would	  have	  during	  visit	  #	  2.	  We	  will	  provide	  you	  with	  a	  snack	  and	  a	  beverage	  following	  
before	  you	  leave.	  	  
	  
6.	  What	  are	  my	  benefits	  of	  being	  in	  this	  study?	  	  
You	  will	  earn	  $100	  for	  completion	  of	  the	  entire	  protocol,	  this	  means	  all	  visits	  and	  testing.	  	  
We	  hope	  that	  your	  participation	  in	  the	  study	  may	  help	  investigators	  to	  determine	  whether	  
short-­‐term	  inactivity	  has	  an	  effect	  on	  the	  biological	  aging	  of	  cells	  in	  your	  blood.	  	  This	  
information	  will	  help	  to	  determine	  if	  exercise	  and	  inactivity	  can	  cause	  relatively	  rapid	  changes	  
in	  cellular	  aging	  in	  humans.	  	  	  
	  
Your	  participation	  in	  this	  research	  is	  completely	  voluntary	  and	  you	  may	  choose	  not	  to	  take	  part	  
at	  all.	  You	  are	  free	  to	  ask	  questions	  at	  any	  time	  without	  penalty.	  If	  you	  decide	  to	  participate	  in	  
this	  research,	  you	  may	  stop	  participating	  at	  any	  time.	  If	  you	  decide	  not	  to	  participate	  in	  this	  
project	  or	  if	  you	  stop	  participating	  at	  any	  time,	  you	  will	  not	  be	  penalized	  or	  lose	  any	  benefits	  to	  
which	  you	  otherwise	  qualify.	  	  
	  
7.	  	  WHAT	  ARE	  my	  RISKS	  OF	  being	  in	  THIS	  STUDY?	  	  
The	  following	  risks	  are	  associated	  with	  your	  participation	  in	  this	  study:	  
1)	  There	  is	  risk	  of	  bruising	  and	  infection	  associated	  with	  blood	  drawing.	  These	  risks	  will	  be	  
minimized	  by	  the	  use	  of	  sterile	  techniques	  and	  by	  having	  experienced	  personnel	  draw	  all	  blood	  
samples.	  	  There	  may	  also	  be	  a	  chance	  of	  fainting	  during	  the	  blood	  draw.	  	  We	  will	  ask	  about	  any	  
history	  of	  fainting	  during	  your	  screening	  visit.	  	  	  To	  minimize	  the	  risk	  of	  fainting	  or	  effects	  of	  




2)	  The	  risk	  of	  stopping	  your	  exercise	  for	  10	  days	  is	  that	  your	  risk	  factors	  for	  cardiovascular	  
disease	  and	  aging	  may	  deteriorate.	  It	  is	  unlikely	  that	  substantial	  changes	  will	  take	  place	  over	  
the	  space	  of	  the	  10	  days	  without	  exercise.	  Furthermore,	  you	  will	  be	  able	  to	  start	  exercising	  
again	  immediately	  after	  these	  10	  days	  without	  exercise.	  	  
3)	  Physical	  Activity	  Monitoring:	  There	  are	  no	  known	  risks	  associated	  with	  monitoring	  your	  
physical	  activity	  with	  either	  the	  ActiGraph	  activity	  monitor	  or	  Omron	  pedometer.	  	  	  
4)	  You	  will	  be	  asked	  to	  fast	  for	  12	  hours	  on	  two	  occasions	  (prior	  to	  visits	  2	  and	  3).	  Fasting	  for	  
this	  time	  period	  may	  result	  in	  some	  discomfort.	  	  You	  will	  be	  allowed	  to	  take	  in	  water	  during	  this	  
period.	  	  In	  addition,	  you	  will	  be	  given	  a	  snack	  and	  beverage	  following	  your	  testing	  during	  visits	  2	  
and	  3.	  
5)	  Your	  involvement	  may	  involve	  some	  inconveniences,	  such	  as	  time	  spent	  in	  travel,	  performing	  
the	  screening	  and	  testing	  procedures,	  and	  stopping	  your	  physical	  activity.	  Your	  parking	  costs	  
will	  be	  covered.	  	  	  
	  
8.	  how	  will	  my	  personal	  information	  be	  protected?	  	  
We	  will	  do	  our	  best	  to	  keep	  your	  personal	  information	  confidential.	  To	  help	  protect	  your	  
confidentiality,	  all	  data	  are	  kept	  in	  a	  secure	  locked	  office	  with	  access	  available	  only	  to	  study	  
personnel.	  Furthermore,	  all	  electronic	  files	  (e.g.,	  database,	  spreadsheet,	  etc.)	  containing	  
identifiable	  information	  will	  be	  password	  protected.	  	  Computers	  with	  data	  from	  this	  study	  will	  be	  
protected	  by	  a	  password	  and	  only	  available	  to	  be	  accessed	  by	  authorized	  personnel	  involved	  
with	  the	  study.	  Only	  the	  members	  of	  the	  research	  staff	  will	  have	  access	  to	  the	  passwords.	  	  	  
	  
Blood	  samples	  will	  be	  labeled	  with	  a	  unique	  code,	  not	  your	  name	  or	  any	  other	  identifying	  
information.	  	  By	  agreeing	  to	  participate	  in	  this	  study,	  you	  release	  ownership	  of	  blood	  samples	  to	  
the	  University	  of	  Massachusetts	  Molecular	  Cardiovascular	  Physiology	  Laboratory.	  The	  study	  
investigators	  may	  store	  some	  samples	  for	  future	  analysis,	  for	  a	  maximum	  of	  3	  years,	  after	  which	  
point	  the	  samples	  will	  be	  safely	  destroyed	  as	  per	  the	  University’s	  Environmental	  Health	  and	  Safety	  
guidelines.	  	  The	  samples	  will	  be	  stored	  in	  a	  -­‐80˚C	  freezer	  in	  our	  lab.	  They	  will	  be	  identified	  by	  a	  
unique	  code.	  	  The	  key	  to	  the	  codes	  will	  be	  kept	  in	  a	  locked	  and	  secure	  cabinet.	  Only	  the	  study	  





If	  we	  write	  a	  report	  or	  article	  about	  this	  research	  project,	  your	  identity	  will	  be	  protected	  to	  the	  
maximum	  extent	  possible.	  Information	  will	  be	  presented	  in	  summary	  format	  and	  you	  will	  not	  be	  
identified	  in	  any	  publications	  or	  presentations.	  	  Your	  information	  may	  only	  be	  shared	  with	  
representatives	  of	  the	  University	  of	  Massachusetts	  or	  government	  authorities	  if	  you	  or	  
someone	  else	  is	  in	  danger	  or	  if	  we	  are	  required	  to	  do	  so	  by	  law.	  	  Our	  records	  of	  the	  research	  will	  
be	  maintained	  for	  3	  years	  following	  study	  completion.	  
	  
Please	  indicate	  if	  you	  agree	  or	  disagree	  to	  having	  us	  store	  your	  samples	  for	  a	  maximum	  of	  three	  
years,	  for	  further	  analysis,	  under	  the	  conditions	  described	  above	  (check	  only	  one	  of	  the	  two	  boxes	  
below):	  
	  
□	  I	  agree	  to	  have	  my	  samples	  stored	  for	  future	  analysis	  under	  the	  conditions	  	  	  mentioned	  above	  	  
□	  I	  do	  not	  agree	  to	  have	  my	  samples	  stored	  for	  future	  analysis	  under	  the	  conditions	  mentioned	  
above	  
	  
9.	  WHAT	  IF	  I	  HAVE	  QUESTIONS?	  
Take	  as	  long	  as	  you	  like	  before	  you	  make	  a	  decision.	  We	  will	  be	  happy	  to	  answer	  any	  question	  you	  
have	  about	  this	  study.	  If	  you	  have	  further	  questions	  about	  this	  project	  or	  if	  you	  have	  a	  research-­‐
related	  problem,	  you	  may	  contact	  the	  principal	  investigator,	  Sarah	  Witkowski	  at	  
switkows@kin.umass.edu	  or	  413-­‐545-­‐6102	  or	  graduate	  student,	  Gayatri	  Guhanarayan	  at	  
gguhanar@kin.umass.edu	  or	  973-­‐572-­‐8941.	  	  If	  you	  have	  any	  questions	  concerning	  your	  rights	  
as	  a	  research	  subject,	  you	  may	  contact	  the	  University	  of	  Massachusetts	  Amherst	  Human	  
Research	  Protection	  Office	  (HRPO)	  at	  (413)	  545-­‐3428	  or	  humansubjects@ora.umass.edu.	  
	  
11.	  CAN	  I	  STOP	  BEING	  IN	  THE	  STUDY?	  
You	  do	  not	  have	  to	  be	  in	  this	  study	  if	  you	  do	  not	  want	  to.	  	  If	  you	  agree	  to	  be	  in	  the	  study,	  but	  later	  
change	  your	  mind,	  you	  may	  drop	  out	  at	  any	  time.	  	  There	  are	  no	  penalties	  or	  consequences	  of	  any	  
kind	  if	  you	  decide	  that	  you	  do	  not	  want	  to	  participate.	  	  You	  will	  be	  notified	  of	  all	  significant	  new	  





12.	  WHAT	  IF	  I	  AM	  INJURED?	  
The	  University	  of	  Massachusetts	  does	  not	  have	  a	  program	  for	  compensating	  subjects	  for	  injury	  
or	  complications	  related	  to	  human	  subjects	  research,	  but	  the	  study	  personnel	  will	  assist	  you	  in	  
getting	  treatment.	  	  Medical	  treatment	  will	  be	  available	  at	  the	  University	  Health	  Services	  for	  a	  
fee.	  
	  
13.	  SUBJECT	  STATEMENT	  OF	  VOLUNTARY	  CONSENT	  
I	  have	  read	  this	  form	  and	  decided	  that	  I	  will	  participate	  in	  the	  project	  described	  above.	  	  The	  
general	  purposes	  and	  particulars	  of	  the	  study	  as	  well	  as	  possible	  hazards	  and	  inconveniences	  
have	  been	  explained	  to	  my	  satisfaction.	  	  I	  understand	  that	  I	  can	  withdraw	  at	  any	  time.	  	  	  
________________________	  	   ____________________	   	   __________	  
Participant	  Signature:	  	   	   Print	  Name:	   	   	   	   Date:	  
By	  signing	  below	  I	  indicate	  that	  the	  participant	  has	  read	  and,	  to	  the	  best	  of	  my	  knowledge,	  
understands	  the	  details	  contained	  in	  this	  document	  and	  has	  been	  given	  a	  copy.	  
_________________________	  	  	  	   ____________________	   	   __________	  
Signature	  of	  Person	   	   	   Print	  Name:	   	   	   	   Date:	  
Obtaining	  Consent	  





6.2:	  Health	  history	  questionnaire	  
	  
Participant	  ID:	  	  
	  Molecular	  and	  Cardiovascular	  Physiology	  Laboratory	  University	  of	  Massachusetts	  	  
DEPARTMENT	  OF	  KINESIOLOGY,	  	  
TOTMAN	  BUILDING,	  30	  EASTMAN	  LA,	  AMHERST	  MA	  01003	  	  
(413)	  545-­‐6012	  (413)	  545-­‐2906	  FAX	  	  
Health	  History	  Questionnaire	  
GENERAL	  HEALTH	  	  
Height__________	  Weight__________	  	  
How	  would	  you	  describe	  your	  overall	  physical	  health?	  ____	  excellent	  ____	  good	  ____	  fair	  
____	  poor	  Have	  you	  undergone	  a	  physical	  examination	  in	  t	  he	  last	  5	  years?	  □	  Yes	  □	  No	  Are	  
you	  on	  a	  special	  diet?	  □	  Yes	  □	  No	  If	  yes,	  what	  type:__________________________	  Have	  
you	  gained	  or	  lost	  more	  than	  10	  lbs	  in	  the	  last	  6	  months?	  □	  Yes	  □	  No	  Have	  you	  had	  any	  
illness	  in	  the	  last	  2	  weeks?	  □	  Yes	  □	  No	  If	  yes,	  specify:	  ___________________________	  Do	  
you	  have	  documented	  heart	  disease?	  □	  Yes	  □	  No	  If	  yes,	  how	  long	  ago	  was	  it	  documented?	  
____________	  years	  Has	  a	  doctor	  ever	  told	  you	  that	  you	  have	  an	  ulcer?	  □	  Yes	  □	  No	  Has	  a	  
doctor	  ever	  told	  you	  that	  you	  have	  any	  type	  of	  bleeding	  disorder?	  □	  Yes	  □	  No	  	  
Have	  you	  ever	  experienced	  dizziness	  or	  fainting	  during	  a	  blood	  draw?	  □	  Yes	  □	  No	  	  
Have	  you	  ever	  been	  advised	  by	  your	  doctor	  or	  any	  medical	  professional	  that	  you	  should	  not	  
exercise	  or	  engage	  in	  any	  sort	  of	  strenuous	  physical	  activity?	  □	  Yes	  □	  No	  	  
If	  yes,	  please	  explain:_________________________________	  Participant	  ID:	  	  
Have	  you	  ever	  had	  any	  of	  the	  following	  
conditions/symptoms?	  Leave	  blank	  for	  “	  no”	  
.	  Indicate	  “	  yes”	  with	  a	  check	  mark	  and	  
indicate	  year	  of	  onset.	  Check	  	  
Year	  of	  	  
for	  yes	  	   Onset	  	  
_______	  High	  blood	  pressure	  	  
_______	  Heart	  attack	  /coronary	  problem	  	  
_______	  Heart	  murmur	  	  
_______	  Heart	  disease	  	  




_______	  Palpitations/rapid	  heart	  beat	  	  
_______	  Phlebitis	  	  
_______	  Stroke	  	  
_______	  Lung/respiratory	  problem	  s	  	  
_______	  Diabetes	  	  
_______	  Varicose	  veins	  	  
_______	  High	  cholesterol	  	  
_______	  Anemia	  	  
_______	  Thyroid	  problems	  	  
_______	  Cancer	  	  
	  




6.3:	  Physical	  activity	  questionnaire	  
	  
Participant	  ID:	  	  
	  Molecular	  and	  Cardiovascular	  Physiology	  Laboratory	  University	  of	  Massachusetts	  	  
DEPARTMENT	  OF	  KINESIOLOGY,	  	  
TOTMAN	  BUILDING,	  30	  EASTMAN	  LA,	  AMHERST	  MA	  01003	  	  
(413)	  545-­‐6012	  (413)	  545-­‐2906	  FAX	  	  
Physical	  Activity	  and	  Performance	  Questionnaire	  	  
Physical	  Activity	  Information	  	  
How	  many	  times	  a	  week	  do	  you	  exercise?	  
_____________________________________________	  	  
How	  many	  minutes	  do	  you	  spend	  exercising	  per	  session?	  ____________________________	  
minutes	  	  
Do	  you	  ever	  exercise	  twice	  a	  day?	  □	  No	  □	  Everyday	  □	  Occasionally	  _______________________	  	  
Mode(s)	  of	  exercise	  (check	  all	  that	  apply):	  	  
□	  Running	  □	  Cycling	  □	  Swimming	  □	  Other	  _____________________________________	  	  
What	  is	  the	  approximate	  pace	  (minutes/mile)	  for	  your	  exercise	  sessions?	  
____________________________	  	  
How	  many	  miles	  do	  you	  run/cycle/swim/etc.	  in	  an	  average	  week?	  	  
Running	  ________	  Cycling	  ________	  Swimming	  ________	  Other	  ___________________	  	  
Have	  you	  been	  exercising	  continuously	  since	  high	  school	  or	  college?	  □	  Yes	  □	  No	  	  
If	  no,	  how	  many	  years	  elapsed	  until	  you	  resumed	  exercising?	  	  
_____________________________________	  	  
How	  many	  years	  have	  you	  been	  exercising	  continuously	  in	  the	  last	  20	  years?	  




Please	  outline	  a	  typical	  week’s	  work	  out	  schedule	  giving	  distance	  covered	  and	  times	  registered:	  	  
EXERCISE	  MODE	  MILEAGE	  COVERED	  DURATION	  	  
(run/cycle/etc)	  	  
SUNDAY	  _________________	  _________________	  ________________	  	  
MONDAY	  _________________	  _________________	  ________________	  	  
TUESDAY	  _________________	  _________________	  ________________	  	  
WEDNESDAY	  _________________	  _________________	  ________________	  	  
THURSDAY	  _________________	  _________________	  ________________	  	  
FRIDAY	  _________________	  _________________	  ________________	  	  
SATURDAY	  _________________	  _________________	  ________________	  	  
Please	  use	  the	  space	  below	  to	  provide	  any	  additional	  information	  regarding	  your	  
exercise/activity	  history	  that	  you	  feel	  will	  be	  helpful	  to	  us.	  









During	  the	  baseline	  week	  you	  will	  be	  asked	  to	  continue	  your	  regular	  dietary	  habits.	  A	  
researcher	  will	  email	  you	  twice	  during	  the	  week	  and	  once	  during	  the	  weekend,	  in	  the	  morning,	  
to	  ask	  you	  to	  recall	  what	  you	  ate	  the	  day	  before.	  Please	  be	  as	  accurate	  as	  possible	  and	  
complete	  the	  dietary	  recall	  before	  midnight	  of	  the	  day	  that	  you	  receive	  the	  email.	  
	  
ACTIGRAPH	  
During	  the	  baseline	  week	  you	  will	  be	  asked	  to	  wear	  an	  Actigraph	  monitor	  and	  continue	  your	  
regular	  exercise	  routines.	  It	  is	  important	  that	  you	  record	  when	  you	  put	  the	  Actigraph	  on	  and	  
when	  you	  take	  it	  off	  in	  the	  Actigraph	  Record	  Chart	  (next	  page).	  Indicate	  the	  reason	  for	  taking	  
the	  Actigraph	  off	  (sleep,	  shower,	  exercise,	  other).	  Please	  follow	  these	  instructions:	  
• The	  Actigraph	  is	  worn	  on	  the	  right	  hip,	  in	  line	  with	  the	  right	  armpit	  and	  knee	  
• Be	  sure	  the	  monitor	  firmly	  placed	  and	  snug	  around	  the	  waist	  and	  the	  monitor	  is	  
oriented	  correctly	  with	  the	  arrow	  pointing	  up	  
• This	  monitor	  will	  be	  worn	  during	  you	  waking	  ours	  (from	  the	  time	  you	  wake	  up	  until	  the	  
time	  you	  go	  to	  bed)	  for	  the	  seven-­‐day	  baseline	  period	  
o You	  will	  record	  the	  times	  you	  put	  the	  monitor	  on	  in	  the	  morning	  and	  the	  times	  
you	  took	  it	  off	  at	  night	  on	  your	  monitor	  log	  for	  each	  day	  
o You	  will	  also	  record	  other	  times	  during	  the	  day	  when	  you	  took	  the	  monitor	  off	  
(for	  things	  like	  swimming	  and	  showering)	  for	  each	  day	  
• Do	  not	  wear	  monitor	  in	  water	  
o If	  you	  do	  bathe	  or	  participate	  in	  water-­‐based	  activities,	  please	  remove	  monitors	  
o Record	  the	  times	  the	  monitor	  is	  removed	  and	  put	  back	  on	  in	  you	  monitor	  log	  
• Please	  be	  sure	  to	  record	  times	  with	  AM	  or	  PM	  indicated	  
	  
PEDOMETER	  
During	  the	  baseline	  week	  you	  will	  be	  asked	  to	  wear	  a	  pedometer	  throughout	  the	  day.	  Please	  
take	  the	  pedometer	  off	  only	  during	  exercise,	  sleep,	  and	  anytime	  it	  would	  get	  wet	  (swimming	  or	  
bathing).	  Please	  record	  the	  times	  you	  take	  it	  off	  and	  put	  it	  back	  on	  on	  the	  Pedometer	  Record	  





Actigraph	  Record	  Chart	  
• Record	  time	  on	  and	  off	  for	  each	  day,	  Record	  reason	  (sleep,	  shower,	  exercise,	  other)	  
• Indicate	  AM	  or	  PM	  










































	   	   	   	   	   	   	   	  
Pedometer	  Record	  Chart	  




• Indicate	  AM	  or	  PM	  















































	   	   	   	   	   	   	   	  
	  




6.5:	  Baseline-­‐	  checklist	  for	  exercise	  and	  diet	  (for	  visit#2)	  
	  
Participant:	  
Checklist	  for	  Cardiovascular	  Study:	  
Thank	  you	  for	  being	  part	  of	  our	  study!	  Here	  is	  a	  checklist	  of	  things	  we	  will	  need	  you	  to	  do	  
before	  coming	  in	  for	  your	  testing	  visit	  on	  ______________.	  	  
□ Please	  follow	  the	  low-­‐nitrate	  diet	  (based	  on	  the	  recommendations	  attached)	  for	  3	  days	  
prior	  to	  your	  testing	  visit.	  Starting	  on	  ___________	  
	  
□ You	  must	  exercise*	  24	  hours	  prior	  to	  your	  testing	  visit.	  This	  can	  be	  anytime	  between	  the	  
hours	  of	  __________(time)	  on	  _____________(date)	  	  
*This	  should	  consist	  of	  your	  normal	  exercise	  routine	  (which	  can	  include	  running,	  cycling,	  
swimming)	  but	  CANNOT	  include	  weight-­‐lifting.	  Do	  not	  over-­‐exert	  yourself	  since	  this	  can	  
affect	  the	  study	  outcomes.	  	  
o Please	  do	  not	  exercise	  after	  this	  time.	  
	  
□ You	  CANNOT	  consume	  the	  following	  substances	  24	  hours	  prior	  to	  you	  visit:	  	  
starting	  at	  __________	  (time)	  on	  _________	  (date)	  
	  
1. Medications	  (including	  vitamins	  and	  allergy	  medications)	  




□ In	  addition	  to	  this,	  you	  will	  need	  to	  be	  in	  a	  fasted	  state	  for	  8	  hours	  prior	  to	  your	  visit.	  
Starting	  at	  ______	  (time)	  on	  ________	  (date).	  During	  those	  8	  hours	  you	  can	  only	  have	  
water.	  
o We	  strongly	  recommend	  that	  you	  have	  plenty	  of	  water	  before	  coming	  in	  for	  the	  
visit.	  
	  
□ On	  the	  morning	  of	  the	  testing	  visit	  on	  ________	  we	  will	  need	  you	  to	  take	  2	  
measurements	  of	  your	  pulse	  over	  the	  course	  of	  1	  minute	  BEFORE	  YOU	  GET	  OUT	  OF	  BED	  
(carotid	  or	  brachial	  will	  do).	  Please	  note	  the	  readings	  down	  below	  and	  bring	  them	  in	  





If	  you	  have	  any	  questions	  or	  concerns	  please	  don’t	  hesitate	  to	  contact	  me	  Gayatri	  (Gaya):Email:	  




6.6:	  Low-­‐nitrate	  diet	  instructions	  (for	  3	  days	  prior	  to	  visits#	  2	  and	  3)	  
	  
1.	  Dietary	  Restriction	  List	  
Since	  diet	  influences	  your	  blood	  pressure	  and	  sodium	  excretion	  rate,	  certain	  dietary	  restrictions	  
(low	  nitrate	  diet)	  apply	  to	  this	  part	  of	  the	  study.	  We	  ask	  that	  for	  3	  days	  you	  exclude	  from	  your	  
diet	  the	  foods	  and	  drinks	  that	  are	  listed	  on	  this	  page.	  Therefore	  you	  will	  be	  on	  this	  diet	  2	  days	  
prior	  to	  your	  blood	  pressure	  measurement	  and	  urine	  collection,	  and	  remain	  on	  the	  diet	  during	  
your	  blood	  pressure	  measurement	  and	  urine	  collection.	  This	  will	  help	  ensure	  the	  accuracy	  of	  
the	  results	  of	  your	  urine	  collection	  test.	  
Upon	  completion	  of	  your	  6	  months	  of	  exercise	  training,	  this	  booklet	  will	  be	  given	  back	  to	  you,	  
and	  you	  will	  be	  asked	  to	  mimic	  this	  diet	  prior	  to	  your	  final	  urine	  collection	  and	  blood	  pressure	  
measurement.	  	  
LOW	  NITRATE	  DIET	  	  
(http://www.nhlbi.nih.gov/labs/7east/lowNdiet.htm)	  
	  
FOOD	  GROUP	   FOODS	  ALLOWED	   FOODS	  NOT	  ALLOWED	  
Meat	  or	  
Substitutes	  
• All	  plain	  fresh	  or	  frozen	  beef,	  
poultry,	  lamb,	  veal	  or	  pork	  	  
• All	  seafood	  (shellfish,	  salt	  water	  or	  
fresh	  water	  fish)	  	  
• All	  cured,	  smoked,	  preserved,	  
canned	  or	  processed	  meats,	  e.g.,	  
cold	  cuts,	  bacon,	  sausage,	  ham,	  
hotdogs,	  pepperoni,	  corned	  beef,	  
pastrami	  	  
• All	  canned	  meats	  and	  fish,	  
including	  tuna	  	  
• Tofu,	  soybeans,	  legumes	  	  
• Nuts,	  peanut	  butter	  	  
• Vegetarian	  burgers	  made	  with	  
lentils,	  soybeans	  or	  other	  legumes	  
Vegetables	   • NONE	  	   • All	  vegetables	  (raw	  or	  cooked)	  	  
• Pickles,	  olives,	  relish	  	  
• Raw	  or	  cooked	  garlic	  and	  onions	  	  
• All	  vegetable	  based	  products	  such	  
as	  tomato	  sauces,	  ketchup,	  and	  






• Rice,	  pasta,	  noodles	  	   • All	  white	  or	  sweet	  potatoes	  
including	  potato	  chips,	  french	  fries	  	  
• Any	  prepared	  with	  cheeses	  or	  
vegetables,	  including	  tomatoes,	  
tomato	  sauces	  	  
Eggs	   • Any	  except	  as	  listed	  	   • Any	  to	  which	  "foods	  not	  allowed"	  
have	  been	  added,	  e.g.,	  cheese	  
omelet	  	  
Dairy	   • Milk-­‐-­‐whole,	  2%,	  skim,	  
chocolate	  	  
• Yogurt,	  plain	  or	  with	  allowed	  
fruits	  	  
• Cottage	  cheese,	  cream	  cheese	  	  
• Ice	  cream	  or	  ice	  milk	  (vanilla,	  
chocolate)	  	  
• Cream	  	  
• Yogurt	  with	  non-­‐allowed	  fruits	  	  
• All	  other	  cheese-­‐-­‐e.g.,	  cheddar,	  
swiss,	  blue,	  american,	  mozzarella	  	  
• Ice	  cream	  with	  non-­‐allowed	  fruit	  
or	  nuts	  	  
• Sour	  cream	  	  
Fruit	  or	  Fruit	  
Juice	  
• Any	  except	  as	  listed	  	   • Strawberries	  	  
• Bananas	  	  
• Melons	  
Soup	  
• No	  commercial	  soup	  	  
• (Homemade,	  made	  with	  
allowed	  ingredients	  is	  OK	  
• All	  soups,	  broths,	  and	  brines	  
should	  be	  avoided	  
Fats	  
• Butter,	  margarine,	  
mayonnaise,	  vegetable	  oils	  	  
• Vinegar	  &	  oil	  salad	  dressing	  	  
• Salt	  pork,	  salad	  dressings	  
containing	  tomato	  sauce	  	  
• Worcestershire	  sauce	  or	  other	  
ingredients	  not	  allowed	  	  
Breads	  and	  
Cereal	   • Pretzels	  	  
• Graham	  crackers	  	  
• Any	  cereal,	  crackers,	  
doughnuts	  or	  sweet	  rolls,	  
breads/rolls,	  muffins,	  snack	  
crackers,	  except	  as	  listed	  	  
• Any	  prepared	  with	  "foods	  not	  
allowed,	  e.g.,	  cheese	  bread,	  
popcorn,	  doughnut	  with	  
strawberry	  filling,	  	  
• Cereals	  containing	  nuts	  (such	  as	  
some	  granolas)	  	  
• Banana	  bread	  




popsicles,	  frozen	  desserts,	  
except	  as	  listed	  	  
cream,	  non-­‐allowed	  fruits	  	  
\Beverages	   • Allowed	  bottled	  water	  	  
• Montgomery	  County	  tap	  
water	  (limit	  to	  2	  cups	  daily)	  	  
• Beverages	  prepared	  with	  
allowed	  water	  	  
• Soda-­‐limit	  to	  1	  can/day	  	  
• Non-­‐allowed	  bottled	  water	  	  
• Private	  well	  water	  	  
• Beer,	  wine,	  liquor,	  non-­‐alcoholic	  
beer	  	  
Miscellaneous	   • Sugar,	  syrup,	  spices,	  
seasonings,	  herbs,	  salt,	  
pepper,	  honey,	  jelly	  (not	  
strawberry),	  mustard,	  
chewing	  gum,	  vinegar,	  vanilla,	  
onion	  and	  garlic	  salt	  or	  
powder	  	  
• Candy	  with	  nuts,	  	  
• Soy	  sauce,	  catsup,	  steak	  sauce,	  
chili,	  cocktail	  sauce,	  
worcestershire	  sauce,	  tomato	  
containing	  sauces,	  tabasco	  sauce	  	  
• Tobacco	  	  
SAMPLE	  MEALS:	  
Breakfast	  Menus	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  #1	  
• Orange	  Juice	  	  
• Rice	  Krispies	  	  
• Low-­‐fat	  Milk	  	  
• Wheat	  Toast	  	  
• Grape	  jelly	  	  
• Margarine	  	  
• Tea	  or	  coffee	  	  
• Cream	  or	  Sugar	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  #2	  
• Apple	  Juice	  	  
• Pancakes/syrup	  	  
• Scrambled	  eggs	  	  
• English	  Muffin	  	  
• Orange	  Slices	  	  
• Margarine	  	  
• Low-­‐fat	  Milk	  	  
• Tea	  or	  Coffee	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  #3	  
• Cranberry	  Juice	  	  
• Oatmeal	  	  
• Blueberry	  Muffin	  	  
• Peaches	  (warmed	  if	  
desired)	  	  
• Apple	  Butter	  	  
• Bagel	  	  
• Cream	  Cheese	  	  
• Tea	  or	  Coffee	  
Do	  not	  use	  strawberry	  jelly,	  strawberry	  jam,	  strawberry	  preserves,	  strawberry	  syrup	  or	  
strawberry	  cream	  cheese.	  Avoid	  all	  doughnuts	  and	  bagels	  made	  with	  strawberries.	  Do	  not	  add	  






	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  #1	  
• Plain	  hamburger	  on	  
bun	  	  
• Pretzels	  	  
• Fresh	  Pear	  	  
• Oreo	  Cookies	  	  
• Soda	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  #2	  
• Sliced	  turkey	  Sandwich	  	  
• Mayonnaise	  	  
• Fresh	  Grapes	  	  
• Blueberry	  Yogurt	  	  
• Low	  Nitrate	  Bottled	  
Water	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  #3	  
• Grilled	  Chicken	  Sandwich	  	  
• Plain	  Pita	  Chips	  	  
• Mandarin	  Oranges	  	  
• Mayonnaise/Mustard	  	  
• Brownie	  (without	  nuts)	  	  
• Low-­‐fat	  Milk	  	  
Please	  remember	  that	  the	  only	  condiments	  allowed	  for	  burgers	  and	  sandwiches	  are	  mustard	  
and	  mayonnaise.	  
Do	  not	  add	  lettuce,	  tomato,	  or	  pickles	  to	  sandwiches.	  	  
Remember	  that	  strawberry	  fruited	  yogurt	  is	  not	  allowed.	  
Remember	  to	  drink	  only	  1	  can	  of	  soda	  daily	  
Fruit	  salads	  are	  great	  -­‐	  as	  long	  as	  they	  do	  not	  contain	  bananas,	  strawberries,	  or	  melons.	  
	  
Dinner	  Menus	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  #1	  
• Grilled	  Pork	  Chops	  	  
• Steamed	  Pasta	  	  
• Applesauce	  	  
• Plain	  Dinner	  Roll	  	  
• Grape	  jelly	  	  
• Margarine	  	  
• Tea	  or	  coffee	  	  
• Angel	  Food	  Cake	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  #2	  
• Honey	  Roasted	  Chicken	  	  
• Fried	  Rice	  (don't	  add	  
onions)	  	  
• Poached	  Pears	  	  
• Plain	  Popovers	  	  
• Orange	  Slices	  	  
• Margarine	  	  
• Apple	  Pie	  	  
• Tea	  or	  Coffee	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  #3	  
• Broiled	  Steak	  	  
• Steamed	  Rice	  	  
• Microwaved	  Peach	  
Slices	  	  
• Peaches	  (warmed	  if	  
desired)	  	  
• French	  Bread	  	  
• Margarine	  	  
• Orange	  Sherbet	  	  
• Tea	  or	  Coffee	  
Rice	  can	  be	  fried	  in	  oil	  with	  herbs	  and	  spices,	  but	  do	  not	  add	  vegetables.	  
	  Make	  sure	  your	  tea	  and	  coffee	  are	  made	  with	  low	  nitrate	  water,	  or	  are	  part	  of	  your	  tap	  water	  
allowance.	  




6.7:	  rPA-­‐	  activity	  and	  diet	  log	  
	  
Information	  Packet	  
10	  day	  reduced	  activity	  period	  
DIET	  
Please	  Login	  to	  www.myfitnesspal.com	  every	  other	  day	  to	  enter	  your	  dietary	  information.	  Start	  
by	  filling	  it	  out	  on	  the	  first	  and	  second	  day	  that	  you	  start	  your	  reduced	  activity	  so	  that	  you	  are	  
able	  to	  modulate	  your	  eating	  habits	  to	  meet	  the	  daily	  calorie	  “goal”	  that	  is	  set	  for	  you	  on	  the	  
website.	  
Goal:____________	  
The	  login	  information	  that	  you	  need	  is	  to	  access	  your	  account	  on	  myfitnesspal	  is-­‐	  
Username:	  _________	  
Password:	  _________	  
Please	  check	  your	  weight	  whenever	  possible	  to	  make	  sure	  you	  don’t	  gain/lose	  weight	   	  
Weight	  day2:_______,	  day4:_______,	  day6:_______,	  day	  8:_______	  
ACTIGRAPH	  
During	  the	  ten-­‐day	  reduced	  activity	  period	  you	  will	  be	  asked	  to	  wear	  an	  Actigraph	  and	  stop	  all	  
structured	  physical	  activity.	  See	  note	  on	  “How	  to	  reduce	  physical	  activity.”	  It	  is	  important	  that	  
you	  record	  when	  you	  put	  the	  Actigraph	  on	  and	  when	  you	  take	  it	  off	  in	  the	  Actigraph	  Record	  
Chart.	  Indicate	  the	  reason	  for	  taking	  the	  Actigraph	  off	  (sleep,	  shower,	  exercise,	  other).	  	  
Please	  follow	  these	  instructions:	  
• The	  Actigraph	  is	  worn	  on	  the	  right	  hip,	  in	  line	  with	  the	  right	  armpit	  and	  knee	  
• Be	  sure	  the	  monitor	  firmly	  placed	  and	  snug	  around	  the	  waist	  and	  the	  monitor	  is	  
oriented	  correctly	  with	  the	  arrow	  pointing	  up	  
• This	  monitor	  will	  be	  worn	  during	  your	  waking	  hours	  (from	  the	  time	  you	  wake	  up	  until	  
the	  time	  you	  go	  to	  bed)	  for	  the	  ten-­‐day	  reduced	  activity	  period	  
o You	  will	  record	  the	  times	  you	  put	  the	  monitor	  on	  in	  the	  morning	  and	  the	  times	  
you	  took	  it	  off	  at	  night	  on	  your	  monitor	  log	  for	  each	  day	  
o You	  will	  also	  record	  other	  times	  during	  the	  day	  when	  you	  took	  the	  monitor	  off	  
(for	  things	  like	  swimming	  and	  showering)	  for	  each	  day	  
• Do	  not	  wear	  monitor	  in	  water	  
o If	  you	  do	  bathe	  or	  participate	  in	  water-­‐based	  activities,	  please	  remove	  monitors	  
o Record	  the	  times	  the	  monitor	  is	  removed	  and	  put	  back	  on	  in	  you	  monitor	  log	  






During	  the	  ten	  day	  reduced	  activity	  period	  you	  will	  be	  asked	  to	  wear	  a	  pedometer	  throughout	  
the	  day.	  Be	  sure	  to	  stay	  at	  or	  below	  the	  maximum	  number	  of	  steps	  per	  day	  as	  advised	  by	  the	  
researchers.	  Please	  take	  the	  pedometer	  off	  only	  during	  sleep,	  and	  anytime	  it	  would	  get	  wet	  
(swimming	  or	  bathing).	  Please	  record	  the	  times	  you	  take	  it	  off	  and	  put	  it	  back	  on	  on	  the	  
Pedometer	  Record	  Chart.	  
Limit	  for	  steps/day	  :	  _________________________	  
	  
HOW	  TO	  BE	  INACTIVE:	  
1. No	  running,	  weight	  lifting,	  elliptical,	  or	  any	  form	  of	  exercise	  
2. Avoid	  walking	  long	  distances	  and	  sprinting	  	  
3. Take	  the	  bus,	  car	  and	  use	  elevator	  whenever	  you	  can	  
4. Sit	  as	  much	  as	  you	  can	  
5. Do	  not	  participate	  in	  recreation	  sports	  








Actigraph	  Record	  Chart	  
• Record	  time	  on	  and	  off	  for	  each	  day,	  Record	  reason	  (sleep,	  shower,	  other)	  
• Indicate	  AM	  or	  PM	  













































	   	   	   	   	   	   	   	  
Day	  10	  
Date:	  






Pedometer	  Record	  Chart	  
• Record	  time	  on	  and	  off	  for	  each	  day,	  Record	  reason	  (sleep,	  shower,	  other)	  
• Indicate	  AM	  or	  PM	  













































	   	   	   	   	   	   	   	  
Day	  9	  
Date:	  










	   	   	   	   	   	   	   	  
	  
	  




6.8:	  rPA-­‐	  checklist	  for	  diet	  (for	  visit#3)	  
Participant:	  
Checklist	  for	  Cardiovascular	  Study:	  
Thank	  you	  for	  being	  part	  of	  our	  study!	  Here	  is	  a	  checklist	  of	  things	  we	  will	  need	  you	  to	  do	  
before	  coming	  in	  for	  your	  testing	  visit	  on	  ______________.	  	  
	  
□ Please	  follow	  the	  low-­‐nitrate	  diet	  (based	  on	  the	  recommendations	  attached)	  for	  3	  days	  
prior	  to	  your	  testing	  visit.	  Starting	  on	  ___________	  
	  
□ You	  CANNOT	  consume	  the	  following	  substances	  24	  hours	  prior	  to	  you	  visit:	  	  
starting	  at	  __________	  (time)	  on	  _________	  (date)	  
	  
5. Medications	  (including	  vitamins	  and	  allergy	  medications)	  




□ In	  addition	  to	  this,	  you	  will	  need	  to	  be	  in	  a	  fasted	  state	  for	  8	  hours	  prior	  to	  your	  visit.	  
Starting	  at	  ______	  (time)	  on	  ________	  (date).	  During	  those	  8	  hours	  you	  can	  only	  have	  
water.	  
o We	  strongly	  recommend	  that	  you	  have	  plenty	  of	  water	  before	  coming	  in	  for	  the	  
visit.	  
	  
□ On	  the	  morning	  of	  the	  testing	  visit	  on	  ________	  we	  will	  need	  you	  to	  take	  2	  
measurements	  of	  your	  pulse	  over	  the	  course	  of	  1	  minute	  BEFORE	  YOU	  GET	  OUT	  OF	  BED	  
(carotid	  or	  brachial	  will	  do).	  Please	  note	  the	  readings	  down	  below	  and	  bring	  them	  in	  






If	  you	  have	  any	  questions	  or	  concerns	  please	  don’t	  hesitate	  to	  contact	  me	  Gayatri	  (Gaya):	  
Email:	  gguhanar@kin.umass.edu	  	  





6.9:	  CFU-­‐Hill	  assay	  protocol	  
	  




(5)	  K3EDTA	  7	  ml	  blood	  drawing	  tubes	  
(6)	  50	  ml	  polypropylene	  conical	  tubes	  
(3)	  15	  ml	  polypropylene	  conical	  tube	  
(1)	  6-­‐well	  fibronectin	  coated	  plate	  
Transfer	  pipette	  
Sterile	  pipettes	  	  
Pipetter	  
Micropipettes	  (p20,	  p200)	  
Pipette	  tips	  
Hemacytometer	  
Solutions	  &	  Reagents	  
	  3%	  Acetic	  Acid	  with	  Methylene	  Blue	  (220	  ul/sample	  
PBS	  (~14	  ml/sample)	  
Ficoll	  Paque	  PLUS	  (15	  ml/sample)	  
EndoCult	  Medium	  (7ml/sample)	  
PBS	  +	  2%	  FBS	  (up	  to	  52	  ml/sample)	  
	  
Preparation	  of	  EndoCult	  Medium	  
1) Thaw	  EndoCult	  Supplement	  under	  refrigeration	  (2-­‐8oC)	  overnight	  or	  at	  RT	  
2) Add	  2	  ml	  Supplement	  for	  every	  8	  ml	  of	  Basal	  Medium	  
a. Alternatively,	  add	  entire	  bottle	  of	  Supplement	  (20	  ml)	  to	  entire	  bottle	  of	  
basal	  medium	  (80	  ml).	  
b. Mixed	  EndoCult	  Medium	  is	  stable	  for	  ~	  1	  month	  at	  2-­‐8oC	  
3) Add	  1	  ml	  of	  Penicillin	  +	  Streptomycin	  Antibiotic	  Solution	  per	  100	  ml	  of	  EndoCult	  
Medium	  
a. Thaw	  antibiotic	  solution	  in	  37o	  C	  water	  bath	  until	  just	  thawed.	  
b. 1.5	  ml	  aliquots	  are	  in	  -­‐20o	  freezer.	  	  DO	  NOT	  REFREEZE	  ALIQUOTS!	  
c. Once	  antibiotic	  is	  added,	  EndoCult	  medium	  must	  be	  used	  within	  1WEEK.	  







Day	  0:	  Density	  centrifugation	  and	  plating	  
	  
1) Set	  the	  big	  centrifuge	  at	  25	  deg	  C	  	  
2) Collect	  blood	  in	  5	  purple	  top	  (EDTA)	  10	  ml	  vacutainer	  tubes	  and	  1	  red	  top	  tube	  
	  
3) Prepare	  mononuclear	  cell	  suspension	  
a) Add	  Blood	  to	  50	  ml	  conical	  tube,	  then	  add	  an	  equal	  volume	  of	  PBS	  to	  the	  same	  
tube	  
b) Add	  15ml	  of	  Ficoll-­‐Paque	  PLUS	  to	  a	  NEW	  50	  ml	  conical	  tube	  
i. Carefully	  layer	  the	  diluted	  blood	  on	  top	  of	  the	  15	  ml	  of	  Ficoll	  DO	  NOT	  MIX	  
BLOOD	  AND	  FICOLL)	  
ii. Use	  the	  manual	  pipette	  or	  seriological	  pipette	  if	  confident	  enough	  
c) Centrifuge	  at	  300	  x	  g	  (1250	  rpm	  -­‐	  CCL)	  for	  25	  min	  at	  RT	  with	  BRAKE	  OFF	  
d) At	  this	  point	  bring	  the	  pbs/fbs	  out	  to	  thaw	  in	  a	  50ml	  tube,	  in	  incubator	  
e) Collect	  mononuclear	  layer	  into	  a	  NEW	  50	  ml	  conical	  tube	  using	  transfer	  pipette	  
f) Add	  PBS	  +	  2%	  FBS	  to	  bring	  final	  volume	  up	  to	  40	  ml	  





4) Remove	  supernatant	  and	  re-­‐suspend	  pellet	  	  
a) Re-­‐suspend	  with	  6	  ml	  of	  PBS	  +2%	  FBS	  
b) Transfer	  cell	  solution	  to	  15	  ml	  conical	  tube	  
c) Rinse	  the	  50	  ml	  conical	  tube	  with	  6	  ml	  of	  PBS	  +	  2%	  FBS	  and	  transfer	  this	  cell	  
solution	  to	  the	  same	  15	  ml	  conical	  tube	  
d) Centrifuge	  at	  300	  x	  g	  (1250	  rpm	  -­‐	  CCL)	  for	  7	  min	  at	  RT	  with	  BRAKE	  ON	  to	  pellet	  
cells	  
	  
5) Remove	  supernatant	  and	  re-­‐suspend	  cells	  in	  3	  ml	  of	  EndoCult	  Medium	  
	  
6) Count	  nucleated	  cells	  	  
a) Perform	  1:20	  dilution	  of	  cells	  using	  3%	  Acetic	  Acid	  with	  Methylene	  Blue	  




b) Use	  10	  ul	  cells	  and	  190	  ul	  Acetic	  Acid	  with	  Methylene	  Blue	  
i. This	  is	  a	  dilution	  factor	  of	  20	  
c) Count	  cells	  using	  hemacytometer	  and	  4	  outside	  squares	  
Carefully	  clean	  hemacytometer	  and	  coverslip	  with	  kimwipes	  and	  70%	  Ethanol	  
Place	  the	  coverslip	  over	  the	  hemacytometer.	  Thoroughly	  mix	  the	  cell	  
suspension.	  Carefully	  load	  the	  2	  V	  shaped	  wells	  of	  the	  hemacytometer.	  Count	  
(under	  10x	  objective)	  the	  number	  of	  viable	  (live)	  cells	  in	  the	  4	  corner	  boxes	  of	  
each	  side.	  
	  
Cell	  count	  (for	  the	  cells	  that	  are	  touching	  the	  border-­‐	  only	  include	  cells	  that	  are	  
in	  the	  top	  and	  bottom	  borders	  of	  every	  quadrant)	  












d) Cell	  count	  per	  ml	  =	  Avg	  #	  of	  cells	  per	  square	  *	  dilution	  factor	  *	  104	  
	  
Cell	  count	  per	  ml	  =	  ___________	  *	  20	  *	  104	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  =	  	  ___________	  cells/ml	  
e) Calculate	  the	  volume	  for	  5	  x	  106	  =	  5	  x	  106	  	  /number	  from	  d	  (above)	  *	  1000uL	  
	  
f) Volume	  of	  cell	  solution	  needed	  per	  well	  =	  	  5	  x	  106	  	  /_________	  *	  1000uL	  
	  
	  	  	  	  	  =	  _________	  uL	  
7) Add	  2	  ml/well	  of	  EndoCult	  medium	  to	  a	  6-­‐well	  fibronectin	  plate	  
a) PlateALL	  6	  WELLS!	  




b) Label	  Plate	  As	  follows	  






8) Incubate	  for	  2	  days	  at	  37o	  C,	  5%	  CO2,	  ≥	  95%	  humidity	  
Notes:	  
	  
Day	  2	  –	  Collection	  and	  re-­‐plating	  of	  non-­‐adherent	  cells	  
	  
	  
1.	  Setup:	  	  Clean	  hood	  and	  all	  equipment	  that	  goes	  in	  the	  hood	  with	  10%	  	  bleach.	  Bring	  out	  the:	  
Methylene	  blue,	  4	  of	  the	  15ml	  conical	  tubes,	  4	  microfuge	  tubes,	  1000uL	  pipettes,	  200uL	  
pipettes,	  10uL	  pipettes	  and	  tips.	  Also	  bring	  out	  the	  media	  and	  keep	  it	  in	  the	  hood	  to	  get	  to	  get	  it	  
to	  be	  at	  room	  temperature	  when	  you	  are	  going	  to	  plate	  the	  cells.	  Take	  out	  a	  24-­‐well	  fibronectin	  
plate	  from	  the	  refrigerator	  and	  allow	  it	  to	  come	  to	  room	  temperature	  in	  a	  sterile	  environment.	  	  
Pre-­‐label	  all	  the	  microfuge	  tubes	  and	  15ml	  tubes.	  	  
	  
2.	  Collecting	  non-­‐adherent	  cells:	  Using	  a	  1000ul	  pipette,	  pipette	  the	  medium	  in	  the	  well	  up	  and	  
down	  3-­‐4	  times.	  	  This	  will	  remove	  any	  non-­‐adherent	  cells	  that	  may	  be	  stuck	  to	  other	  cells.	  	  The	  
cells	  that	  are	  adherent	  will	  be	  firmly	  attached	  to	  the	  fibronectin	  medium	  so	  washing	  can	  be	  
vigorous.	  
	  
3.	  Transfer	  these	  non-­‐adherent	  cells	  from	  each	  well	  to	  a	  separate	  15ml	  tube.	  	  
	  
4.	  Cell	  count:	  
a) Perform	  1:10	  dilution	  of	  cells	  using	  3%	  Acetic	  Acid	  with	  Methylene	  Blue	  
b) Use	  10	  ul	  cells	  and	  90	  ul	  Acetic	  Acid	  with	  Methylene	  Blue	  
i. This	  is	  a	  dilution	  factor	  of	  10	  




c) Count	  cells	  using	  hemacytometer	  and	  4	  outside	  squares	  
Carefully	  clean	  hemacytometer	  and	  coverslip	  with	  kimwipes	  and	  70%	  Ethanol	  
Place	  the	  coverslip	  over	  the	  hemacytometer.	  Thoroughly	  mix	  the	  cell	  
suspension.	  Carefully	  load	  the	  2	  V	  shaped	  wells	  of	  the	  hemacytometer.	  Count	  
(under	  10x	  objective)	  the	  number	  of	  viable	  (live)	  cells	  in	  the	  4	  corner	  boxes	  of	  
each	  side.	  
Cell	  count	  (for	  the	  cells	  that	  are	  touching	  the	  border-­‐	  only	  include	  cells	  that	  are	  in	  the	  
top	  and	  bottom	  borders	  of	  every	  quadrant)	  












d) Cell	  count	  per	  ml	  =	  Avg	  #	  of	  cells	  per	  square	  *	  dilution	  factor	  *	  104	  
	  
Cell	  count	  per	  ml	  =	  ___________	  *	  10	  *	  104	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  =	  	  ___________	  cells/ml	  
	  
	  
e) Calculate	  the	  volume	  for	  1	  x	  106	  =	  1	  x	  106	  	  /number	  from	  “d”	  (above)	  *	  1000uL	  
	  
Volume	  of	  cell	  solution	  needed	  per	  well	  =	  	  1	  x	  106	  	  /_________	  *	  1000uL	  
	  






f) Volume	  of	  CFU-­‐Hill	  Media	  that	  will	  be	  needed	  in	  each	  well	  (the	  total	  volume	  in	  
each	  well	  needs	  to	  be	  1ml	  or	  1000uL)	  =	  1000uL	  –	  number	  from	  “e”	  (above)	  
	  
Volume	  of	  media	  needed	  =	  1000uL	  –	  _______	  
	  	  	  	  	  	  	  	  	  	  
=	  _________	  uL	  
	  
	  
6.	  	  Map	  out	  where	  you	  are	  going	  to	  plate	  the	  cells	  (see	  next	  page).	  First	  add	  1x106	  cells	  in	  
duplicate	  to	  a	  24-­‐well	  fibronectin-­‐coated	  plate.	  	  Then	  add	  the	  corresponding	  type	  of	  media	  
(Normal	  or	  Glucose)	  to	  a	  final	  volume	  of	  1.0mL	  per	  well.	  Repeat	  this	  process	  for	  the	  other	  3	  
groups.	  
7.	  Label	  Plate	  As	  follows	  (don’t	  write	  on	  top	  of	  the	  wells	  with	  cells	  and	  media)-­‐	  






8.	  Incubate	  at	  37ºC	  5%	  CO2	  with	  ≥	  95%	  humidity	  for	  3	  days.	  























































































Day	  5–	  Colony	  Counting	  
	  




2.	  Prepare	  microscope	  with	  plate	  stage	  and	  20x	  objective	  
3.	  Identify	  the	  wells	  to	  be	  counted.	  
4.	  Count	  colonies	  by	  scanning	  well	  in	  an	  up	  –	  to	  –	  down	  pattern	  as	  you	  move	  from	  left	  to	  right.	  	  
Be	  certain	  to	  look	  to	  the	  edges	  for	  colonies	  as	  they	  like	  to	  grow	  there.	  
5.	  Have	  a	  second	  person	  count	  to	  verify	  the	  number.	  Fill	  it	  in	  the	  	  








6.10:	  CD34+	  cell	  isolation	  protocol	  
	  








	  (3)	  K3EDTA	  10	  ml	  blood	  drawing	  tubes	  
(10)	  50	  ml	  polypropylene	  conical	  tubes	  
(3)	  15	  ml	  polypropylene	  conical	  tube	  
Transfer	  pipette	  
Sterile	  pipettes	  	  
Pipetter	  




Solutions	  &	  Reagents	  (based	  on	  30mls	  of	  	  blood)	  
	  	  
~80	  ml	  FBS/PBS	  
30ml	  Ficoll	  Paque	  PLUS	  
~10	  ml	  FBS/PBS	  +1mM	  EDTA	  (recommended	  media	  for	  EasySep)	  
EasySep	  Human	  CD34+	  selection	  cocktail	  	  





Preparing	  a	  mononuclear	  cell	  suspension:	  
	  
9) Prepare	  50ml	  of	  recommended	  media-­‐	  PBS/2%FBS	  +	  1mM	  EDTA-­‐	  	  
a) Add	  18.612mg	  EDTA	  in	  50ml	  of	  PBS/2%FBS	  for	  a	  1mM	  solution-­‐	  Mol	  wt	  of	  EDTA	  
is	  372.24	  
b) Add	  500uL	  of	  this	  recommended	  media	  to	  each	  pellet;	  to	  have	  a	  total	  of	  1mL	  of	  
PBS/2%FBS+EDTA.	  	  Measure	  total	  actual	  volume	  by	  setting	  pipette	  to	  1000uL	  
and	  let	  volume	  down	  until	  liquid	  comes	  out.	  That	  is	  the	  actual	  volume	  of	  the	  cell	  
solution.	  Combine	  the	  two	  500uL	  tubes	  to	  make	  a	  cell	  solution	  in	  a	  5mL	  
polystyrene	  tube.	  Count	  from	  here.	  	  
	  
CD34+	  Selection	  with	  the	  Magnet	  (see	  diagram):	  
	  
1. Prepare	  a	  mononuclear	  cell	  suspension	  in	  the	  recommended	  medium	  after	  calculating	  
TOTAL	  CELLS	  (see	  table)-­‐	  	  
	  




<2	  x	  10^7	   100	  uL	  
2	  x	  10^7	  –	  2	  x	  10^8	   Suspend	  cells	  at	  2	  x	  10^8	  cells/ml	  
2	  –	  5	  x	  10^8	   1ml	  
	  
For	  *TOTAL	  CELLS	  (starting)	  count-­‐	  
	  
a) Use	  1:20	  dilution	  with	  acetic	  acid	  and	  methylene	  blue	  (AA+MB).	  Use	  10uL	  of	  cell	  
solution	  in	  190uL	  of	  AA+MB.	  Load	  10uL	  of	  this	  dilution	  in	  the	  hemocytometer	  














c) Cell	  count	  per	  ml=	  Avg	  #	  of	  cells	  per	  square	  *	  dilution	  factor	  (usually	  10	  or	  20)	  *	  
104	  
	  
Cell	  count	  per	  ml	  =	  ___________	  *	  ________	  *	  104	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  =	  	  ___________	  cells/ml	  
	  
	  
d) Total	  Cells	  =	  Cell	  count	  per	  ml	  from	  “c”	  (above)	  *	  Actual	  measured	  
volume	  from	  EDTA	  step)	  	  
Total	  Cells	  =	  ___________	  *	  _________	  *	  _________	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	   	  	  	  	  	  	  =	  	  ___________	  Total	  cells	  
	  
	  
















If	  the	  cells	  are	  over-­‐diluted	  then	  spin	  the	  tube	  down	  at	  300xg	  for	  5	  minutes.	  Take	  
out	  the	  media	  in	  there	  that	  is	  in	  excess.	  So	  if	  the	  calculations	  say	  that	  it	  should	  be	  
in	  750uL	  then	  spin	  it	  down	  and	  remove	  250uL	  for	  the	  1ml	  (or	  whatever	  actual	  
volume)	  that	  the	  cells	  were	  suspended	  in.	  
	  
c) Cells	  must	  be	  placed	  in	  a	  5ml	  (12	  x	  75mm)	  polystyrene	  tube	  to	  properly	  fit	  into	  
the	  EasySep	  magnet.	  	  
	  
2. Add	  EasySep	  positive	  selection	  cocktail	  at	  100uL/mL	  cells	  (eg.	  For	  1ml	  of	  cells,	  add	  100	  






Amount	  of	  cocktail	  mix	  added	  (in	  uL)=	  ________________	  
	  
3. Mix	  Easy	  Sep	  Magnetic	  nanoparticles	  to	  ensure	  that	  they	  are	  in	  a	  uniform	  suspension	  by	  
vigorously	  pipetting	  up	  and	  down	  more	  than	  5	  X.	  DO	  NOT	  VORTEX.	  Add	  the	  particles	  at	  
100uL/mL	  cells	  (eg.	  for	  1ml	  of	  cells,	  add	  100uL	  of	  nanoparticles).	  Mix	  well	  and	  incubate	  







Amount	  of	  nanoparticles	  particle	  added	  (in	  uL)=	  ________________	  
	  
4. Bring	  the	  cell	  suspension	  to	  a	  total	  volume	  of	  2.5	  mL	  by	  adding	  recommended	  medium.	  
Aliquot	  about	  5ml	  of	  medium	  in	  a	  separate	  tube	  for	  this	  step	  so	  that	  pipette	  tip	  doesn’t	  
have	  to	  be	  changed.	  Mix	  the	  cells	  in	  the	  tube	  by	  gently	  pipetting	  up	  and	  down	  2-­‐3	  X.	  
Place	  the	  tube	  without	  the	  cap	  into	  the	  magnet.	  Set	  aside	  for	  10	  mins.	  
	  
5. Pick	  up	  the	  magnet,	  and	  in	  one	  continuous	  motion	  invert	  the	  magnet	  and	  tube,	  pouring	  
off	  the	  supernatant	  fraction	  into	  another	  5ml	  polysterene	  tube	  (labeled	  “pour	  1”).	  The	  
magnetically	  labeled	  cells	  will	  remain	  inside	  the	  tube,	  held	  by	  the	  magnetic	  field	  of	  the	  
EasySep	  Magnet.	  Leave	  the	  magnet	  and	  tube	  in	  inverted	  position	  for	  2-­‐3	  seconds,	  then	  
return	  to	  upright	  position.	  DO	  NOT	  SHAKE	  OR	  BLOT	  OFF	  ANY	  DROPS	  THAT	  MAY	  REMAIN	  





6. Remove	  the	  tube	  from	  the	  magnet	  and	  add	  2.5mL	  recommended	  medium.	  Again,	  
aliquot	  about	  5ml	  of	  medium	  in	  a	  separate	  tube	  for	  this	  step	  so	  that	  pipette	  tip	  doesn’t	  
have	  to	  be	  changed.	  Mix	  the	  cell	  suspension	  by	  gently	  pipetting	  up	  and	  down	  2-­‐3	  X.	  
Place	  the	  tube	  back	  in	  the	  magnet	  and	  set	  aside	  for	  10	  mins.	  Place	  the	  tube	  from	  the	  1st	  
pour	  “pour	  1”	  into	  the	  2nd	  magnet	  for	  10	  mins.	  
	  
7. After	  the	  10	  minutes	  with	  your	  original	  tube	  going	  through	  its	  second	  time	  and	  your	  
pour	  1	  tube	  going	  through	  the	  first	  time,	  pour	  off	  the	  “pour	  1”	  labeled	  tube	  in	  a	  15mL	  
conical	  tube	  labeled	  CD34-­‐.	  Pour	  your	  original	  tube	  into	  a	  5mL	  polystyrene	  tube	  labeled	  
“pour	  2.”	  Place	  “Pour	  2”	  tube	  into	  the	  magnet	  for	  10	  minutes.	  Pour	  this	  into	  the	  CD34-­‐	  
labeled	  conical	  tube.	  
	  
8. At	  this	  point	  you	  should	  have	  3	  of	  the	  5ml	  tubes-­‐	  the	  original	  tube,	  tube	  from	  “pour	  1”	  
and	  tube	  from	  “pour	  2”	  with	  CD34+	  cells.	  Aliquot	  about	  1ml	  of	  media	  again.	  Suspend	  
tubes	  in	  100uL	  of	  1xPBS,	  transfer	  contents	  of	  the	  pour	  tubes	  to	  the	  original	  tube	  using	  
the	  same	  pipette	  tip.	  Measure	  total	  volume	  by	  setting	  the	  1000uL	  pipet	  and	  letting	  out	  
air	  until	  just	  before	  liquid	  comes	  out.	  This	  is	  the	  final	  actual	  volume.	  The	  positively	  
selected	  cells	  are	  now	  ready	  for	  use.	  	  
	  
9. Spin	  the	  CD34-­‐	  labeled	  15mL	  conical	  tube	  at	  300xg	  for	  7min.	  Pour	  off	  the	  supernatant	  
and	  re-­‐suspend	  in	  500uL	  of	  trizol	  in	  1.5mL	  tubes.	  Label	  and	  put	  in	  -­‐80o.	  
	  
	  
((The	  following	  is	  best	  done	  in	  Morrill.	  Recount	  if	  done	  in	  Totman	  then	  going	  to	  Morrill	  
for	  NOi.))	  
	  
10. Count	  the	  #	  of	  CD34+	  cells	  using	  1:10	  dilution	  with	  acetic	  acid	  and	  methylene	  blue.	  Use	  














e) Cell	  count	  per	  ml	  =	  Avg	  #	  of	  cells	  per	  square	  *	  dilution	  factor	  (10)	  *	  104	  
	  
Cell	  count	  per	  ml	  =	  ___________	  *	  ________	  *	  104	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  





f) Total	  Cells	  =	  Cell	  count	  per	  ml	  from	  “c”	  (above)	  *	  1ml	  (since	  we	  diluted	  cells	  in	  
1ml)	  	  
	  
Total	  Cells	  =	  ___________	  *	  _________	  *	  _________	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	   	  	  	  	  	  	  =	  	  ___________	  Total	  cells	  
We	  need	  1.5	  *	  10^5	  cells	  for	  the	  DAF-­‐FM	  protocol	  so	  budget	  accordingly	  	  
Put	  the	  rest	  of	  the	  amount	  of	  CD	  34+	  and	  CD34-­‐	  cells	  in	  a	  total	  of	  500uL	  trizol.	  
	  
6.11:	  CFU-­‐Hill	  NOi	  assay	  protocol	  
	  
PROTOCOL	  FOR	  INTRACELLULAR	  NITRIC	  OXIDE	  in	  CFU-­‐Hill	  
	  
	  
A.	  Preparing	  DAF-­‐FM	  diacetate	  
	  
	  	  	  	  	  1)	  	  	  Add	  20uL	  of	  DMSO	  to	  the	  50ug	  vial	  of	  DAF-­‐FM	  diacetate	  (invitrogen)	  
a) This	  gives	  us	  a	  ~5mM	  stock	  solution	  
b) Aliquot	  in	  smaller	  quantities	  for	  later	  use	  to	  reduce	  freeze/thaw	  
	  
B.	  Preparing	  SIN-­‐Dilutions	  	  
	  
1) SIN-­‐1	  is	  206.63	  g/mol	  (the	  sin-­‐1	  that	  we	  have	  had	  4mls	  initially	  added	  to	  it)	  
The	  SIN-­‐1	  dilution	  that	  has	  been	  made	  with	  4ml	  is	  12100uM	  
2) Make	  a	  working	  stock	  of	  150uM	  by	  adding	  796.66uL	  dH2O	  +	  10uL	  of	  the	  original	  SIN	  
dilution	  (which	  is	  at	  12100uM)	  
	  
C.	  Removing	  cells	  from	  Plate	  
1) Remove	  top	  media,	  save	  and	  label.	  Place	  in	  -­‐80o	  
2) Add	  300mL	  1x	  clear	  trypsin	  per	  well.	  Rainbow	  wash	  x3	  
3) Incubate	  10	  minutes	  in	  37o	  	  
4) Combine	  in	  15mL	  conical	  tube,	  check	  plate	  on	  scope	  for	  no	  “left	  over”	  colonies/cells.	  Add	  
more	  trypsin	  if	  cells	  left	  on	  plate	  
5) Spin	  15mL	  conical	  tube	  for	  2-­‐3	  minutes	  for	  pellet.	  Toss	  supernatant	  
6) Resuspend	  in	  500uL	  1x	  PBS.	  
7) Count	  cells	  	  
	  
D.	  Combining	  the	  CFU-­‐Hill	  cells	  and	  DAF-­‐FM:	  
	  
10) Count	  the	  #	  of	  CFU-­‐Hill	  cells	  using	  1:10	  dilution	  with	  acetic	  acid	  and	  methylene	  blue.	  Use	  
















a) Cell	  count	  per	  ml	  =	  Avg	  #	  of	  cells	  per	  square	  *	  dilution	  factor	  (10)	  *	  104	  
	  
Cell	  count	  per	  ml	  =	  ___________	  *	  ________	  *	  104	  =	  	  ___________	  cells/ml	  
To	  determine	  mL	  need	  per	  well	  to	  achieve	  1.5	  x	  105	  cells/well:	  
	   	  
1.5	  x	  105	  /	  _________cells/mL=_______________	  mL	  of	  cell	  solution	  per	  well	  
	  
	  
b) Total	  cells	  =	  Cell	  count	  per	  ml	  from	  “c”	  (above)	  *	  1ml	  (since	  we	  diluted	  cells	  in	  
1ml)	  	  
Total	  Cells	  =	  ___________	  *	  _________	  *	  _________	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	   	  	  	  	  	  	  =	  	  ___________	  Total	  cells	  
	  
2)	  	  	  Create	  a	  DAF-­‐FM	  dilution	  of	  75uM,	  unless	  volume	  of	  cells	  to	  be	  added	  is	  greater	  than	  
	   130uL;	  this	  is	  atypical	  see	  #3.	  	  
a)	  Take	  out	  an	  aliquot	  of	  5mM	  from	  -­‐20.	  Thaw,	  vortex,	  and	  centrifuge.	  If	  no	  aliquot,	  	  
	   	   make	  one	  according	  to	  part	  B.	  Remember	  DAF-­‐FM	  is	  light	  sensitive.	  
b)	  To	  make	  75uM	  add	  197uL	  dH2O	  and	  3	  uL	  5mM	  DAF-­‐FM	  to	  1.5	  mL	  tube.	  
c)	  Vortex	  and	  centrifuge	  the	  new	  DAF-­‐FM	  dilution.	  	  	  
3) Combine	  cells,	  PBS,	  and	  DAF-­‐FM	  in	  the	  plate	  	  
a)	  Use	  96	  well	  plate,	  black	  sides,	  clear,	  flat	  bottom,	  with	  lid	  on.	  Save	  box!	  
b)	  The	  volume	  of	  75uM	  DAF-­‐FM	  to	  add	  will	  be	  20uL	  throughout	  
	   The	  volume	  of	  1xPBS	  will	  be	  130uL-­‐volume	  of	  cell	  solution	  to	  be	  added	  	   	   	  
	   Ex.	  if	  cell	  volume	  =	  30uL	  then	  PBS	  to	  be	  added	  will	  be	  130uL-­‐30uL=100uL	  
c)	  Plate	  in	  order	  from	  largest	  to	  smallest	  volume.	  
d)	  Incubate	  cells	  in	  37degC	  for	  60mins.	  	  
4) If	  cell	  solution	  to	  be	  added	  is	  >130uL	  but	  <150uL	  a	  75uM	  DAF-­‐FM	  stock	  will	  not	  work	  
	   a)	  Troubleshoot	  using	  M1V1=M2V2	  To	  create	  a	  working	  stock	  that	  will	  result	  in	  a	  final	  
DAF-­‐FM	  concentration	  of	  10uM	  in	  the	  total	  150uL/well	  solution	  
5) Plate-­‐reader	  (set	  this	  up	  during	  the	  incubation	  time)	  
c) The	  optics	  used	  have	  3	  wires,	  2	  silver	  ones	  (one	  with	  blue	  and	  one	  with	  yellow	  





d) No	  spacers	  are	  needed	  for	  these	  plates	  
e) Select	  “Gaya	  NOi	  CFU	  protocol”	  for	  preset	  settings	  
f) Insert	  plate	  with	  lid	  on	  and	  well	  A1	  in	  upper	  left	  hand	  corner.	  
g) Click	  measure	  and	  click	  the	  gain	  adjustment	  (plate)	  setting	  (top	  left	  corner)	  
h) Click	  OK	  	  




































ONLY	   	   	  
CELLS+DAF-­‐
FM	  +PBS	   CELLS+DAF+PBS	  
SIN	  
80+dH2O	  









6.12:	  CD34+	  cells	  NOi	  protocol	  
	  
	  
PROTOCOL	  FOR	  INTRACELLULAR	  NITRIC	  OXIDE	  in	  CD	  34+	  
	  
A.	  Preparing	  DAF-­‐FM	  diacetate	  
	  
	  	  	  	  	  1)	  	  	  Add	  20uL	  of	  DMSO	  to	  the	  50ug	  vial	  of	  DAF-­‐FM	  diacetate	  (invitrogen)	  
j) This	  gives	  us	  a	  ~5mM	  stock	  solution	  
k) Aliquot	  in	  smaller	  quantities	  for	  later	  use	  to	  reduce	  freeze/thaw	  
	  
B.	  Preparing	  SIN-­‐Dilutions	  	  
	  
6) SIN-­‐1	  is	  206.63	  g/mol	  (the	  sin-­‐1	  that	  we	  have	  had	  4mls	  initially	  added	  to	  it)	  
The	  SIN-­‐1	  dilution	  that	  has	  been	  made	  with	  4ml	  is	  12100uM	  
7) Make	  a	  working	  stock	  of	  150uM	  by	  adding	  796.66uL	  dH2O	  +	  10uL	  of	  the	  original	  SIN	  
dilution	  (which	  is	  at	  12100uM)	  
	  
	  
C.	  Combining	  the	  34+	  cells	  and	  DAF-­‐FM:	  
	  
11) Count	  the	  #	  of	  CD34+	  cells	  using	  1:10	  dilution	  with	  acetic	  acid	  and	  methylene	  blue.	  Use	  













a) Cell	  count	  per	  ml	  =	  Avg	  #	  of	  cells	  per	  square	  *	  dilution	  factor	  (10)	  *	  104	  
Cell	  count	  per	  ml	  =	  ___________	  *	  ________	  *	  104	  =	  	  ___________	  cells/ml	  
To	  determine	  mL	  need	  per	  well	  to	  achieve	  1.5	  x	  105	  cells/well:	  
	   1.5	  x	  105	  /	  _________cells/mL=_______________	  mL	  of	  cell	  solution	  per	  well	  
b) Total	  cells	  =	  Cell	  count	  per	  ml	  from	  “c”	  (above)	  *	  1ml	  (since	  we	  diluted	  cells	  in	  
1ml)	  	  
Total	  Cells	  =	  ___________	  *	  _________	  *	  _________	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	   	  	  	  	  	  	  =	  	  ___________	  Total	  cells	  
	  
2)	  	  	  Create	  a	  DAF-­‐FM	  dilution	  of	  75uM,	  unless	  volume	  of	  cells	  to	  be	  added	  is	  greater	  than	  




a)	  Take	  out	  an	  aliquot	  of	  5mM	  from	  -­‐20.	  Thaw,	  vortex,	  and	  centrifuge.	  If	  no	  aliquot,	  	  
	   	   make	  one	  according	  to	  part	  B.	  Remember	  DAF-­‐FM	  is	  light	  sensitive.	  
b)	  To	  make	  75uM	  add	  197uL	  dH2O	  and	  3	  uL	  5mM	  DAF-­‐FM	  to	  1.5	  mL	  tube.	  
c)	  Vortex	  and	  centrifuge	  the	  new	  DAF-­‐FM	  dilution.	  	  	  
8) Combine	  cells,	  PBS,	  and	  DAF-­‐FM	  in	  the	  plate	  	  
a)	  Use	  96	  well	  plate,	  black	  sides,	  clear,	  flat	  bottom,	  with	  lid	  on.	  Save	  box!	  
b)	  The	  volume	  of	  75uM	  DAF-­‐FM	  to	  add	  will	  be	  20uL	  throughout	  
	   The	  volume	  of	  1xPBS	  will	  be	  130uL-­‐volume	  of	  cell	  solution	  to	  be	  added	  	   	   	  
	   Ex.	  if	  cell	  volume	  =	  30uL	  then	  PBS	  to	  be	  added	  will	  be	  130uL-­‐30uL=100uL	  
c)	  Plate	  in	  order	  from	  largest	  to	  smallest	  volume.	  
d)	  Incubate	  cells	  in	  37degC	  for	  60mins.	  	  
9) If	  cell	  solution	  to	  be	  added	  is	  >130uL	  but	  <150uL	  a	  75uM	  DAF-­‐FM	  stock	  will	  not	  work	  
	   a)	  Troubleshoot	  using	  M1V1=M2V2	  To	  create	  a	  working	  stock	  that	  will	  result	  in	  a	  final	  
DAF-­‐FM	  concentration	  of	  10uM	  in	  the	  total	  150uL/well	  solution	  
10) Plate-­‐reader	  (set	  this	  up	  during	  the	  incubation	  time)	  
l) The	  optics	  used	  have	  3	  wires,	  2	  silver	  ones	  (one	  with	  blue	  and	  one	  with	  yellow	  
edges)	  and	  a	  gray	  wire.	  Set	  according	  to	  picture	  
	  
m) No	  spacers	  are	  needed	  for	  these	  plates	  
n) Select	  “Gaya	  NOi	  34+	  protocol”	  for	  preset	  settings	  
o) Insert	  plate	  with	  lid	  on	  and	  well	  A1	  in	  upper	  left	  hand	  corner.	  
p) Click	  measure	  and	  click	  the	  gain	  adjustment	  (plate)	  setting	  (top	  left	  corner)	  
q) Click	  OK	  	  
r) Store	  readout	  as	  an	  excel	  file	  on	  desktop	  and	  upload	  on	  thumb-­‐drive	  
	  






























ONLY	   	   	  
CELLS+DAF-­‐
FM	  +PBS	   CELLS+DAF+PBS	  
SIN	  
80+dH2O	  





6.13:	  RNA	  protocol	  
	  
	  
PROTOCOL:	  RNA	  Isolation	  of	  Endothelial	  Progenitor	  Cells	  
	  
1x	  PBS	  
Sterile	  1.5ml	  microcentrifuge	  tubes	  	  
Tri-­‐reagent	  (trizol)	  (Sigma	  T9424)	  [Totman]	  
Chloroform	  (Sigma	  C2432)	  (light	  sensitive)	  [Totman]	  
Isopropyl	  alcohol	  [Totman]	  
Glycogen	  [Totman]	  
Ethanol	  (75%)	  
TE	  Buffer	  [Totman]	  
	  
Samples:	  	  EPCs	  are	  collected	  ~24	  hours	  after	  replating	  on	  24-­‐well	  fibronectin	  coated	  culture	  
plates	  (Day	  5	  of	  Hill	  CFU	  Assay)	  or	  after	  isolating	  CD34+	  and	  CD34-­‐	  cells	  
	  
RNA	  ingredients	  (in	  uL)-­‐	  based	  on	  starting	  quantity	  of	  trizol	  (except	  glycogen	  and	  
TE)	  
Trizol	  (starting	  qty)	   250	   500	   750	   	   	   	  
Cholroform	   50	   100	   150	   	   	   	  
Isopropanol	   125	   250	   375	   	   	   	  
glycogen	   5	   5	   5	   	   	   	  
75%Etoh	   375	   750	   1125	   	   	   	  
1xte	  buffer	   25	   25	   25	   	   	   	  
	  
	  
1) Setup:	  	  
a. clean	  the	  work	  space	  and	  fume	  hood	  with	  bleach	  and	  ethanol	  
b. set	  the	  RNA	  centrifuge	  at	  40	  C	  	  
c. ice-­‐bucket	  for	  keeping	  the	  samples	  	  
d. aliquot	  reagents	  (this	  is	  per	  500uL	  trizol):	  100uLchloroform,	  250uLisopropanol,	  
750uL	  of	  75%	  ethanol,	  25uL	  TE	  buffer	  
2) Chloroform	  (light	  sensitive):	  	  
a. Add	  20µl	  Chloroform	  for	  every	  100µl	  trizol	  (1	  chloroform	  :	  5	  trizol)	  (100µl	  per	  
500uL	  of	  Trizol)	  
b. Invert	  samples	  several	  times	  (turns	  pink)	  
c. Place	  in	  rotator	  for	  10	  min	  
3) Centrifuge	  12	  min	  @	  40	  @12,000	  x	  g	  	  
4) Carefully	  remove	  50	  –	  75%	  of	  upper	  clear	  layer	  (be	  conservative,	  top	  layer	  =	  desired	  
part)	  
a. Be	  certain	  not	  to	  remove	  middle	  DNA	  layer	  or	  lower	  pink	  layer	  




c. Place	  in	  second	  1.5ml	  tube	  
d. Discard	  unwanted	  trizol	  solution	  still	  in	  tubes	  (there	  is	  a	  medicine	  looking	  white	  
bottle	  in	  the	  room	  in	  Morrill	  with	  the	  centrifuge	  in	  which	  this	  goes)	  
5) Isopropyl	  alcohol	  &	  Glycogen:	  	  
a. Add	  50µl	  isopropyl	  alcohol	  for	  every	  100µl	  trizol	  (1	  isopropyl	  :	  2	  trizol)	  (250µl	  
isopropyl	  per	  500uL	  trizol)	  	  
b. Add	  5µl	  glycogen	  per	  sample	  (per	  500uL)	  	  
c. Invert	  and	  place	  in	  rotator	  for	  10	  min.	  
6) Centrifuge	  for	  8	  min	  @	  40	  C	  @	  12,000	  x	  g	  	  
7) Carefully	  remove	  supernatant	  –	  do	  not	  disturb	  pellet	  
8) Ethanol:	  	  
a. Add	  150µl	  ethanol	  for	  every	  100	  µl	  of	  trizol	  (1.5	  ethanol	  :	  1	  trizol)	  (750	  µl	  per	  
500uL	  trizol)	  
b. Vortex	  briefly	  –	  pellet	  should	  not	  go	  into	  solution,	  only	  knocked	  loose	  
c. Incubate	  @	  RT	  for	  5	  min	  (keep	  closed)	  
9) Centrifuge	  for	  5	  min	  @	  40	  C	  @	  7500	  x	  g	  
10) Remove	  as	  much	  ethanol	  as	  possible	  without	  disturbing	  pellet	  
11) Allow	  pellet	  to	  air-­‐dry	  for	  ~10	  –	  15	  min	  (keep	  open	  to	  let	  it	  dry	  outside)	  
a. Pellet	  will	  become	  clear	  
b. DO	  NOT	  let	  the	  pellet	  become	  completely	  dry	  
12) Add	  25µl	  of	  TE	  buffer	  
13) Incubate	  at	  55	  –	  600	  C	  for	  10	  min	  (keep	  closed)	  
14) Freeze	  -­‐800	  C	  (lower	  right	  side	  of	  freezer)	  
	  
NUMBER	  OF	  SAMPLES:	  ________________	  
SUBJECT	  ID/IDs:	  _________________	  
LOCATION	  OF	  SAMPLES:	  _______________	  
LABELS	  ON	  THE	  TUBES:	  
	   SUB	  ID:	  _______	  
	  
	   DATE:	  ________	  
	  
	   INITIALS:	  ______	  
	  




6.14:	  RNA	  quantification	  for	  cDNA	  synthesis	  
	  
Nanodrop-­‐	  	  
RNA	  for	  cDNA	  syntehsis	  
	  
RNA	  samples	  
0.1-­‐2	  uL	  pipettes	  +	  tips	  
Kimwipes	  
Nucelase	  free	  water	  




The	  original	  RNA	  stock	  should	  be	  taken	  out	  of	  the	  -­‐80	  freezer	  and	  be	  placed	  in	  a	  bucket	  of	  ice	  
	  
Dilution:	  
1. Dilution	  for	  RNA	  from	  cells-­‐	  1:25	  
a. In	  a	  new	  microtube,	  take	  48uL	  of	  1xTE	  Buffer	  and	  add	  2uL	  of	  your	  original	  RNA	  
stock	  to	  it	  
b. Pipette	  mix	  first	  and	  then	  add	  2uL	  of	  your	  original	  RNA	  stock	  to	  the	  buffer	  
c. Remember	  to	  pipette	  mix	  the	  original	  stock	  well	  after	  it	  has	  been	  added	  to	  the	  
buffer	  to	  get	  a	  homogenous	  mixture	  
2. Dilution	  for	  RNA	  from	  tissue-­‐	  1:50	  	  
a. In	  a	  new	  microtube,	  take	  98uL	  of	  1xTE	  Buffer	  	  	  
b. Pipette	  mix	  first	  and	  then	  add	  2uL	  of	  your	  original	  RNA	  stock	  to	  the	  buffer	  
c. Remember	  to	  pipette	  mix	  the	  original	  stock	  well	  after	  it	  has	  been	  added	  to	  the	  
buffer	  to	  get	  a	  homogenous	  mixture	  
Setup:	  
1. Clean	  all	  equipment	  with	  Ethanol,	  wipe	  workspace	  with	  10%	  bleach	  
2. Clean	  the	  pedestal	  and	  arm	  with	  Kimwipes	  (if	  looks	  contaminated,	  can	  you	  5.25%	  bleach	  
solution)	  
3. Click	  on	  ND-­‐1000	  icon	  
4. Choose	  Nucleic	  acids	  option	  for	  RNA	  
Initialize:	  
5. When	  the	  software	  starts,	  you	  should	  see	  this	  message:	  “click	  OK	  to	  initialize	  the	  
spectrometer.	  Load	  a	  water	  sample	  onto	  the	  pedestal	  first	  for	  best	  calibration”	  
6. Load	  a	  2uL	  nuclease	  free	  water	  sample	  (small	  bottle	  with	  green	  top)	  onto	  the	  pedestal	  
and	  close	  the	  arm	  (no	  need	  to	  press	  it	  down)	  	  
7. Click	  OK	  
Blanking:	  
8. If	  using	  sample	  directly	  then	  your	  1x	  TE	  Buffer	  is	  the	  “blank”	  
9. Click	  on	  BLANK	  	  
10. Repeat	  the	  first	  step	  of	  blanking	  




12. This	  result	  should	  have	  a	  spectrum	  that	  varies	  no	  more	  than	  0.05	  A	  from	  the	  zero	  
baseline	  	  
Re-­‐blanking*	  
13. Repeat	  first	  step	  of	  blanking	  	  
14. Click	  Re-­‐BLANK	  
15. The	  following	  message	  should	  appear	  “blank	  applied	  to	  displayed	  spectrum”	  
Sample	  ID:	  
16. Enter	  the	  sample	  ID	  to	  identify	  the	  measurement	  being	  made	  
17. Make	  sure	  “RNA-­‐40”	  is	  selected	  under	  sample-­‐type	  
Load	  sample:	  
18. Pipette	  mix	  again	  	  
19. Load	  2uL	  of	  sample	  	  
20. Place	  on	  pedestal	  and	  close	  the	  arm,	  but	  not	  all	  the	  way	  down	  
21. Click	  MEASURE	  
Measures:	  
Measure	  5	  readings	  in	  TOTAL.	  Discard	  the	  first	  2	  readings-­‐	  
NEED	  A	  MINIMUM	  OF	  3	  READINGS	  (THAT	  ARE	  CONSISTENT)	  FROM	  EACH	  SAMPLE	  DILUTION	  
	  
	   1	   2	   3	   4	   5	  
A260	   	   	   	   	   	  
A280	   	   	   	   	   	  
260/280	   	   	   	   	   	  
ng/uL	   	   	   	   	   	  
[RNA]	  
calculated	  
	   	   	   	   	  
	  
If	  you	  feel	  like	  the	  A260	  readings	  seem	  to	  be	  off,	  you	  can	  re-­‐blank	  with	  the	  buffer	  again.	  
However,	  remember	  that	  the	  sample	  that	  was	  most	  recently	  measured	  will	  be	  re-­‐calculated	  
based	  on	  the	  re-­‐blank.	  And	  all	  the	  measures	  thereafter	  will	  also	  be	  calculated	  based	  on	  this	  
new	  re-­‐blank	  value.	  	  
Can	  print	  report	  for	  these	  readings	  as	  well	  but	  if	  you	  are	  working	  in	  pairs,	  one	  person	  can	  
note	  these	  values.	  	  
	  
Calculations:	  
Concentration	  of	  RNA-­‐	  
[RNA]=	  	  [A260*40ug/ml*50]/1000	  
	  
NOTE:	  50	  =	  dilution	  factor	  of	  sample	  used	  for	  spec	  analysis	  
	  40=	  the	  conversion	  factor	  for	  RNA	  
	  
Main	  measurements	  to	  look	  for	  and	  what	  they	  mean	  -­‐260/280-­‐	  ~1.8	  is	  pure	  for	  DNA,	  2.0	  is	  
pure	  for	  RNA	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